On behalf of the Society for Investigative Dermatology (SID), welcome to the 2017 Annual Meeting in Portland. Portland is a city that’s known for being a little bit “different”. In fact, one of the unofficial mottos, displayed on a large mural near the famous 24-hour Voodoo Doughnut, is “Keep Portland Weird”. Known for being environmentally conscious, we’re confident you’ll be delighted by what sets this “Green” city apart.

Portland is home to the nation’s favorite airport, an efficient light rail system and pedestrian-friendly city blocks – uncommon qualities that are easy to get used to. You’ll find retailers large and small, international and indie within easy reach of downtown hotels. With no sales tax, it is a haven for shoppers. There is also a staggering selection of food and drink options in Portland from hundreds of inexpensive food carts all over town to nationally acclaimed chef-driven restaurants. Thirsty? Portland has more craft breweries than any other city on earth as well as more than a dozen urban wineries and a myriad of coffee roasters.

To counteract all those delicious meals, Portlanders love to burn calories in the great outdoors. Hit the pavement on more than 100 miles of trails and paths, see Portland by bicycle or take a hike in one of the country’s largest urban forests. Within two hours of downtown you can visit the Oregon Coast beaches, Mount Hood ski resorts or Columbia River Gorge waterfalls. We hope you will find time to sample all that Oregon has to offer and we are confident you will enjoy your stay.

As always, we are grateful to the Committee on Scientific Programs which has once again planned an exciting and enlightening program for us.

Since its founding in 1937, the SID has been committed to facilitating the careers of young investigators by providing a dynamic forum in which a diverse group of scientists can interact. We remain fully committed to this goal and to offer programming that reaches all members of the dermatology and cutaneous biology research communities.

We have scheduled a variety of activities to highlight scientific advances made by our community, and social events that will celebrate our international scientific community and the culture and beauty of Portland.

Welcome to what promises to be another truly outstanding SID Annual Meeting!
SID Governance

GOVERNANCE
Officers and Directors

President
Angela Christiano, PhD

Vice President
Martin Weinstock, MD/PhD

President-Elect
Russell Hall, MD

Vice President-Elect
Lisa Beck, MD

Secretary-Treasurer
Alice P. Pentland, MD

Secretary-Treasurer
Richard L. Gallo, MD/PhD

Immediate Past President
Mark C. Udey, MD/PhD

JID Editor
Barbara A. Gilchrest, MD

Directors
Cheng-Ming Chuong, MD/PhD
Mitchell Denning, PhD
James T. Elder, MD/PhD
Valentina Greco, PhD
Ryan Hobbs, PhD*
Sam Hwang, MD/PhD
Maranke I. Koster, PhD
David J. Margolis, MD/PhD
Anthony E. Oro, MD/PhD
John Seykora, MD/PhD
Cory Simpson, MD/PhD*
J.P. Therrien, PhD*

Resident/Post-Doctoral Members
J.P. Therrien, PhD*

SID Administrative Staff
Jim Rumsley
Chief Operating Officer
Rebecca Minnillo, DM/MPA
Chief Program and Development Officer
Robyn Cipolletti
Director, Association Services
Stephanie Flanagan
Manager, Membership Services
Deborah Kovacs
Director, Program Services
Wendy Talerman
Manager, Communications and Development

JID Administrative Staff
Elizabeth Nelson Blalock
Managing Editor, JID
Sarah Forging
Editorial Process Manager

JOURNAL OF INVESTIGATIVE DERMATOLOGY
Editor
Barbara A. Gilchrest, MD

Editor-Elect
Mark C. Udey, MD/PhD

Advisor Board
Paul R. Bergstresser, MD
Lowell A. Goldsmith, MD
Erwin Tschachler, MD

Deputy Editor
Angela Christiano, PhD

Statistical Editor
Beverley Adams-Huet

JID Connector Editor
Kavitha K. Reddy, MD

JID Jottings Editor
Lowell Goldsmith, MD

Cells to Surgery Quiz Editor
Keyvan Nouri, MD

Meet the Investigator Editor
Ayman Grada, MD

Meeting Reports Editor
Gerald S. Lazarus, MD

Milestones Editor
Hensin Tsao, MD/PhD

Podcast Editors
Abigail Baird Waldman, MD
Robert Dellavalle, MD
Olivier Gaide, MD/PhD

Research Techniques Made Simple
Jodi Lynn Johnson, PhD, Editor

SnapshotDx Quiz Editor
Mariya Miteva, MD

Section Editors
Masayuki Amagai, MD/PhD
Tilo Biedermann, MD
Vladimir Botchkarev, MD/PhD
Paul E. Bowden, MD/PhD
Tatiana Efimova, MD
James T. Elder, MD/PhD
Meenhard Herlyn, DVM
Sam Hwang, MD/PhD
Alan D. Irvine, MD
Ethan A. Lerner, MD/PhD
John McGrath, MD
Tamar Nijsten, PhD
Thomas Schwartz, MD
Vijayasaradhi Setaluri, PhD
John R. Stanley, MD
Robert S. Stern, MD
Robert Swerlick, MD
Jouni Uttilo, MD/PhD
Thomas Werfel, MD/PhD
Stuart Yuspaa, MD

Editors Emeriti
Marion B. Sulzberger, 1938-1949
Naomi M. Kanof, 1949-1967
Richard Stoughton, 1967-1972
Irwin M. Freedberg, 1972-1974
Kathleen J. Green, 1977-1978
Howard P. Baden, 1982-1987
David A. Norris, 1987-1992
Richard L. Eckert, PhD
Michelle A. Lowes, MD/PhD
David Margolis, MD/PhD
Alexander G. Marneros, MD/PhD
Alain Mauvial, PhD
Caterina Missero, PhD
Akimichi Morita, MD/PhD
Paul Nghiem, MD/PhD
Manabu Ohyama, MD
Amy S. Paller, MD
Andrey A. Panteleyev, PhD
Vincent Piquet, MD
Carlo Pincelli, MD
Graca Raposo, PhD
Dennis Roop, PhD
Sarbajit S. Saini, MD
Fernanda Sakamoto, MD/PhD
Helmut Schaider, MD
Christoph Schlapbach, MD/PhD
Martin Schmelz, MD/PhD
Julia A. Segre, PhD
John Seykora, MD/PhD
Jan C. Simon, MD
Eli Sprecher, PhD
Richard Spritz, MD
Phyllis I. Spuls, MD/PhD
Georg Stingl, MD
Makoto Sugaya, MD
John P. Sundberg, PhD
Narafah Tomic-Canic, PhD
Sergey M. Troyanovskiy, PhD
Mark C. Udey, MD/PhD
Maurice van Steensel, MD/PhD
Baoxi Wang, MD
Xiao-Jing Wang, MD/PhD
Nico L. Ward, MD
Stephanie Weidinger, MD
Wendy Weinberg, PhD
Philip Wertz, PhD
Traci Wilgus, PhD
Giovanna Zambruno, MD
Xuejun Zhang, MD/PhD
Bin Zheng, PhD
Dietel Zielikens, MD

Associate Editors
Maryam Asgari, MD/PhD
Martine Bagot, MD/PhD
Boris Bastian, MD
Cheng-Ming Chuong, MD/PhD
Julide Celebi, MD
Leena Bruckner-Tuderman, MD
Joke Bouwstra, PhD
Jan Nico Bouwes Bavinck, MD
Wendy B. Bollag, PhD
Luca Borradori, MD
Jan Nicollah Bouwman, MD
Abigail Baird Waldman, MD
Robert Dellavalle, MD
Olivier Gaide, MD/PhD

Medical Writer
Heather Yarnall Schultz, PhD

Conrad Hauser, 1997-2002
David A. Norris, 1987-1992
Howard P. Baden, 1982-1987
Richard L. Eckert, PhD
Michelle A. Lowes, MD/PhD
David Margolis, MD/PhD
Alexander G. Marneros, MD/PhD
Alain Mauvial, PhD
Caterina Missero, PhD
Akimichi Morita, MD/PhD
Paul Nghiem, MD/PhD
Manabu Ohyama, MD
Amy S. Paller, MD
Andrey A. Panteleyev, PhD
Vincent Piquet, MD
Carlo Pincelli, MD
Graca Raposo, PhD
Dennis Roop, PhD
Sarbajit S. Saini, MD
Fernanda Sakamoto, MD/PhD
Helmut Schaider, MD
Christoph Schlapbach, MD/PhD
Martin Schmelz, MD/PhD
Julia A. Segre, PhD
John Seykora, MD/PhD
Jan C. Simon, MD
Eli Sprecher, PhD
Richard Spritz, MD
Phyllis I. Spuls, MD/PhD
Georg Stingl, MD
Makoto Sugaya, MD
John P. Sundberg, PhD
Narafah Tomic-Canic, PhD
Sergey M. Troyanovskiy, PhD
Mark C. Udey, MD/PhD
Maurice van Steensel, MD/PhD
Baoxi Wang, MD
Xiao-Jing Wang, MD/PhD
Nico L. Ward, MD
Stephanie Weidinger, MD
Wendy Weinberg, PhD
Philip Wertz, PhD
Traci Wilgus, PhD
Giovanna Zambruno, MD
Xuejun Zhang, MD/PhD
Bin Zheng, PhD
Dietel Zielikens, MD

Associate Editors
Maryam Asgari, MD/PhD
Martine Bagot, MD/PhD
Boris Bastian, MD
Cheng-Ming Chuong, MD/PhD
Julide Celebi, MD
Leena Bruckner-Tuderman, MD
Joke Bouwstra, PhD
Jan Nico Bouwes Bavinck, MD
Wendy B. Bollag, PhD
Luca Borradori, MD
Jan Nicollah Bouwman, MD
Abigail Baird Waldman, MD
Robert Dellavalle, MD
Olivier Gaide, MD/PhD

Medical Writer
Heather Yarnall Schultz, PhD

Conrad Hauser, 1997-2002
David A. Norris, 1987-1992
Howard P. Baden, 1982-1987
Howard P. Baden, 1982-1987
Richard L. Eckert, PhD
Michelle A. Lowes, MD/PhD
David Margolis, MD/PhD
Alexander G. Marneros, MD/PhD
Alain Mauvial, PhD
Caterina Missero, PhD
Akimichi Morita, MD/PhD
Paul Nghiem, MD/PhD
Manabu Ohyama, MD
Amy S. Paller, MD
Andrey A. Panteleyev, PhD
Vincent Piquet, MD
Carlo Pincelli, MD
Graca Raposo, PhD
Dennis Roop, PhD
Sarbajit S. Saini, MD
Fernanda Sakamoto, MD/PhD
Helmut Schaider, MD
Christoph Schlapbach, MD/PhD
Martin Schmelz, MD/PhD
Julia A. Segre, PhD
John Seykora, MD/PhD
Jan C. Simon, MD
Eli Sprecher, PhD
Richard Spritz, MD
Phyllis I. Spuls, MD/PhD
Georg Stingl, MD
Makoto Sugaya, MD
John P. Sundberg, PhD
Narafah Tomic-Canic, PhD
Sergey M. Troyanovskiy, PhD
Mark C. Udey, MD/PhD
Maurice van Steensel, MD/PhD
Baoxi Wang, MD
Xiao-Jing Wang, MD/PhD
Nico L. Ward, MD
Stephanie Weidinger, MD
Wendy Weinberg, PhD
Philip Wertz, PhD
Traci Wilgus, PhD
Giovanna Zambruno, MD
Xuejun Zhang, MD/PhD
Bin Zheng, PhD
Dietel Zielikens, MD
Committee on Diversity & Inclusion
Angela Christiano, PhD, Chair
Niroshana Anandasabapathy, MD/PhD
Oscar Colegio, MD/PhD
Lynn Cornelius, MD
Richard L. Gallo, MD/PhD
Barbara Gilchrest, MD
Donald Glass, MD/PhD
Valentina Greco, PhD
Valérie Horsley, PhD
Akemi Ishida-Yamamoto, MD/PhD (USID representative)
Kurt Lu, MD
Sarah Millar, PhD
Paul Nghiem, MD/PhD
Carien Niessen, PhD (ESSDR representative)
Cory Simpson, MD/PhD
Nicole Ward, PhD

Committee on Scientific Programs
Ponciano Cruz, MD, Co-Chair
Paul T. Nghiem, MD/PhD, Co-Chair
Spiro Getsios, PhD
Daniel Kaplan, MD/PhD
Ethan Lerner, MD/PhD
Lloyd Miller, MD/PhD
Peggy Myung, MD/PhD
Kevin Wang, MD/PhD
Nicole Ward, PhD
Victoria P. Werth, MD
Angela Christiano, PhD, President (ex-officio)
Alice P. Pentland, MD, Secretary-Treasurer (ex-officio)
Richard L. Gallo, MD/PhD, Secretary-Treasurer (ex-officio)
Jim Rumsey, Staff Liaison
Robyn Cipolletti, Staff Liaison

Ad Hoc Reviewers for Committee on Scientific Programs
Niroshana Anandasapathy, MD/PhD
Marta Bertolini, PhD
Suephy Chen, MD
Raymond Cho, MD/PhD
Keith Choate, MD/PhD
Benjamin Chong, MD
Mary-Margaret Chren, MD
Shawn Demehri, MD/PhD
Anna DiNardo, MD/PhD
Ryan Driskell, PhD
Luis Garza, MD/PhD
Joel Gelfand, MD
Emma Guttmann-Yassky, MD/PhD
Alain Hovnanian, MD/PhD
Mayumi Ito, PhD
Sewong Kang, MD
Akinori Kawakami, MD/PhD
Masaoki Kawasumi, MD/PhD
Heidi Kong, MD
Alexa Mattheyes, PhD
Amanda McLeod, MD
Maksim Pikus, PhD
Brian Pollack, MD/PhD
Christian Posch, MD
Thomas Ruenger, MD/PhD
Eric Simpson, MD
Jean Tang, MD/PhD
Marjana Tomic-Canic, PhD
George Wondrak, PhD

Executive Committee
Angela Christiano, PhD
JT Elder, MD/PhD
Russell Hall, MD
Richard L. Gallo, MD/PhD
Barbara A. Gilchrest, MD
Alice Pentland, MD
Mark C. Udey, MD/PhD
Jim Rumsey, MD/PhD (ex-officio)
Becky Minnillo, DM/MPA, (ex-officio)

Honorary Members
H. Baden
E. Bauer
P. Bergstresser
E. Beutner
D. Bickers
O. Braun-Falco
I. Braverman
A. Breathnach
R. A. Briggaman
W. Bullough
H. D. Chen
L. H. Chiung
E. Christophers
R. Degos
L. Diaz
R. Dobson
R. Eady
R. Edelson
A. Eisen
P. Elias
A. ELMofty
E. Epstein
J. Fernandez
I. Freedberg
R. Freinkel
B. Gilchrest
I. Gigi
L. Goldsmith
R. Goltz
M. Greaves
H. Green
J. Grupenhoff
G. Hambrick, Jr.
J. Hanifan
F. Hu
Y. Ishibashi
S. Jablonska
R. Jordon
S. Katz
A. Kligman
K. Kraemer
G. Krueger
A. Kukita
C. Lapierre
G. Lazarus
I. Leigh
A. Lerner
J. Leyden
W. Lobitz, Jr.
D. Lowy
I. Magnus
Y. Mishima
T. Nishikawa
D. Norris
S. Ofuji
H. Ogawa
J. Parrish
S. Pinnell
M. Prunieras
W. Quevedo, Jr.
H. Rorsman
W. Shelley
B. Shrook
S. Shuster
F. Snyder
D. Stevanovic
G. Stingl
J. Strauss
H. Tagami
N. Thyresson
J. Uitto
E. Van Scott
J. Voorhees
P. Weary
G. Weinstein
C. Wheeler, Jr.
K. Wolff
K. L. Yang
SID Governance

SID AWARDS

Stephen Rothman Memorial Award Recipients
Presented for distinguished service to investigative cutaneous medicine.
1967 Marion Sulzberger
1968 Donald Pillsbury
1969 Harvey Blank
1970 Thomas Fitzpatrick
1971 Aaron Lerner
1972 William Montagna
1973 Rudolf Baer
1974 Hermann Pinkus
1975 Eugene Van Scott
1976 Albert Kligman
1977 Irvin Blank
1978 George Oidland
1979 Clayton Wheeler, Jr.
1980 Clarence Livingood
1981 Isadore Bernstein
1982 J. Lamar Callaway
1983 Richard Stoughton
1984 A. Gedeon Matoltsy
1985 Herman Bereman
1986 Otto Braun-Falco
1987 Walter Shelley
1988 John Strauss
1989 Walter Lobitz, Jr.
1990 Walter Lever
1991 Robert Goldz
1992 Irwin Freedberg
1993 Arthur Eisen
1994 Ruth Freinkel
1995 Howard Baden
1996 Irma Gigli
1997 Stephen Katz
1998 Klaus Wolff
1999 Lowell Goldsmith
2000 Richard Dobson
2001 Robert Briggaman
2002 Eugene Bauer
2003 Georg Stingl
2004 Stuart Yuspia
2005 John Voorhees
2006 Thomas Lawley
2007 Barbara Gilchrest
2009 Luis Parada
2010 Douglas Lowey
2011 David Lane
2012 R. Rox Anderson
2013 R. Rox Anderson
2014 Jouni Uitto
1989 Tung-Tien Sun
1990 Karen Holbrook
1991 Luis Diaz
1992 Dennis Roop
1993 Ervin Epstein, Jr.
1994 John Stanley
1995 Elaine Fuchs
1996 Thomas Kupper
1997 Barbara Gilchrest
1998 Günter Blobel
1999 Philippa Marrack
2000 Robert Langer
2001 William Haseltine
2002 Ronald DePinho
2003 Thomas Jessell
2004 Robert Weinberg
2005 Timothy Ley
2006 Ama Sehgal
2007 Stuart Schreiber
2008 John McGrath
2009 Daniel Kastner
2010 Raymond Schinazi
2011 Jennifer Lippincott-Schwartz
2012 Mina Bissell
2013 Allan Balmain
2014 Hensin Tsao
2016 Anthony Oro

Eugene M. Farber Lectureship
This lecture is presented by an investigator whose work is relevant to expanding our insights into the pathophysiology and treatment of psoriasis.
2007 Brian Nickoloff
2008 Enno Christophers
2009 James T. Elder
2010 James Krueger
2011 Kevin Cooper
2012 Frank Nestle
2014 Joel Gelfand
2015 Christopher E.M. Griffiths
2016 Nicole Ward

Albert M. Kligman/Phillip Frost Leadership Lecture & Award
This award is made to an individual in acknowledgment of significant contributions to the understanding of structure and function of skin in the past five years.
2008 Jouni Uitto
2009 Stephen Katz
2010 John R. Stanley
2011 Peter Elias
2012 Robert Laverker
2013 Elaine Fuchs
2014 Robert Modlin
2015 Kathleen J. Green
2016 Cheng-Ming Chuong

William Montagna Lectureship
This annual award is intended to honor and reward young active investigators. Primary emphasis is given to researchers in skin biology.
1987 Jouni Uitto
1988 Stuart Yuspia
1989 Tung-Tien Sun
1990 Karen Holbrook
1991 Luis Diaz
1992 Dennis Roop
1993 Ervin Epstein, Jr.
1994 John Stanley
1995 Elaine Fuchs
1996 Thomas Kupper
1997 Barbara Gilchrest
1998 Günter Blobel
1999 Philippa Marrack
2000 Robert Langer
2001 William Haseltine
2002 Ronald DePinho
2003 Thomas Jessell
2004 Robert Weinberg
2005 Timothy Ley
2006 Ama Sehgal
2007 Stuart Schreiber
2008 John McGrath
2009 Daniel Kastner
2010 Raymond Schinazi
2011 Jennifer Lippincott-Schwartz
2012 Mina Bissell
2013 Allan Balmain
2014 Hensin Tsao
2016 Anthony Oro

Julius Stone Lectureship
This lecture is intended to promote the advancement of knowledge in immunology as it relates to the skin and skin disease.
1999 Eli Gilboa
1999 Stephen Johnston
1999 Jeffrey Trent
2000 Nigel Bunnett
2000 Ronald Crystal
2000 Ralph Steinman
2001 Roland Martin
2002 Gerald Crabtree
2003 Adrian Hayday
2004 Polly Matzinger
2006 Alexander Rudensky
2007 Donald Y. Leung
2009 Damey Marth
2011 Rafi Ahmed
2011 Casey Weaver
2012 Rebecca Buckley
2014 Alice P. Pentland
2015 Arlene H. Sharpe
2016 John O’Shea

Herman Beerman Lectureship
This lecture is given by a distinguished medical scholar, traditionally from fields other than dermatology.
1961 Rene Dubos
1962 Hans Selye
1963 Rupert Billingham
1964 Curt Stern
1965 Albert Szent-Gyorgyi
1966 Jerome Gross
1967 G.J.V. Nossal
1968 John B. Betzner-Jansch
1969 Henry Kunkel
1970 Norman Wessells
1971 Aiden Breathnach
1972 Frank Dixon
1973 H. Hugh Fudenberg
1974 Charles Cochrane
1975 David Katz
1976 Bert O’Malley
1977 Russell Ross
1978 Hilary Koprowski
1979 Michael Brown
1980 Phil Leder
1981 Pedro Cuelcascas
1982 Frank Ruddle
1983 Lawrence Lichtenstein
1984 Robert Gallo
1985 Thomas Waldmann
1986 Torsten Wiesel
1987 Leroy Hood
1988 Joseph Goldstein
1989 Pierre Chambon
1990 Ronald Herberman
1991 K. Frank Austen
1992 Bert Vogelstein
1993 Charles Janeway, Jr.
1994 Solomon Snyder
1995 Eric Lander
1996 Irving Weissman
1997 Michael Karin
1998 Günter Blobel
1999 Philippa Marrack
2000 Robert Langer
2001 William Haseltine
2002 Ronald DePinho
2003 Thomas Jessell
2004 Robert Weinberg
2005 Timothy Ley
2006 Ama Sehgal
2007 Stuart Schreiber
2008 John McGrath
2009 Daniel Kastner
2010 Raymond Schinazi
2011 Jennifer Lippincott-Schwartz
2012 Mina Bissell
2013 Allan Balmain
2014 Hensin Tsao
2015 Drew M. Pardoll
2016 Tom Misteli

Naomi M. Kanof Clinical Investigator Award
This award is given to enlighten present and future workers about the importance of clinical investigation. It honors an individual who has made significant contributions to our understanding of clinical medicine.
1993 Alvan Feinstein

Eugene M. Farber Lectureship
This lecture is presented by an investigator whose work is relevant to expanding our insights into the pathophysiology and treatment of psoriasis.
2007 Brian Nickoloff
2008 Enno Christophers
2009 James T. Elder
2010 James Krueger
2011 Kevin Cooper
2012 Frank Nestle
2014 Joel Gelfand
2015 Christopher E.M. Griffiths
2016 Nicole Ward

Albert M. Kligman/Phillip Frost Leadership Lecture & Award
This award is made to an individual in acknowledgment of significant contributions to the understanding of structure and function of skin in the past five years.
2008 Jouni Uitto
2009 Stephen Katz
2010 John R. Stanley
2011 Peter Elias
2012 Robert Laverker
2013 Elaine Fuchs
2014 Robert Modlin
2015 Kathleen J. Green
2016 Cheng-Ming Chuong
Selected ePoster Discussions

In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk. See the venue map when on site for dates, times, categories, featured posters, and moderators.

Speed Dating at SID
April 28, 2017, 12:00 pm – 2:00 pm

This signature SID event features a novel interface between academic investigators and industry representatives. The SID office schedules meetings by matching keywords defined by industry that match submitted abstracts, based on synergistic areas of research. Partners meet for 15 minutes to determine if there is potential for collaboration. #speeddatingatsid

Note: These individual meetings are all pre-arranged and confirmed before the session.

Come See My Poster

Following in the success of both the ESDR and JSID’s innovative programming, the SID will once again offer three 15-minute sessions during the Annual Meeting, titled “Come See My Poster.”

These sessions will give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute/one slide introduction to their submitted abstract. This rapid paced session is in advance of one of the SID’s Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

Trainee/Faculty Breakfast

Throughout the years, the SID has encouraged meetings between Residents and Post-Doc Fellows. To continue its promotion of collegiality, the SID presents a Trainee Breakfast. These small group small group meetings in which senior/junior scientists and a group of four to six residents and post-doc fellows to discuss issues over coffee and light fare. These sessions provide an opportunity to talk informally about subject matter of interest including research opportunities in dermatology, life in academia or how to combine clinical work with research.
**Going Mobile**

Navigate the 76th Annual Meeting from your mobile device! In partnership with Cadmium CD, the SID is proud to present the 2017 Annual Meeting mobile event app.

This year’s app will make it easy for attendees, exhibitors, and speakers to connect. Attendees can access their personal schedules right from the palm of their hand. They can track the exhibitors they’ve visited, see all the full text abstracts, have access to the meeting schedule and floor plans, apply for CME credit, take notes, call for an Uber ride, check the weather, check-in with their airline, access social media sites, and interact with fellow attendees to name just a few of the features.

Download the 2017 SID Annual Meeting Mobile app from the Apple ITunes and the Google Play Stores.

---

**A Guide to Using the SID 2017 Annual Meeting App**

**STEP 1**

Download the "SID 2017 Annual Meeting" app from the Apple App Store or Google Play Store. To start using the app, select “Create Account” and type your name and email address. If you already have an account, select “Login” and enter your username (your email) and password.

**STEP 2**

Browse the event schedule and create a personal schedule by selecting the star adjacent presentation titles. Starred presentations can be found under “My Schedule.” Review presentation, speaker and exhibitor details. Take notes in the schedule and exhibitors modules.

**STEP 3**

If you don’t have a device that is able to download the app, you can use your laptop. As long as you have an internet connection, you can view the schedule, speaker information, and exhibitor information through your laptop via the following website link: https://tinyurl.com/SID-Annual-2017

If you already have an account on a mobile device, use the same account information that was emailed to you. Otherwise follow the steps to create an account.
CME Statement & Objectives

The University of Rochester, Center for Experiential Learning presents:

The 2017 Society for Investigative Dermatology (SID) Annual Meeting

COMMERCIAL SUPPORT STATEMENT
Commercial Support Acknowledgment: This CME activity is supported by educational grants. A complete list of supporters will be published in the course syllabus.

STATEMENT OF NEED
The educational programming of the SID is designed to develop, maintain, and/or increase the abilities, skills, and professional performance of its target audiences. SID CME activities will:
1) Disseminate updated evidence-based knowledge of skin biology/disease and applications for maintaining health and preventing, diagnosing, and treating disease in a manner that fosters scientific excellence, elevates the standard of care, and meets high ethical standards.
2) Provide target audiences with a relevant forum for the exchange of cutting-edge scientific ideas, information, and methodology.
3) Advance the science involved in basic skin biology and clinical care of patients with skin disease.
4) Provide exposure to novel science (both concepts and methods) which may be relevant in the future to understanding and treatment of skin disease.

TARGET AUDIENCE
The primary target audiences for SID CME activities include all of the sectors of the dermatology community, consisting of research investigators, clinicians, research and clinical trainees, members of industry, and community advocates for skin health/disease.

LEARNING OBJECTIVES
At the conclusion of this activity, participants should be able to:
- Identify which disease states require new or additional research.
- Evaluate state-of-the-art information relating to basic skin biology research.

• Describe how newly discovered, evidence-based scientific information may or may not be applied to the current practice of investigative or clinical dermatology.
• Apply strategies to structure and design successful research proposals, abstracts, and manuscripts.
• Facilitate interdisciplinary and/or collaborative investigation in clinical dermatology and skin biology to improve research hypotheses, processes and/or techniques.
• Incorporate knowledge gained from interactions between basic scientists and clinicians into daily decision-making.

FACULTY LISTING
Activity Medical Director:
Alice P. Pentland, MD
Chair, Department of Dermatology
University of Rochester

SUMMARY OF FACULTY DISCLOSURE/CONFLICT RESOLUTION
Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.

Resolution of Conflicts of Interest
In accordance with the ACCME Standards of Commercial Support of CME, the University of Rochester School of Medicine and Dentistry will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.

UNAPPROVED USE DISCLOSURE STATEMENT
The University of Rochester requires CME faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Faculty will not be discussing information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

DISCLAIMER
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

INSTRUCTIONS ON HOW TO RECEIVE CREDIT
In order to receive CME credit, participants must sign-in, review the CME information (accreditation, learning objectives, faculty disclosures, etc.) and attend the CME activity. To access the program evaluation, claim CME Credits, or print your certificate go to www.cme.urmc.edu or use the QR Code.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Rochester School of Medicine and Dentistry and the Society for Investigative Dermatology. The University of Rochester School of Medicine and Dentistry is accredited by the ACCME to provide continuing medical education for physicians.

AMA CREDIT STATEMENT
The University of Rochester School of Medicine and Dentistry designates this live activity for a maximum of 26.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Planning Committee / Speaker Declarations

All of the planning committee members and speaker listed below have disclosed that they have no relevant financial interests/arrangements or affiliations with organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s).

Hasan Erbil Abaci, PhD, Katrin Abulabara, MD/MA/MSc, Katrin Abulabara, MD/MA/MSc, Shivani Agrawal, PhD, Feras Al-Ghazawi, PhD/MD/MSc, Timothy Almassian, MD, Sasany Anand, PhD, Niruohana Anandasabapathy, MD/PhD, Nita Archer, PhD, Christopher Arnette, PhD, Kaushal Asrani, PhD/MBBS, Kwabena Badu-Nanaasi, PhD, John Cannon, BA, Brian Capell, MD/PhD, Joseph Carroll, PhD, Yue Ling Chang, BA, Peter Chansky, BA, Yongche Wu, BS, Mei Chen, PhD, Raymond Cho, MD/PhD, Keith Chuate, MD/PhD, Abigail Coffman, PhD, Ian Cohen, PhD, Maclain Cook, MD, Acacia Crouch, MS, Dang Huei Dai, PhD, Landon D'Oel, PhD, Lornie Dorman, Daniel S. Duan, PhD, K. Sanjana P. Devi, PhD, Sally Dickinson, PhD, Joanna Dong, BA, John Doux, MD, Peter Elias, MD, Christopher Ellisbrecht, MD, Robert Eisenstein, BS, Cheng Feng, BS, Alexander Fischer, MPh, Agnieszka Forthuber, PhD, Chisako Fujisawa, Pre-Doctoral Student, Yuki Furutachi, MD, Lili Garbyan, MD/PhD, Tara Gelb, PhD, Brian Gibbs, PhD/MD/MPH, Barbara Gilchrest, MD, Ayman Gradl, MD/MS, Teri Greiling, PhD, Douglas Grossman, MD/PhD, Zongyou Guo, PhD, Thomas Haarmann-Stamm, PhD, Robert Hanaoka, PhD, Helen Hu, BS, Nicholas Heitman, Ryan Hobbs, PhD, Xin-Yen Huang, PhD, Anke Hues, MSc, Bin-Jin Hwang, PhD candidate, Kimberly Kahn, PhD, Pankaj Kahol, PhD, Saiseen Kasham, PhD, Michelle Kerns, MD, Habib Khani, BA, Dongye Kim, MD, Jin Yong Kim, PhD, Tetsuro Kobayashi, PhD, Heidi Kong, MD, MHC, Heidi Kong, MD, MHS, Heather Kornreich, BS, Thomas Kupper, PhD, Michael Kwa, BA, Shawn Kwatra, MD, Eunjeong Kwon, PhD, Lu Li, MD, PhD, Chantale Le Faivre, PhD, Dustin Lee, BS, Je Lei, Master, Katharine Levandoski, BS, Jonathan Leonvich, BA, Katharine Lewandoski, PhD, Joshua Lewis, PhD (in progress), Xi Li, Liang Liang, MD, Chung-Ping Liao, PhD, Young Lim, BS, Yuanqiang Liu, PhD, Hsin-Ling Liu, PhD, Vanessa Lopez-Pajares, PhD, Catherine Lu, PhD, Kirti Lu, MD, David Margolis, MD/PhD, Anubhav Mathur, MD/PhD, Mary Mathur, BA, Akiva Mattheyses, PhD, Aubrey McEvoy, BA, John McGrath, MD, PhDNei, Alex May, MD, Tery Mcdermott, MD, Eric Merrill, BA, Ankei Mesler, BS, Natalia Miller, PhD, Michael Milikien, MD/MPH, Amir Mirza, BA, Carolina Moser-Cattorn, PhD student, Tenasa Murata, MD/PhD, Alexis Mylonas, MSc, *Peeggy Nyung, MD, Kellie Nair, Seitaro Nakagawa, MD, Tenaka Nakatsui, PhD, Benjamin Nanes, MD/PhD, Tran Nguyen, Bachelor of Pharmacy, Megan Nutter, MD/MPh, Hisashi Nomura, MD, John O'Malley, MD, Mari Oda, MD, Landon Oetjen, Ryosuke Ono, MD/PhD, Anthony Oros, MD, Harish Pai, MD, Amy Palwar, MD, Youndong, Pan, PhD, Jeanie Park, BA, Chang Soo Park, MD/PhD, Irena Pastar, PhD, Matthew Patrick, MD, *Alisa Perlandt, MD, Manosikra Periera, MBBS, Bethany Perez White, PhD, Lynn Petukhova, PhD, Joanie Pinard, MD, Hyomin Pomerantz, MD, Steven Preitzl, MD, Jo Ann Raff, MD, PhD, Ranae Rass healthier, MD, Claire Rogerson, MA/Msc, Rebecca Rusell, BA, Julie Ryan Wolf, PhD/MD/Ph, Ryan Saciet, BS, Rosyai Saigusa, MD, Ashley Sample, MS, Jennis Rae Samsen, BA, Karen Sanchez Armendariz, MD, Freda Sansaricq, MD, Mraial Sarkar, PhD, Markus Schober, PhD, Donna Sebas, MBB/MD, Susan Sereda Shtait, MD, Pakal Shakh, PhD Candidate, Yohya Shigehara, MD, Daniel Shin, PhD, Brett Shook, PhD, Sigun Sigurdardottir, MD, Caroline Simard, MD, Cory Simpson, MD/PhD, Jeffrey Smith, BS, Kevin Sonderheimmer, Toxicology, Cutamas Sunanpradit, MD, William Swendlin, PhD/MS, Katsuto Tamai, MD/PhD, Catherine Tarchan-Quesso, Fos, MD/HS, Hisashi Taniu, MD, Nicholas Theodosakis, PhD, Chen Ting, PhD, Jakub Todor, MD, PhD, Lam Tsoi, PhD, Rosas Venturina, BS, Steven Verian, BA, James Walt, PhD, Eddy Hu, WANG, MD, Ewetam Tran, PhD, Wee Lin Yap, MD, PhD, *Youwei Zhang, PhD, Zheping Wang, MD, Nyan Wang, MD/PhD, *Aalok Wholelinda, ND, Ramon Whitboron, PhD, Marlos Winges, MD/PhD, Julie Wu, Nan Xu, MD, Mingang Xu, PhD, Takeshi Yamauchi, MD, Kun Ying, PharmD, Lucio Zapata, BS, Zili Zhai, PhD, Lingjun Zhang, PhD, Jennifer Zhang, PhD, Jingyi Zhao, MD, Guannan Zhu, MD/PhD. * Planning Committee Members

The following planning committee members and speakers have disclosed financial interest/arrangements or affiliations with organizations on which they could be perceived as a real or apparent conflict of interest in the context of the subject of their presentation(s). Only current arrangements/interests are included:

Nihal Ahmad, PhD, Grant/Research Support: California Table Grape Commission
Jonathan Barker, MD, BS, Grant/Research Support: Abbvie, Pfizer, J&J, Novartis, Celgene, GlaxoSmithKline; Other: Advisory Board/Speakers; Abbvie, Pfizer, J&J, Novartis, Celgene, Sun Pharmaceuticals, Almirall
Bruce Baule, MD, Other Financial or Material Support: Pfizer
Vladimir Botchkarev, MD, PhD, Grant/Research Support: Amway Research Grant
Angela Christiano, PhD, Grant/Research Support: NIH/NIAMS NCI, NCATS, NAAAF, NYSTEM, DEBRA, Pfizer, Consultant: Aclaris Therapeutics; Stock Shareholder: Aclaris Therapeutics; Other: Patents from Columbia University licensed to Aclaris Therapeutics.
Raphael Clynes, MD, PhD, Consultant: Aclaris Therapeutics; Shareholder (minor): Aclaris Therapeutics
George Cotsarelis, MD, Grant/Research Support: Allergan, Johnson and Johnson; Consultant: Casioppea, Lilly, Other Financial or Material Support: Folica, Scientific Advisory Board
*Ponciano Cruz, MD, Grant/Research Support: Astellas
Vishal Daswani, MD, Other Financial or Material Support: Samumed LLC Employee, and Employee Equity
Ariane Dimitrov, MD, Other: L'Oreal Employee
Alodial Dobry, BS, Grant/Research Support: Pfizer
Jessica Fulthor, BS Biology, Grant/Research Support: Principa BioPharma Inc., Other Financial or Material Support: California Research Institute of Regenerative Medicine
*Richard Gallo, MD, PhD, Consultant: Sente Inc., MaciSiy Biotechnologies
*Spiro Gekos, PhD, Grant/Research Support: AbbVie
Eric Ghorab, MD, Other: Sanofi Genzyme Employee
Michael Girard, MD, Other Financial or Material Support: Inventor on Yale University-owned patent rights, and Executive at StraDEFY, LLC a spinout company.
Johann Godinjon, MD/PhD, Grant/Research Support: Pfizer, Genentech, AbbVie, AnaptixBio, Novartis, Consultant: Novartis
Christian Guerrero-Juarez, MD Candidate, Grant/ Research Support: NSF MBBS- I3MO; Other: Co-Inventor on patent filed by U Penn describing the BMP pathway as a target for promoting neoepithelial formation
Emma Guttman, MD/PhD, Consultant: Inventor on Yale University-owned patent rights, and Executive at StraDEFY, LLC a spinout company.
Johann Godinjon, MD/PhD, Grant/Research Support: Pfizer, Genentech, AbbVie, AnaptixBio, Novartis, Consultant: Novartis
*Daniel Kaplan, MD/PhD, Grant/Research Support: Hapten Pharmaceuticals
Youn Kim, MD, Grant/Research Support: Seattle Genetics; Takeda; Other (please identify): Advanced and stage; Seattle Genetics; Steering Committee member for Takeda
*Ethan Lermer, PhD, Consultant: Tescan Pharmaceuticals, Tigo Pharmaceuticals, Nuro Research, Proctor & Gamble (Speaker), Dermira, Kirinke Pharmaceuticals
Haiyun Liu, PhD, Grant/Research Support: Pfizer; Other Financial or Material Support: Amgen, Genentech
Julian Mackay-Wiggins, MD, Grant/Research Support: Locks of Love; Consultant Aclaris Therapeutics, Inc, Concert Pharmaceuticals, Inc; Other Financial or Material Support: Advisory Board for BiologicalsMD
David Margolis, MD/PhD, Grant/Research Support: Valant Pharmaceuticals Pediatric, Eccema Elective Registry; Consultant: Sanofi/ Regeneron GlaxoSmithKline
Katherine McHale, PhD, Other Financial or Material Support: Novan, Inc. Employee
Sarah Milar, PhD, Consultant: Samumed
*Lloyd Miller, PhD, MD, MD, PhD, Grant/Research Support: Medimmune, Pfizer, Chan-Soon-Shing Institute for Advanced Health, Nanoteks, BioAegis Therapeutics, Regeneron Pharmaceuticals; Consultant: Chan-Soo-Shing Institute for Advanced Health, Nanoteks, Novocyte Biotech真正做到; Syntor, Major Stock Shareholder: Novocytes
Paul Nghiem, MD/PhD, Grant/Research Support: Bristol-Myers Squibb, Consultant: EMD Serono
Atsushi Otsuka, MD, PhD, Grant/Research Support: OHD Pharmaceutical LTD.
Aimee Payne, MD/PhD, Grant/Research Support: Sanofi; Consultant: Syntimmune
John Seykora, MD/PhD, Grant/Research Support: NIH, Rohto Pharmaceutical, P expressive Pharmaceuticals; Consultant: Samumed; Other Financial or Material Support: Speakers Bureau For Myriad Genetics
Stuart Shanley, MD, Major Stock Shareholder: Aclaris Therapeutics; Other Financial or Material Support: Executive at Aclaris Therapeutics; Other: Allergen
Zurab Strachilishvi, PhD, Other Financial or Material Support: Autologous skin graft LEAES technology was licensed to Alonsena Therapists who is funding phase 2 trial
Neal Walker, DO/FAAD/MBA, Major Stock Holder: Aclaris Therapeutics Relates Therapeutics; Sebastian neoepithelial or Financial or Material Support: CEO at Aclaris Therapeutics; Other (please identify): Allergen
Patricia Walker, MD/PhD, Consultant: Neothetics, Sebastian; Other Financial or Material Support: President of Brickell Biotech
*Nicole Ward, PhD, Grant/Research Support: Allergan; Consultant: AbbVie; Other Financial or Material Support: Raegers from Amgen, Eli Lilly
*Victoria Werth, MD, Grant/Research Support: Celenze, Janssen, Biogen, Roche, Corbus Pharmaceuticals; Consultant: Celenze, Janssen, Genentech, Rocky, Principles, Pfizer, Biogen, Momenta, MedImmune, Xoma, Cipher, Lilly, Resolve, Malinckrodt, Syntorben, Other Financial or Material Support: Pern owns the copyright for the CLASI and CDASI
David Woodley, MD, Consultant: Biofusion, Shire, Lotus
Bin Zheng, PhD, Consultant: Erlirum
* Planning Committee Members
Meeting-At-A-Glance

**TUESDAY, APRIL 25, 2017**

- **Resident Retreat**
  - Registration and Informal Networking: By Invitation Only
  - Program Session: 12:00 pm – 1:00 pm
  - B113-116

- **PhD Retreat**
  - Registration and Informal Networking: By Invitation Only
  - Program Session: 12:00 pm – 1:00 pm
  - B113-116

- **Resident/PhD Retreat**
  - Welcome Dinner and Reception: By Invitation Only
  - 6:30 pm – 6:35 pm
  - Lobby B

**WEDNESDAY, APRIL 26, 2017**

- **Resident/PhD Retreat**
  - Breakfast: By Invitation Only
  - 7:00 am – 8:00 am
  - B113-116

- **Resident Retreat**
  - Program Session: By Invitation Only
  - 7:15 am – 12:00 pm
  - B113-116

- **PhD Retreat**
  - Program Session: By Invitation Only
  - 7:15 am – 12:00 pm
  - B113-116

- **Registration**
  - 8:00 am – 7:00 pm
  - Pre-Function A Foyer

**THURSDAY, APRIL 27, 2017**

- **Trainee/Faculty Breakfast**
  - 7:00 am – 8:00 am
  - B110-112

**Meeting-At-A-Glance**

- **Plenary Session I**
  - Eugene M. Farber Lecture: 8:00 am – 9:30 am
  - Oregon Ballroom 201-202

- **Clinical Scholars Program Session I**
  - 10:15 am - 12:00 pm
  - Oregon Ballroom 201-202

- **Poster Session I/Coffee Break**
  - Odd Poster #: 625-935
  - Even Poster #: 002-312
  - Odd Late-Breaking Poster #: 987-1007
  - Even Late-Breaking Poster #: 936-960
  - 10:15 am – 12:15 pm
  - Exhibit Hall A

- **Selected ePoster Discussions I**
  - 10:45 am – 11:45 am
  - See Page #46
  - Exhibit Hall A Foyer

- **Aclaris Sponsored Symposium**
  - You Don’t Know JAK: 12:00 pm – 1:45 pm
  - Oregon Ballroom 201-202

- **Concurrent Mini-Symposia**
  - 1. Adaptive and Autoimmunity: Oregon Ballroom 204
  - 2. Clinical Research: Oregon Ballroom 203
  - 4. Pigmentation and Melanoma: A105-106
  - 5. Skin and Hair Developmental Biology: C123-124

- **Mini-Symposia Mixers**
  - 4:30 pm – 5:00 pm
  - Individual Concurrent Meeting Rooms
### FRIDAY, APRIL 28, 2017

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>7:30 am - 4:30 pm</td>
<td>Pre-Function A Foyer</td>
</tr>
<tr>
<td><strong>Plenary Session II</strong></td>
<td>8:00 am - 9:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td><strong>Stephen Rothman Memorial Award</strong></td>
<td>9:00 am - 9:15 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>Presented to Amy Paller, MS/MD</td>
<td></td>
</tr>
<tr>
<td><strong>Julius Stone Lecture</strong></td>
<td>9:15 am - 9:45 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice Bruce Beutler, MD</td>
<td></td>
</tr>
<tr>
<td><strong>State-of-the-Art Plenary Lecture III</strong></td>
<td>9:45 am - 10:15 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>Border Patrol and Melanoma: Keeping the Peace at a Cost? Niroshana Anandasabapathy, MD/PhD</td>
<td></td>
</tr>
<tr>
<td><strong>State-of-the-Art Plenary Lecture IV</strong></td>
<td>10:15 am - 10:45 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>3D Bioprinting-An Emerging Paradigm in Tissue Engineering Pankaj Karande, PhD</td>
<td></td>
</tr>
</tbody>
</table>

### SATURDAY, APRIL 29, 2017

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>7:30 am - 12:00 pm</td>
<td>Pre-Function A Foyer</td>
</tr>
<tr>
<td><strong>Plenary Session III</strong></td>
<td>8:00 am - 9:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td><strong>William Montagna Lecture</strong></td>
<td>9:00 am - 9:30 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>From Morphogenesis to Disease: A Wnt’ers Tale Sarah Millar, PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Herman Beerman Lecture</strong></td>
<td>9:30 am - 10:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>How to Make Antibodies for Tumor Immunotherapy Alan J. Korman, PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Come See My Poster III</strong></td>
<td>10:00 am - 10:15 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td></td>
<td>Poster #’s 033, 091, 107, 127, 253, 279, 287, 348, 424, 478, 512</td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Scholars Program Session II</strong></td>
<td>10:15 am - 12:00 pm</td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td></td>
<td>Emerging Immunotherapies</td>
<td></td>
</tr>
</tbody>
</table>

### 2017 EDUCATIONAL TRACKS

- **YOUNG INVESTIGATOR/TRAINEE**
- **INFLAMMATORY SKIN DISEASE**
- **SKIN CANCER**
### Associate Groups: Meeting-At-A-Glance

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TUESDAY, APRIL 25, 2017</strong></td>
<td>International Pachyonychia Congenita Consortium (IPCC) Meeting 2017</td>
<td>12:00 pm - 6:00 pm</td>
<td>C123-124</td>
</tr>
<tr>
<td><strong>WEDNESDAY, APRIL 26, 2017</strong></td>
<td>International Pachyonychia Congenita Consortium (IPCC) Meeting 2017</td>
<td>8:00 am - 1:00 pm</td>
<td>C123-124</td>
</tr>
<tr>
<td></td>
<td>Pan-Pacific Skin Barrier Symposium (PAPSBRS)</td>
<td>9:00 am - 4:30 pm</td>
<td>A105-106</td>
</tr>
<tr>
<td></td>
<td>American Acne and Rosacea Society (AARS)</td>
<td>12:00 pm - 3:00 pm</td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td><strong>THURSDAY, APRIL 27, 2017</strong></td>
<td>Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology Session</td>
<td>7:00 am - 8:00 am</td>
<td>A105-106</td>
</tr>
<tr>
<td></td>
<td>International Transplant Skin Cancer Collaborative (ITSCC) Symposium</td>
<td>7:00 am - 8:00 am</td>
<td>B117-119</td>
</tr>
<tr>
<td></td>
<td>debra of America’s EB Symposium</td>
<td>12:00 pm - 2:00 pm</td>
<td>B117-119</td>
</tr>
<tr>
<td><strong>FRIDAY, APRIL 28, 2017</strong></td>
<td>Women’s Dermatologic Society Networking &amp; Breakfast</td>
<td>6:30 am - 7:15 am</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Panel Discussion</td>
<td>7:15 am - 8:00 am</td>
<td>B117-119</td>
</tr>
<tr>
<td></td>
<td>Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology Session</td>
<td>7:00 am - 8:00 am</td>
<td>A105-106</td>
</tr>
<tr>
<td></td>
<td>International Eczema Council</td>
<td>12:00 pm - 1:30 pm</td>
<td>Oregon Ballroom 204</td>
</tr>
<tr>
<td></td>
<td>International Psoriasis Council</td>
<td>12:00 pm - 1:30 pm</td>
<td>B113-116</td>
</tr>
<tr>
<td></td>
<td>American Dermato-Epidemiology Network (ADEN) Symposium</td>
<td>12:00 pm - 1:30 pm</td>
<td>B117-119</td>
</tr>
<tr>
<td></td>
<td>Medical Dermatology Society</td>
<td>12:00 pm - 1:45 pm</td>
<td>A105-106</td>
</tr>
<tr>
<td></td>
<td>International Society for Cutaneous Lymphomas / Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)</td>
<td>12:00 pm - 1:30 pm</td>
<td>C123-124</td>
</tr>
<tr>
<td></td>
<td>Research in Cutaneous Surgery Mini-Symposium</td>
<td>12:00 pm - 1:30 pm</td>
<td>B112</td>
</tr>
<tr>
<td></td>
<td>National Eczema Association</td>
<td>6:00 pm - 7:00 pm</td>
<td>A105-106</td>
</tr>
<tr>
<td></td>
<td>North American Hair Research Society (NAHRS)</td>
<td>6:00 pm - 8:30 pm</td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td></td>
<td>National Psoriasis Foundation Reception</td>
<td>6:00 pm - 7:30 pm</td>
<td>B117-119</td>
</tr>
<tr>
<td></td>
<td>SATO Japan Scientific Forum</td>
<td>6:30 pm - 9:30 pm</td>
<td>C123-124</td>
</tr>
</tbody>
</table>
The SID is pleased to offer special educational tracks/special collections of focused topics within the 2017 Annual Meeting: The Skin Cancer, Inflammatory Skin Disease, and Trainee Tracks. The SID has been increasing the variety of sessions offered at the Annual Meeting that are geared toward residents, fellows, students and clinicians. The Track system is an easy way for attendees to identify components of the Meeting that provide in-depth coverage.

Session components of each track are indicated with initials on the ‘Meeting at a Glance’ pages:

- Young Investigator/Trainee Track (T)
- Inflammatory Skin Disease (I)
- Skin Cancer Track (S)

Tracks include portions of the meeting that offer a density of thematic content, providing a cohesive learning experience. They also provide significant opportunities for networking and collaboration, as attendees share common clinical and research interests.

Note: These tracks merely highlight themes that run throughout the meeting. Attendees are encouraged to select sessions by conducting keyword searches for disease, mechanism, gene, etc.

**YOUNG INVESTIGATOR/TRAINEE**

There are several sessions offered during the SID meeting that are designed for Trainees. They are intended to provide an overview of basic, clinical and translational science, along with opportunities to interact with senior faculty. The target audience includes medical and biomedical science students, research fellows, Dermatology residents, PhD/Post-doctoral candidates, and Junior Faculty.

**TRACK COMPONENTS**

- **Wednesday, April 26**
  - Translational Science Symposium
  - Irvin H. Blank Forum

- **Thursday, April 27**
  - Clinical Scholars Program Session I
  - Mini-Symposia Mixers

- **Friday, April 28**
  - Julius Stone Lecture
  - Mini-Symposia Mixers

- **Saturday, April 29**
  - Clinical Scholars Program Session II

**INFLAMMATORY SKIN DISEASE**

This track includes special sessions occurring over the four-day SID meeting, and offers an in-depth view of Inflammatory Skin Diseases, both common and rare, through a variety of lenses. Presentations span the full translational continuum—from animal surrogate models to human trials, utilizing genetic, mechanistic, epidemiological, and technical approaches.

**TRACK COMPONENTS**

- **Thursday, April 27**
  - Plenary Session I
  - Eugene M. Farber Lecture
  - Concurrent Mini-Symposia 1: Adaptive and Autoimmunity
  - Concurrent Mini-Symposia 2: Clinical Research: Pathophysiology and Therapeutics
  - Concurrent Mini-Symposia 3: Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis

- **Friday, April 28**
  - Julius Stone Lecture
  - Concurrent Mini-Symposia 7: Genetic Disease, Gene Regulation, Gene Therapy
  - Concurrent Mini-Symposia 8: Innate Immunity, Microbiology, Inflammation

- **Saturday, April 29**
  - Plenary Session III
  - Concurrent Mini-Symposia 13: Epidermal Structure and Barrier Function

**SKIN CANCER**

A significant amount of research will be presented during this year’s SID meeting. More than a fourth of abstracts submissions relate to all types of skin cancers, and many of the Invited/Named Lectures relate to emergent areas of cutaneous oncology.

**TRACK COMPONENTS**

- **Thursday, April 27**
  - Naomi M. Kanof Lecture
  - Concurrent Mini-Symposia 2: Clinical Research: Pathophysiology and Therapeutics
  - Concurrent Mini-Symposia 4: Pigmentation and Melanoma

- **Friday, April 28**
  - Plenary Session II
  - State-of-the Art Plenary Lecture III
  - Concurrent Mini-Symposia 9: Photobiology

- **Saturday, April 29**
  - Plenary Session III
  - Herman Beerman Lecture
  - Clinical Scholars Program Session II
  - Concurrent Mini-Symposia 11: Carcinogenesis and Cancer Genetics
2017 SID Retreat Attendees & Travel Awardees

2017 SID RETREAT ATTENDEES

Annalise Abiodun, MD
Richard Ahn, PhD
Christopher Arnette, PhD
Adam Aronson, MD
Velina Atanasova
John Barbieri, MD/MBA
Nicole Bender, MD
Elizabeth Berry, MD
Daniel Butler, MD
Natasha Carter, MD/PhD
Elizabeth Chao, MD/PhD
Yeun Ja Choi, PhD
Nashay Clemetson, MD
Emily Cole, MD
K. Sanjana P. Devi, PhD
Brittany Dulmage, MD
Robert Feehan
Cheng Feng
Jade Fettig, MD
Teal Furnholm, PhD
Maria Gnarra, MD/PhD
Farzam Gorouhi, MD
Tamar Hajarm, MD
Claire Hamilton, MD/PhD
Natasha Hill, PhD
Chante Karimkhani, MD
Nour Kibbi, MD
Grace Kim, MD
Chelsey Kline, PhD
Sara Knowlden, PhD
Betty Kong, MD/PhD
Karen Kuo, MD
Ryan Lane, PhD
Jamie Langenhan, MD
Nayoung Lee, MD
Katherine Lewandowski, PhD
Joshua Lewis, PhD
Chung-Ping Liao, PhD
Isabelle Lorthois, PhD student
Olivia Lucero, MD
Silvia Mancebo, MD
Matthew Marsh, MD
Jeffrey McBride, MD/PhD
Jason Meyer, MD/PhD
Michael Milliken, MD/MPH
Yukari Mizukami, MD
Christine Monteleon, PhD
Ata Moshiri, MD/MPH
Farah Moustafa, MD
Era Murzaku, MD
Caroline Nelson, MD
Tran Nguyen
Neda Nikbakht, MD/PhD
Lauren Ogrich, MD
Xiaoming Ouyang, PhD
Andrew Overmiller
Joshua Owen, MD/PhD
Youdong Pan, PhD
Elyse Paterson, PhD
David Perry, MD/PhD
Eyemim Pomerantz, MD
Mehdi Rashighi, MD
Jason Rizzo, MD/PhD
Clare Rogerson, MA/MSc
Daiki Rokunohe, MD/PhD
Veronica Rotemberg, MD/PhD
James Sanford
Timothy Schmidt, MD/PhD
Brittney Schultz, MD
Yevgeniy Semenov, MD
Jessica Shiu, MD/PhD
Leonid Shmylovitch, MD/PhD
Sigrun Sigurdardottir, PhD
Titilola Sode, MD
Rivka Stone, MD/PhD
Kumar Sukhdeo, MD/PhD
Joel Sunshine, MD/PhD
Jutamas Suwanpradid, PhD
Rie Takahashi, MD/PhD
Shivani Tripathi, MD
Amanda Truong
Akihiko Uchiyama, MD/PhD
Antia Veal
Priyanka Vedak, MD
Benjamin Voisin, PhD
Elizabeth Wallace, MD
Chen Wang, MD/PhD
Vivian (Wai Chong) Wong, MD/PhD
Chao Yang, MD
Zhaolin Zhang, PhD

2017 SID/ALBERT M. KLIGMAN TRAVEL FELLOWSHIP Awardees

Timothy Almazan, MD
Kausal Asrani, PhD
Kwabena Badu-Nkansah
Peter Chansky
Isan Cohen, PhD
Allison Dobry
Cheng Feng
Agnes Forsthuber, MSc
Tara Gelb, PhD
Ayman Grada, MD
Helen He
Sakeen Kashem, PhD
Heather Kornmehl
Jonathan Levinsohn
Xi Li, MD
Haiyun Liu, PhD
Aubriana McEvoy
Eric Dean Merrill
Natalie Miller, PhD
Amar Mirza
Terusa Muruta, MD

2017 SID STUDENT RESEARCH/FELLOW TRAVEL Awardees

Shivani Agarwal, PhD
Feras Al-Ghazawi, MD/PhD
Christopher Arnette, PhD
Carolina Catarino
Mohammed Dany, PhD
Sally Dickinson, PhD
Jessica Fuhriman
Robert Hamanaka, PhD
Habib Khan
Dongwon Kim, PhD
Jin Yong Kim
Sergei Korolov, PhD
Michael Kwa
Shawn Kwatra, MD
Eunjeong Kwon, PhD
Katherine Levandoski
Joshua Lewis
Alexander Means, MD
Terry Medier, PhD
Arlee Mesler
Michael Milliken, MD/PhD
Shin Morizane, MD/PhD
Tran Nguyen
Hisashi Nomura, MD
Matthew Patrick, PhD
Ashley Sample
Catherine Tchanque-Fossuo, MD
Nicholas Theoosakis, PhD
Steven Vernali
Yan Wang, MD/PhD
Nan Xu, MD
Kun Yang
Lucio Zapata, Jr.
Jingyi Zhao, MD
REPRODUCTION AND PHOTOGRAPHY POLICY
Any photography, filming, taping, recording or reproduction in any medium of any of the programs, exhibits, or lectures (oral or posters) presented at the 2017 SID Annual Meeting is strictly forbidden. Failure to comply with this rule may lead to the removal of your meeting credentials.

ON-SITE REGISTRATION
On-site registration will take place at the SID Registration Counter in the Pre-Function A Foyer during the following hours:

- Wednesday, April 26, 2017  8:00 am – 7:00 pm
- Thursday, April 27, 2017  7:30 am – 4:30 pm
- Friday, April 28, 2017  7:30 am – 4:30 pm
- Saturday, April 29, 2017  7:30 am – 12:00 pm

BADGES
Badges for both advanced and on-site registration can be picked up at the SID Registration Counter in the Pre-Function A Foyer. Meeting attendees are required to wear their badges at all times for entry to all sessions and other meeting activities.

TABLETOP EXHIBITORS
Aclaris Therapeutics
www.aclaristx.com

American Acne and Rosacea Society
www.acneandrosacea.org

International Psoriasis Council
www.psoriasiscouncil.org

National Alopecia Areata Foundation
www.naaf.org

National Eczema Association
www.nationaleczema.org

National Psoriasis Foundation
www.psoriasis.org

Pachyonychia Congenita Project
www.pachyonychia.org

SPECIAL SERVICES FOR THE PHYSICALLY CHALLENGED
The Oregon Convention Center is fully accessible to the physically challenged.

If you have any special needs, please stop at the SID Registration Counter upon arrival or contact Danelle Hauther 503.235.7575 or danellehauther@oregoncc.org.

TECHNICAL EXHIBITS
Exhibits will be on display during the following times in the Exhibit Hall A:

- Thursday, April 27, 2017  10:15 am – 12:15 pm
- Friday, April 28, 2017  11:30 am – 1:30 pm
- Saturday, April 29, 2017  10:15 am – 12:15 pm

THE SID WELCOMES REPRESENTATIVES FROM THE FOLLOWING ORGANIZATIONS
CYTOO
FibroTx
Galderma
Genemarkers
ImaBiotech Corp
Innovaderm Research Inc.
Lilly USA, LLC
MatTek Corporation
Metabolon
NIAMS
Perimed Inc.
Pfizer
Zen-Bio Inc.

COMMERCIAL SUPPORT OF CME SESSIONS AS OF APRIL 1, 2017
Actelion
Galderma
LEO Pharma
Novartis
Sanofi Genzyme and Regeneron Pharmaceuticals
Valeant

SPONSORS AS OF APRIL 1, 2017
Aclaris Therapeutics
Incyte
Pfizer
Rodan and Fields
Sun Pharma
ORAL PRESENTATIONS
All oral presentations and lectures will take place at the Oregon Convention Center (OCC). Minisymposium and Plenary oral presentations are scheduled at the rate of five (5) per hour. This allows ten (10) minutes for presentation and two (2) minutes for discussion. In order to coordinate sessions, the time limit will be strictly adhered to, or you will be asked to terminate your presentation by the session moderators.

LCD projectors will be available in each lecture room. There will be resources to display only with IBM-compatible PowerPoint MS Office 2015 or earlier versions. 35mm projectors will not be available. Computer technicians will be able to download ZIP and CD files. All oral presentations must also be presented as posters.

All presentations must be uploaded at least six (6) hours prior to your presentation and uploads are to be completed in the Speaker Ready Room (A103). Technical support will be available.

CONFLICT OF INTEREST
Due to CME guidelines, all oral presentations must include a disclosure slide at the beginning of your presentation. If there is a real or perceived conflict of interest pertaining to your work, an announcement must be made prior to your oral presentation and also displayed on your poster.

SPEAKER READY ROOM WILL BE HELD IN ROOM A103 ON THE LOWER LEVEL
The room will be available to all presenters during the following hours:

<table>
<thead>
<tr>
<th>Monday, April 24, 2017</th>
<th>7:00 am - 8:00 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, April 25, 2017</td>
<td>7:00 am - 5:00 pm</td>
</tr>
<tr>
<td>Wednesday, April 26, 2017</td>
<td>7:00 am - 5:00 pm</td>
</tr>
<tr>
<td>Thursday, April 27, 2017</td>
<td>7:00 am - 5:00 pm</td>
</tr>
<tr>
<td>Friday, April 28, 2017</td>
<td>7:00 am - 5:00 pm</td>
</tr>
<tr>
<td>Saturday, April 29, 2017</td>
<td>7:00 am - 2:00 pm</td>
</tr>
</tbody>
</table>

TO VIEW ALL ABSTRACTS PLEASE DOWNLOAD THE MEETING APP (SEE PAGE 7 FOR INSTRUCTIONS) OR SEE THE MAY 2017 SUPPLEMENT TO THE JOURNAL OF INVESTIGATIVE DERMATOLOGY (JID)

POSTER PRESENTATIONS
All poster will be displayed until Saturday, April 29th at 12:15 pm in Exhibit Hall A. Posters will be viewed in three (3) sessions as outlined below. Presenters should be at their posters for the entire discussion session. Posters may not be removed early. The SID is not responsible for posters left unclaimed as of 1:00 pm on Saturday, April 29, 2017, and unclaimed posters will not be returned.

<table>
<thead>
<tr>
<th>Install All Posters</th>
<th>Wednesday, April 26, 2017</th>
<th>8:00 am - 5:00 pm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Poster Session I</td>
<td>Thursday, April 27, 2017</td>
<td>10:15 am - 12:15 pm</td>
</tr>
<tr>
<td>Odd Poster #’s 625-935</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Poster #’s 002-312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odd Late-Breaking Poster #’s 987-1007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Late-Breaking Poster #’s 936-960</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selected ePoster Discussions I</td>
<td>Thursday, April 27, 2017</td>
<td>10:45 am - 11:45 am</td>
</tr>
<tr>
<td>See Page #46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Session II</td>
<td>Friday, April 28, 2017</td>
<td>11:30 am - 1:30 pm</td>
</tr>
<tr>
<td>Odd Poster #’s 001-311</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Poster #’s 314-624</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odd Late-Breaking Poster #’s 937-959</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Late-Breaking Poster #’s 962-984</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selected ePoster Discussions II</td>
<td>Friday, April 28, 2017</td>
<td>12:00 pm - 1:00 pm</td>
</tr>
<tr>
<td>See Page #65</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Session III</td>
<td>Saturday, April 29, 2017</td>
<td>10:15 am - 12:15 pm</td>
</tr>
<tr>
<td>Odd Poster #’s 313-623</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Poster #’s 626-934</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odd Late-Breaking Poster #’s 961-985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Late-Breaking Poster #’s 986-1008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selected ePoster Discussions III</td>
<td>Saturday, April 29, 2017</td>
<td>10:45 am - 11:45 am</td>
</tr>
<tr>
<td>See Page #91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dismantle All Posters</td>
<td>Saturday, April 29, 2017</td>
<td>12:15 pm - 1:00 pm</td>
</tr>
</tbody>
</table>
## Wednesday Sessions

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>Meeting-at-a-Glance</td>
</tr>
<tr>
<td>22</td>
<td>International Pachyonychia Congenita Consortium Meeting (IPCC)</td>
</tr>
<tr>
<td>23</td>
<td>Pan-Pacific Skin Barrier Symposium (PAPSBRS)</td>
</tr>
<tr>
<td>24</td>
<td>American Acne &amp; Rosacea Society (AARS)</td>
</tr>
<tr>
<td>25</td>
<td>Translational Science Symposium</td>
</tr>
<tr>
<td>29</td>
<td>Irvin H. Blank Forum</td>
</tr>
<tr>
<td>31</td>
<td>State-of-the-Art Plenary Lecture I &amp; II / President’s Welcome</td>
</tr>
<tr>
<td>32</td>
<td>American Skin Association (ASA Awards)</td>
</tr>
<tr>
<td>33</td>
<td>Dermatology Foundation</td>
</tr>
<tr>
<td>34</td>
<td>Albert M. Kligman/Phillip Frost Leadership Lecture</td>
</tr>
</tbody>
</table>
Welcome Reception

Wednesday, April 26, 2017                      7:05 pm - 8:30 pm                      Oregon Ballroom Lobby
                                             Oregon Convention Center

All attendees are invited to join us for a Welcome Reception to kick off the 2017 SID Annual Meeting! Gather with your colleagues at the Oregon Convention Center immediately following the last session of the day for cocktails and light snacks.

This event is free of charge, beverage tokens can be found in your meeting registration packet.
### Meeting-At-A-Glance

#### WEDNESDAY, APRIL 26, 2017

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Pachyonychia Congenita Consortium (IPCC) Meeting 2017</td>
<td>8:00 am – 1:00 pm</td>
<td>C123-124</td>
</tr>
<tr>
<td>Resident/PhD Retreat Breakfast</td>
<td>By Invitation Only</td>
<td>7:00 am – 8:00 am</td>
</tr>
<tr>
<td>Resident Retreat Program Session</td>
<td>By Invitation Only</td>
<td>7:15 am – 12:00 pm</td>
</tr>
<tr>
<td>PhD Retreat Program Session</td>
<td>By Invitation Only</td>
<td>7:15 am – 12:00 pm</td>
</tr>
<tr>
<td>Registration</td>
<td>8:00 am – 7:00 pm</td>
<td>Pre-Function A Foyer</td>
</tr>
<tr>
<td>Pan-Pacific Skin Barrier Symposium (PAPSBRS)</td>
<td>9:00 am – 4:30 pm</td>
<td>A105-106</td>
</tr>
<tr>
<td>American Acne and Rosacea Society (AARS)</td>
<td>12:00 pm – 3:00 pm</td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td>Translational Science Symposium</td>
<td>12:00 pm – 3:00 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irvin H. Blank Forum Building Team Science: Creating a Culture of Diversity and Inclusion</td>
<td>3:00 pm – 5:00 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>State-of-the-Art Plenary Lecture I Chimeric Immunoreceptor T cells for Pemphigus: Fighting Autoimmunity with Immunity Aimee Payne, MD/PhD</td>
<td>5:00 pm – 5:30 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>State-of-the-Art Plenary Lecture II Identification of Hair Shaft Progenitors that Create a Niche for Hair Pigmentation and Graying Lu Le, MD/PhD</td>
<td>5:30 pm – 6:00 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>President’s Welcome</td>
<td>6:00 pm – 6:15 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Angela Christiano, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>American Skin Association (ASA Awards)</td>
<td>6:15 pm – 6:30 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Dermatology Foundation</td>
<td>6:30 pm – 6:35 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Albert M. Kligman/Phillip Frost Leadership Lecture</td>
<td>6:35 pm – 7:05 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine Thomas S. Kupper, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>7:05 pm – 8:30 pm</td>
<td>Oregon Ballroom Lobby</td>
</tr>
</tbody>
</table>
International Pachyonychia Congenita Consortium (IPCC) Meeting 2017

New Horizons in Keratoderma Research

Wednesday, April 26, 2017  8:00 am - 1:00 pm  C123-124

8:00 am  Breakfast Buffet

Scanning the PC pain and itch horizons
Michael Polydefkis (Johns Hopkins Medicine, Baltimore)
Pain in PC – why is it a problem and what can we do about it?

9:30 am  Thomas Magin (University of Leipzig, Leipzig)
Keratins at the crossroads of itch and mechanotransduction.

10:00 am  Break

10:15 am  Special Guest Lecture – Howard Chang
(Stanford University, Stanford)
How does palmoplantar epidermis know that it is palmoplantar? Molecular mechanisms controlling development and maintenance of ridged skin.

11:00 am  Break

Towards new horizons – brainstorming session
Group discussion
Themes: Pain in PC
Therapeutic tractability of PPKs – what are the low-hanging fruit?
Drug repurposing in PPKs – genes and screens
Oligonucleotide therapeutics for PPKs
2018 meeting – onwards and upwards

12:30 pm  Box lunch available and discussion continues

1:00 pm  Close of meeting

OPEN TO ALL MEETING ATTENDEES  CME CREDITS: 0
8TH PAN-PACIFIC SKIN BARRIER SYMPOSIUM (PAPSBRS)

Wednesday, April 26, 2017 9:00 am – 4:30 pm A105-106

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td>WELCOME</td>
<td>Drs. Peter M. Elias (VA Med Ctr/UCSF) and Seung Hun Lee (Yonsei U)</td>
<td></td>
</tr>
<tr>
<td>9:15 am</td>
<td>Plenary Talk #1</td>
<td>Eicosanoid derivatives in ichthyosis vulgaris and atopic dermatitis</td>
<td>Dr. M. Schmuth (Innsbruck, AT)</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Platform #1</td>
<td>Mutations in the Epidermal Fatty Acid and Ceramide Metabolic Pathway Reveal Functions of the CLE</td>
<td>Dr. D. Crumrine (UCSF)</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Platform #2</td>
<td>Cellular and metabolic basis for the ichthyotic phenotype in ichthyn deficiency</td>
<td>Dr. E. Mauldin, DVM (UPenn)</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Platform #3</td>
<td>Cold-sensing ameliorated ichthyosis in a patient with Dorfman-Chanarin syndrome</td>
<td>Dr. K. Nakajima (Kochi Med Sch)</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Plenary Talk #2</td>
<td>ABO blood type sugars in brick and mortar</td>
<td>Dr. J-H Chung (Seoul Natl U)</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Platform #4</td>
<td>ER stress regulates epidermal tight junction and PPARalpha activation attenuates ER stress-induced unfolded protein response and TJ damage in cultured keratinocytes</td>
<td>Dr. S.E. Lee (Yonsei Univ)</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>LUNCH BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>Plenary Talk #3</td>
<td>Physiochemical studies of epidermal barrier homeostasis</td>
<td>Dr. M. Denda (Shisheido)</td>
</tr>
<tr>
<td>12:00 pm</td>
<td>Platform #5</td>
<td>3 dimensional ultrastructural analysis of lamellar granules in stratum granulosum by focused ion beam scanning electron microscopy</td>
<td>H. Yamanishi, MSc (Shisheido)</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Platform #6</td>
<td>New insights for skin barrier function analysis: an in vivo quantitative approach through confocal microscopy coupled to image processing</td>
<td>Dr. C. Mainzer (Silab)</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>LUNCH BREAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Platform #7</td>
<td>The ratio of sphingosine to sphinganine in the SC determines lipid lamellar structure packing</td>
<td>Dr. Y. Obata (Hoshi U)</td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Plenary Talk #4</td>
<td>Stratum corneum acidification and its potential clinical application</td>
<td>Dr. E.H. Choi (Yonsei U Wonju)</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Plenary Talk #5</td>
<td>Cutaneous biological responses to external stimuli</td>
<td>Dr. K. Kabashima (Kyoto U)</td>
</tr>
<tr>
<td>2:15 pm</td>
<td>Platform #8</td>
<td>Ilbeta-hydroxysteroid dehydrogenase 1 expression in the skin might have a role in the occurrence of AD</td>
<td>Dr. S.J. Choe (Yonsei U Wonju)</td>
</tr>
<tr>
<td>2:30 pm</td>
<td>Platform #9</td>
<td>Incomplete secretion of KLK7 and upregulated LEKTI are related to hyperkeratosis in stratum corneum in AD</td>
<td>Dr. M. Kishibe (Asahikawa Med U)</td>
</tr>
<tr>
<td>2:45 pm</td>
<td>Platform #10</td>
<td>A randomized trial of a barrier lipid replacement strategy for the prevention of atopic dermatitis and allergic sensitization: PEBBLES pilot study</td>
<td>Dr. A. Lowe (U Melbourne, AU)</td>
</tr>
<tr>
<td>3:15 pm</td>
<td>Plenary Talk #6</td>
<td>Links between barrier function, S. aureus colonization, and Th2 inflammation</td>
<td>Dr. R. Gallo (UC San Diego)</td>
</tr>
<tr>
<td>3:30 pm</td>
<td>Meeting Summary</td>
<td></td>
<td>Dr. W. Holleran</td>
</tr>
<tr>
<td>3:45 pm</td>
<td>COFFEE AND POSTER DISCUSSION</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
American Acne & Rosacea Society

Wednesday, April 26, 2017 12:00 pm – 3:00 pm Oregon Ballroom 203

Register NOW online at: https://acneandrosacea.org/AARS-6th-SID-Symposium

12:00 pm  Welcome and AARS Announcements
Diane Thiboutot, MD, AARS Past President, Hershey, PA, USA

12:15 pm  Global Skin Disease Morbidity and Mortality: An Update from the Global Burden of Disease Study 2013, Chante Karimkhani Aksut, MD, University of Colorado, Department of Dermatology, Aurora, CO, USA. Abstract #181

12:30 pm  Inflammatory Gene Expression in Keratinocytes Is Regulated by HAC8 and HDAC9 and Is Modulated by Metabolites from the Microbiome, James Sanford, PhD, University of California, San Diego, San Diego, CA, USA. Abstract #586

12:45 pm  Phenotype and Functions of Ribotype-Specific Th17 Cells Targeted Propionibacterium Acnes, George Agak, PhD, University of California, Los Angeles, Los Angeles, CA, USA. Abstract #601

1:00 pm  SIG-1459 and SIG-1460: Novel Anti-Acne Phytyl-Cysteine Compounds, Edwardo Perez, PhD, Signum Biosciences, Inc., Princeton, NJ, USA. Abstract #641

1:15 pm  Rosacea Associated with Increased Prevalence of Gastrointestinal Disorders in Absence of Systemic Antibiotics, Hester Gail Lim, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Abstract #175

1:30 pm  Increased LL-37 and KLK5 Expression in Conjunctival Epithelium Associated with Ocular Rosacea Severity, Noori Kim, MD, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Abstract #610

1:45 pm  Influence of Bovine Milk Oligosaccharides on Sebocyte Lipid Content and Inflammatory Mediators, Raja Sivamani, MD, University of California, Davis, Davis, CA, USA. Abstract #878

2:00 pm  Development of a Novel Self-Administered Screening Tool for Early Identification of Hidradenitis Suppurativa, Virginia Moye, MD,MPH, Brown University, Providence, RI, USA. Abstract #166

2:15 pm  iPledge Disproportionately Affects Women, Minorities, and Low-Income Patients: A Retrospective Cohort Study, Fan Di Xia, AB, Harvard Medical School, Boston, MA, USA. Abstract #384

2:30 pm  Acne Core Outcomes Research Network (ACORN) Reaches Consensus on Outcomes to Measure, Diane Thiboutot, MD, AARS Past President, Penn State University College of Medicine, Hershey, PA, USA. Abstract #338

2:45 pm  Closing Comments
Sewon Kang, MD, AARS Immediate Past President, Baltimore, MD, USA

*Presentation times and topics are subject to change.*

Visit www.acneandrosacea.org for more information about the AARS and its membership!

(888) 744-DERM (3376) • info@aarsmember.org
Translational Science Symposium

Bridging the Valley of Death: Moving Technologies from the Lab to the Clinic

Wednesday, April 26, 2017  12:00 pm - 3:00 pm  Oregon Ballroom 201-202

12:00 pm  Opening Remarks
William Ju, MD and Patricia S. Walker, MD/PhD

Keynote Lecture
Introduction: Joseph Carroll, PhD

12:10 pm  Brian J. Druker, MD
Imatinib as a Paradigm of Targeted Cancer Therapies

Opening Lectures
Moderator: Patricia S. Walker, MD/PhD

12:35 pm  Joseph Carroll, PhD
Demystifying Tech Transfer

12:50 pm  Steven J. Prewitt
Creating Intellectual Property

1:05 pm  Real Life Stories
Moderator: William Ju, MD

Panelists:
R. Rox Anderson, MD
George Cotsarelis, MD
Richard Gallo, MD/PhD
Barbara Gilchrest, MD
Michael Girardi, MD
Aimee Payne, MD/PhD
Stuart Shanler, MD
David Woodley, MD

1:50 pm  Shark Tank: Making your Pitch: What do investors/partners look for when evaluating a University-based technology?
Moderator: Neal Walker, DO

Shark Tank Team #1
Shark Tank Team #2
Shark Tank Team #3

Panelists:
Frederick Beddingfield, MD/PhD
Joseph Carroll, PhD
John Doux, MD
William Ju, MD
Donna See
Patricia S. Walker, MD/PhD

Closing Lectures
Moderator: William Ju, MD

2:20 pm  Donna See
Unicorn Hunting: How do academic researchers begin?

2:35 pm  John Doux, MD
What Now?

2:50 pm  Concluding Remarks
William Ju, MD and Patricia S. Walker, MD/PhD

CONTINUED
**CONTINUED: Translational Science Symposium**

**Wednesday, April 26, 2017**

**12:00 pm – 3:00 pm**

**Oregon Ballroom 201-202**

---

**R. Rox Anderson, MD**

Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in Dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. Dr. Anderson’s research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. In addition to research at the Wellman Center, he practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.

**Frederick Beddingfield III, MD/PhD**

Frederick Beddingfield III, MD/PhD is CEO of Sienna Biopharmaceuticals, Inc, a company focused on developing breakthrough products in aesthetics and dermatology. He is also a board-certified dermatologist and dermatologic surgeon. Dr. Beddingfield served as Chief Medical Officer of Kythera Biopharmaceuticals from March 2013 until it was acquired by Allergan in October 2015. Prior to his appointment at Kythera, he held the role of Vice President and Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. Dr. Beddingfield led the development of premier products in the dermatology and aesthetics industry, including KYBELLA®, BOTOX® Cosmetic, JUVEDERM XC®, VOLUMA XC®, and LATISSE®, all market-leading aesthetic treatments in their respective categories. During his tenure at Allergan, Dr. Beddingfield also led programs in acne, rosacea, scarring, hyperhidrosis, and hair loss. Dr. Beddingfield earned an MD Degree with Honors from the University of North Carolina and a PhD in Policy Analysis from RAND Graduate School of Policy Studies.

**Joseph Carroll, PhD**

Dr. Carroll received his PhD in Molecular and Cellular Biology at SUNY-Stony Brook in 1992. He has a background in commercializing and translating genomic technologies in various disease settings. Over his IS year career initiating and managing research efforts in biopharma and biotech, Dr. Carroll has held management positions in companies such as Genetics Institute, Wyeth, Millennium Pharmaceuticals, and Sirna Therapeutics. Dr. Carroll moved back to the academic sector in 2008 (Univ of Colorado), and the Biomedical Diagnostics Inst (Dublin, Ireland) to facilitate greater academic-industry interactions. In his role managing business development for the Knight Cancer Institute, where he helps establish key alliances, partnerships and new ventures.

**George Cotsarelis, MD**

Dr. Cotsarelis received his B.A. and M.D. from the University of Pennsylvania, and did his dermatology residency at Penn. After a Dermatology Foundation Research award and a Howard Hughes Medical Institute Postdoctoral Research Fellowship for Physician Scientists, he joined the faculty at Penn as an Assistant Professor of Dermatology in 1996. He was promoted to Full Professor in 2009, and then was appointed as Milton B Hartzell Professor of Dermatology and Chairman of the Department in 2010. Through his research on epithelial stem cells, Dr. Cotsarelis has impacted dermatology through the launching of the hair follicle stem cell field and his work resulted in understanding the pathogenesis of alopecias. The resulting work has showed that stem cells are destroyed in scarring alopecia, but are still retained in male pattern baldness.

**John Doux, MD**

John Doux is a board certified dermatologist. He obtained his B.S. degree and M.D. from Stanford University, where he was a Howard Hughes Medical Institute Fellow. He completed an M.B.A. at the Wharton School of Business where he was a Palmer Scholar. Since 2004 he has served as an analyst at Palo Alto Investors, an investment fund specializing in healthcare.

**Brian J. Druker, MD**

Dr. Druker is Director of the Knight Cancer Institute at Oregon Health & Science University (OHSU), JELD-WEN Chair of Leukemia Research, and an Investigator of the Howard Hughes Medical Institute. Upon graduating from the University of California, San Diego School of Medicine in 1981, Dr. Druker completed his internship and residency in internal medicine at Barnes Hospital, Washington School of Medicine in St. Louis, Missouri. He trained in oncology at Harvard’s Dana-Farber Cancer Institute and then returned to the lab to begin his research career studying the regulation of the growth of cancer cells and its practical application to cancer therapies. Dr. Druker’s role in the development of imatinib and its application in the clinic has resulted in numerous awards for Dr. Druker, including the Warren Alpert Prize from Harvard Medical School, the 2009 Lasker-DeBakey Award for Clinical Medical Research, the Japan Prize in Healthcare and Medical Technology and the Albany Medical Center Prize in Medicine and Biomedical Research. He was elected to the Institute of Medicine of the National Academies in 2003, the American Association of Physicians in 2006, the National Academy of Sciences in 2007, and the American Academy of Arts and Sciences in 2012.

CONTINUED
CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017 12:00 pm – 3:00 pm Oregon Ballroom 201-202

Richard L. Gallo, MD/PhD
Richard L. Gallo, MD/PhD, is Professor of Medicine and Pediatrics, and Chair for the Department of Dermatology at the University of California, San Diego. His research focuses on the role of the innate immune system in skin health and disease, focusing on antimicrobial peptides and aspects of the basic functions of the skin immune system. He has contributed several landmark observations to the field of Dermatology including the first description of an antimicrobial peptide in mammalian skin, the first demonstration that mammals depend on antimicrobial peptides for defense against infection, and the first association of a human diseases (atopic eczema and Rosacea) with a defect in antimicrobial peptide production. His work has been seen in some of the most prestigious scientific and medical journals and is well supported by grants from the NIH, the Veterans Administration, and private foundations. Dr. Gallo trained in Dermatology at Harvard Medical School where he also completed a post-doctoral fellowship in Cell and Developmental Biology. He received his MD degree at the University of Rochester, where he also received his PhD in Radiation Biology and Biophysics. Prior to Dermatology Dr. Gallo trained in Pediatrics at Johns Hopkins Hospital.

Barbara Gilchrest, MD
Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS. From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post-doctoral research training program. In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and HMS. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; the Editor of the Journal of Investigative Dermatology, as Associate Editor or editorial board member of several other major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors.

Michael Girardi, MD
Dr. Girardi is Professor, Vice Chair, and the Residency Program Director for the Department of Dermatology of the Yale School of Medicine. Dr. Girardi graduated magna cum laude with degrees in Biology and Computer Science from Brown University, and from the Yale School of Medicine with the Honors. He has a broad research experience in cutaneous carcinogenesis and cutaneous immunology, funded by the National Cancer Institute for more than 15 years. His laboratory is credited with major contributions to our understanding of cutaneous immunoregulation of skin cancer, including the relative contributions of gamma-delta T cells, NKG2D ligands, innate lymphoid cells, Langerhans cells, and genetic drivers of cutaneous lymphoma. Dr. Girardi has served as the Co-Director for the Yale Comprehensive Cancer Center’s Immunology and Immunotherapy Program, and is currently the Director of the Photopheresis and Phototherapy Unit. Dr. Girardi holds 4 biomedical patents on skin delivery of therapeutics including novel strategies for skin cancer prevention and treatment, and the efficient and global activation of monocytes for immunotherapy.

William Ju, MD
Dr. Ju is a board-certified dermatologist with over 20 years of experience in the biopharmaceutical industry within a wide variety of therapeutic areas (including dermatology), and in a broad range of entities at different stages of organizational development. This includes leadership positions in business startups to Fortune 100 companies and in nonprofits. Dr. Ju is currently President and a founding trustee of Advancing Innovation in Dermatology, Inc.

Aimee Payne, MD/PhD
Dr. Payne is an Albert M. Kligman Associate Professor of Dermatology at University of Pennsylvania. She obtained her BS in Biology from Stanford University and received her MD/PhD (Molecular and Cellular Biology) Degrees from Washington University School of Medicine in St. Louis. Her career interest has been in pemphigus: diagnosing and treating patients with this potentially fatal autoimmune disease, and performing research to understand what causes disease, with the goal of improving therapy. Her laboratory has contributed to 5 major areas of investigation: 1) cloning and characterization of B-cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; 3) collaborative research to advance clinical trials in autoimmune blistering disease; 4) clinical studies to better understand current diagnostic tests and therapies; and 5) translational research to develop novel targeted therapies. In addition to her research activities, she is a board certified dermatologist with a special focus on autoimmune blistering skin diseases.
CONTINUED:

Translational Science Symposium

Wednesday, April 26, 2017       12:00 pm – 3:00 pm Oregon Ballroom  201-202

Steven J. Prewitt

Steven Prewitt is Schwabe's Intellectual Property Service Group Leader and a member of the firm's Technology Industry Group. He guides companies and research institutions through the technology development, protection, commercialization and enforcement life cycle to maximize the value of their intellectual property. Having drafted and prosecuted over 500 utility and design patent applications in more than 17 years of practice, Mr. Prewitt has a deep understanding of the value of technology as a critical business asset, and what it takes to effectively protect that asset. He has a diverse technical background, which includes biotechnology, medical devices, mechanical devices, and software technology. He holds a B.A. in Biology from the University of Virginia and a J.D. from George Mason University School of Law.

Donna See

Donna has over 15 years of experience in technology commercialization, as an investor, founder, and advisor to dozens of start-ups in the life sciences and technology sectors. Donna is currently a Vice President at Allied Minds, a publicly-traded venture capital firm, and Vice President of Allied-Bristol Life Sciences, a joint venture between Allied Minds and Bristol-Myers Squibb. She leads Allied Minds’ pipeline development, overseeing scouting, diligence, and founding of new ventures based on intellectual property created by Allied Minds’ network of over 160 university and federal lab partners. She currently serves as an advisor, mentor, or reviewer to technology development and translational funds at several universities, including the University of California at Davis, University of Southern California, Emory University, Georgia Tech, Columbia University, and the University of Michigan. Donna previously served as the Director of Licensing and Director of Strategic Initiatives for Columbia Technology Ventures, an internationally-recognized leader in the field of university tech transfer. Prior to Columbia, Donna was a Director of Business Development and Technology Transfer at New York-Presbyterian Hospital, forging strategic alliances with government and industry partners to evaluate, develop, and adopt healthcare innovations. She also spent over a decade in global and domestic public health, working with the World Bank, Centers for Disease Control, and other public and private sector organizations to improve health care access, delivery, and quality. Donna received her MBA from Columbia Business School and her MPH in Health Policy & Management from Columbia University's School of Public Health. She holds a BA in the Natural Sciences from The Johns Hopkins University.

Stuart Shanler, MD

Stuart D. Shanler, M.D. co-founded Aclaris Therapeutics, Inc. and has served as their Chief Scientific Officer since their inception in July 2012. Between July 2011 and July 2012, Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his M.D. degree from Albany Medical College of Union University and received B.S. degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

Neal Walker, DO

Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the pharmaceutical industry. He served as a consultant to a number of pharmaceutical companies, co-founded and served as President and Chief Medical Officer and a member of the board of directors of Vicept Therapeutics, a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan. Previously, Dr. Walker co-founded and led a number of life science companies including Octagon Research Solutions, Trigenesis Therapeutics, and Cutix.

Patricia S. Walker, MD/PhD

Dr. Walker is a Board-Certified Dermatologist and Pharmaceutical industry expert specializing in the fields of medical and aesthetic dermatology. Dr. Walker previously served as Chief Medical Officer of Kythera Biopharmaceuticals, Inc. and also was Executive Vice President and Chief Science Officer at Allergan Medical. From 1997 to 2004, Dr. Walker held positions at Allergan Inc. where she ultimately served as Vice President, Clinical Research and Development for skin care pharmaceuticals. Over the past 10 years, Dr. Walker was involved in key product approvals in dermatology and aesthetic medicine including the development and approval of Tazorac®, Azelaic®, Avegic®, BOTOX® Cosmetic, Hylaform®, Captique®, JUVEDERM®, Biocenterics®, LAP-BAND® and Inamed® Silicone gel-filled Breast Implants, and Kybella. Dr. Walker received an M.D. and a PhD in Physiology and Biophysics from the University of Iowa. Dr. Walker completed a residency in Dermatology and a research fellowship in the Dermatology Branch, National Cancer Institute at the National Institute of Health. Dr. Walker also maintains a private practice.

David Woodley, MD

Dr. Woodley completed his undergraduate degree in English Literature at Washington University in St. Louis and his medical school education at the University of Missouri in Columbia, Missouri. He completed his dermatology residency training at the University of North Carolina in Chapel Hill, North Carolina. He left Chapel Hill in 1989 to be Professor and Associate Chair of the Department of Dermatology at Stanford University. In 1992, he was appointed the Walter Hemin Professor and Chair of Dermatology at Northwestern University. In 1999, he joined the medical faculty at the Keck School of Medicine of the University of Southern California (USC) and in 2004, he was named as the Founding Chair of the USC Department of Dermatology. He is the author of over 200 original articles and is a clinician-investigator with continuous NIH funding since 1992.
Irvin H. Blank Forum

Building Team Science: Creating a Culture of Diversity and Inclusion

Wednesday, April 26, 2017   3:00 pm – 5:00 pm   Oregon Ballroom 201-202

3:00 pm  Welcome and Framing the Challenges

Barbara Gilchrest, MD

Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS. From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post-doctoral research training program. In 2015 she joined the Department of Dermatology at the Massachusetts General Hospital and HMS. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute; the Editor of the Journal of Investigative Dermatology, as Associate Editor or editorial board member of several other major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005). Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the National Academy of Medicine, and a Charter member of the National Academy of Inventors.

3:10 pm  The NIAMS Perspective

Susana Serrate-Sztein, MD

Dr. Serrate-Sztein is responsible for the Division of Skin and Rheumatic Diseases at the National Institute of Arthritis and Musculoskeletal and Skin Diseases. She oversees a large portfolio of grants and contracts dealing with etiology, pathogenesis, diagnosis, treatment and prevention of skin and rheumatic diseases. Dr. Serrate-Sztein also directed the Common Fund Initiative on Patient Reported Outcomes Measurement Information Systems (PROMIS) and the National Institutes of Health (NIH) component of the ongoing private public partnership Accelerating Medicines Partnership (AMP) in rheumatoid arthritis and lupus. Between 1990 and 1993, Dr. Serrate-Sztein was Chief, Autoimmunity Section, Division of Allergy Immunology and Transplantation, National Institute of Allergy and Infectious Diseases where she managed a scientific portfolio dealing with basic and translational research on immune mediated diseases. Before joining the NIH, Dr. Serrate-Sztein was Assistant Professor, Department of Pathology, Uniformed Services University of the Health Sciences, in Bethesda Maryland where she worked on cytokine regulation of cell mediated immune responses. She received postdoctoral training at the laboratory of Immunodiagnosis, National Cancer Institute where she worked on natural killer cell activity against breast tumors in mice. Her clinical training is on anatomic and clinical pathology. Dr. Serrate-Sztein is a graduate of Buenos Aires University School of Medicine.

3:20 pm  Understanding and Counteracting Implicit Bias

Kimberly Kahn, PhD

Dr. Kimberly Barsamian Kahn is an Assistant Professor of Social Psychology at Portland State University. She received her PhD in Social Psychology from the University of California, Los Angeles. Dr. Kahn’s research addresses contemporary forms of implicit bias and subtle prejudice. Her work moves beyond studying broad categorical distinctions between groups to provide a more nuanced and fine-grained analysis of modern prejudice, stereotyping, and discrimination. Using experimental social psychological methods with diverse samples, her work addresses the psychological effects of subtle bias from multiple perspectives: the perceivers’ perspectives, the targets’ perspectives, and the social context.

CONTINUED ON NEXT PAGE
CONTINUED:

Irvin H. Blank Forum

Building Team Science: Creating a Culture of Diversity and Inclusion

Wednesday, April 26, 2017  3:00 pm – 5:00 pm  Oregon Ballroom 201-202

3:40 pm  Brian Gibbs, PhD/MPA

Diversity in Research: Challenges & Opportunities

Dr. Brian Gibbs serves as Vice President for Equity and Inclusion at Oregon Health & Science University (OHSU). In this position he serves as the chief diversity officer for the University, overseeing the Center for Diversity & Inclusion (CDI) and is responsible for diversity initiatives within the clinical, educational, and research missions.

4:00 pm  Charlene E. Le Fauve, PhD

Enhancing Diversity in the Scientific Workforce: An Opportunity and Imperative for Excellence

Charlene E. Le Fauve, PhD, became the first Senior Advisor to the National Institutes of Health (NIH) Chief Officer for Scientific Workforce Diversity (COSWD) in December 2016. In this role, Dr. Le Fauve supports Dr. Hannah Valantine who serves as the NIH COSWD as she leads NIH's effort to diversify the biomedical research workforce by developing a vision and comprehensive strategy to expand recruitment and retention, and promote inclusiveness and equity throughout the biomedical research enterprise. Dr. Le Fauve came to COSWD from the National Institute of Mental Health (NIMH) where she served as Deputy Director of the Office for Research on Disparities & Global Mental Health. Prior to joining NIMH, she was a Senior Policy Coordinator at the Department of Health and Human Services and also served as Branch Chief for the Co-occurring and Homeless Activities Branch at the Substance Abuse and Mental Health Services Administration, Division of State and Community Assistance. Before entering federal service, she served as an Assistant Professor of Human Genetics and Psychiatry at the Medical College of Virginia (MCV), Virginia Commonwealth University (VCU), with an adjunct position in the Department of Community Health and Preventive Medicine. Dr. Le Fauve studied clinical psychology and behavioral medicine at the University of Georgia after completing her undergraduate education at Howard University.

4:20 pm  Caroline Simard, PhD

Creating Inclusive Workplaces: See Bias, Block Bias

Caroline Simard is passionate about building better workplaces through evidence-based solutions. As Senior Director of Research at Stanford’s Center for Advancement of Women’s Leadership in the Clayman Institute of Gender Research, she is responsible for leading research designed to build more effective and inclusive organizations. Previously, she was Associate Director of Diversity and Leadership at the Stanford School of Medicine, where she implemented innovative models for increasing work-life integration to increase faculty satisfaction and retention. Prior to joining Stanford University, Caroline was Vice President of Research and Executive Programs at the Anita Borg Institute (ABI) for Women and Technology, where she led the creation and dissemination of research-based solutions to further gender diversity in scientific and technical careers, working with leading technology companies and academic institutions. Prior to ABI, Simard was a Researcher at the Center for Social Innovation of the Stanford Graduate School of Business and an Associate Director of Executive Programs. Caroline holds a PhD from Stanford University and a Masters from Rutgers University. Her publications have focused on technical human and social capital, solutions to recruit, retain, and advance women in technology, underrepresented minority talent in STEM, the diffusion of best practices, open innovation, and social networks.

4:40 pm  Closing Remarks

Barbara Gilchrest, MD and Susana Serrate-Sztein, MD
STATE-OF-THE-ART PLENARY LECTURES

LECTURE I

*Chimeric Immunoreceptor T cells for Pemphigus: Fighting Autoimmunity with Immunity*

Wednesday, April 26, 2017    5:00 pm – 5:30 pm     Oregon Ballroom 201-202

Introduction by: Lloyd Miller, MD/PhD
Aimee Payne, MD/PhD
University of Pennsylvania, Philadelphia, PA

Dr. Payne is an Albert M. Kligman Associate Professor of Dermatology at University of Pennsylvania. She obtained her BS in Biology from Stanford University and received her MD/PhD (Molecular and Cellular Biology) Degrees from Washington University School of Medicine in St. Louis. Her career interest has been in pemphigus: diagnosing and treating patients with this potentially fatal autoimmune disease, and performing research to understand what causes disease, with the goal of improving therapy. Her laboratory has contributed to 5 major areas of investigation: 1) cloning and characterization of B-cell repertoires to understand how autoimmunity occurs in pemphigus, a model autoantibody-mediated skin blistering disease; 2) cell biologic studies to understand mechanisms for loss of cell adhesion; 3) collaborative research to advance clinical trials in autoimmune blistering disease; 4) clinical studies to better understand current diagnostic tests and therapies; and 5) translational research to develop novel targeted therapies. In addition to her research activities, she is a board certified dermatologist with a special focus on autoimmune blistering skin diseases.

LECTURE II

*Identification of Hair Shaft Progenitors that Create a Niche for Hair Pigmentation and Graying*

Wednesday, April 26, 2017    5:30 pm – 6:00 pm    Oregon Ballroom 201-202

Introduction by: Kevin Wang, MD/PhD
Lu Le, MD/PhD
UT Southwestern Medical Center, Dallas, TX

Dr. Le is a Dermatologist with a scientific focus on neural-crest derived tissue development, regeneration and tumorigenesis, in particular the biology of neurofibromatosis. He graduated from the Medical Scientist Training Program at UCLA and completed residency training in Dermatology and a postdoctoral fellowship in Cancer Biology from UT Southwestern Medical Center. He is currently an Associate Professor and holds the Thomas L. Shield, MD Professorship in Dermatology at UT Southwestern.

OPEN TO ALL MEETING ATTENDEES

CME CREDITS: 1.0

PRESIDENT’S WELCOME

*Angela Christiano, PhD*

Wednesday, April 26, 2017    6:00 pm – 6:15 pm    Oregon Ballroom 201-202
American Skin Association  
(ASA Awards)  

Wednesday, April 26, 2017  6:15 pm – 6:30 pm  Oregon Ballroom 201-202

David Martin Carter Mentor Award  
ASA’s David Martin Carter Mentor Award honors a member of the dermatology community who embodies the characteristics of the late David Martin Carter, MD/PhD that made him an inspiration to many dermatologists/investigators, colleagues and medical students throughout the world.

American Skin Association is delighted to present its’ 2017 David Martin Carter Mentor Award to:

Richard L. Edelson, MD  
Yale School of Medicine

Research Achievement Awards  
Instituted in 1989 to identify established scientists in investigative dermatology and cutaneous biology and to recognize those who have greatly advanced work related to autoimmune and inflammatory skin diseases, skin cancer and melanoma, psoriasis, public policy and medical education, or vitiligo and pigment cell disorders.

American Skin Association is delighted to present its’ 2017 Research Achievement Awards to:

Robert E. Tigelaar, MD  
Yale School of Medicine  
Research Achievement Award in Autoimmune & Inflammatory Skin Disorders

James G. Krueger, MD/PhD  
Rockefeller University  
Research Achievement Award in Psoriasis Research

Ruth Halaban, PhD  
Yale School of Medicine  
Research Achievement Award in Melanoma and Skin Cancer

Zalfa Abdel-Malek, PhD  
University of Cincinnati Cancer Institute  
Research Achievement Award in Vitiligo and Pigment Cell Biology

Henry W. Lim, MD  
Henry Ford Health System  
Research Achievement Award in Public Policy & Medical Education
The Foundation for all of Dermatology

For over fifty years, the Dermatology Foundation has been a major force in the development of the specialty’s academic and scientific base.

The DF identifies and launches the early careers of promising new teachers, researchers and mentors in all aspects of the specialty, enabling advancements in patient care. With DF support, these individuals have the opportunity to begin the work needed to make major contributions to the specialty.

Earlier this year, the Foundation was proud to fund nearly $2.6 million in research awards for 52 promising individuals.

Challenging Times

It is a very difficult time to pursue an investigative career in dermatology. While recently increased, NIH research funding in “real dollars” remains well below the level of support provided in 2003. New investigators are finding it tremendously discouraging to begin careers in the specialty, making the need for DF support urgent.

The Dermatology Foundation plays a crucial role in supporting and retaining emerging thought leaders. The DF’s early career research awards enable today’s newest generation of physician scientists to gain the experience and data needed to compete successfully for NIH grants.

DF support is effective in retaining tomorrow’s leaders. Nearly 80% of all career development awardees have remained in academics, and 74% of these individuals received federal funding.

Individual Support is Essential

The need for DF research funding is critical and ongoing. Individual member support directly impacts the Foundation’s ability to support tomorrow’s new teachers and researchers.

To become a member or increase your support, visit dermatologyfoundation.org. There are many giving opportunities—and every option is meaningful and effective.
Albert M. Kligman / Phillip Frost Leadership Lecture

Memory T Cells and Protective Immunity: Lessons from the Smallpox Vaccine

Wednesday, April 26, 2017          6:35 pm – 7:05 pm          Oregon Ballroom 201-202

Introduction by: Ervin Epstein, Jr., MD

Thomas S. Kupper, MD
Brigham and Women’s Hospital, Harvard Medical School
Boston, Massachusetts

Dr. Kupper is the Thomas B. Fitzpatrick Professor of Dermatology at Harvard Medical School, Chair of the Departments of Dermatology at Brigham and Women’s Hospital and the Dana Farber Cancer Institute, and Director of the Cutaneous Oncology Disease Center at the Dana Farber/Brigham and Women’s Cancer Center (DFBWCC). He cares for Cutaneous T Cell Lymphoma patients, and leads the Cutaneous Lymphoma Program at the DFBWCC. For the past 30 years, he has been funded by the NIH to study skin immunology, inflammation, and skin cancer. His past NIH grants include a MERIT award, a Transformative Research Award, and a Skin Specialized Program of Research Excellence (SPORE). He is a past president of the SID, and is a past Montagna (SID), Sulzberger (AAD), Kihei (JSID) and Touraine (ESDR) lecturer, as well as a past Rook Orator (BJD). He was the founding Director of the BWH Biomedical Research Institute, and is a member of the ASCI and AAP, and is an honorary member of the JSID, the Korean SID, and the Austrian Dermatologic Society. He has made a number of pivotal scientific discoveries regarding epidermal cytokines, T cell trafficking, and T cell recruitment to the skin. Over the past 10 years, a major focus of his work has been on understanding the generation, long term maintenance, and protective properties of CD8 antiviral memory T cells in skin and other tissues. These cells are central to protective immune memory and are an important mechanism of action for successful vaccines. Their dysfunction may underlie many inflammatory dermatologic diseases.

LECTURESHP HISTORY

Established in 2007 by Dr. Phillip Frost, the lectureship is intended to honor Dr. Albert M. Kligman, whose great commitment to dermatology and numerous contributions to the specialty has inspired generations of researchers and practitioners. The award is made to an individual in acknowledgment of significant contributions in the past five years to the understanding of structure and function of skin.
# Thursday Sessions

<table>
<thead>
<tr>
<th>PAGE</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>37</td>
<td>Meeting-At-A-Glance</td>
</tr>
<tr>
<td>38</td>
<td>Trainee/Faculty Breakfast</td>
</tr>
<tr>
<td>39</td>
<td>Pediatric Dermatology Research Alliance/Society for Pediatric Dermatology Session</td>
</tr>
<tr>
<td>40</td>
<td>International Transplant Skin Cancer Collaborative (ITSCC) Symposium</td>
</tr>
<tr>
<td>41</td>
<td>Plenary Session I</td>
</tr>
<tr>
<td>42</td>
<td>Eugene M. Farber Lecture</td>
</tr>
<tr>
<td>43</td>
<td>Naomi M. Kanof Lecture</td>
</tr>
<tr>
<td>44</td>
<td>Come See My Poster I</td>
</tr>
<tr>
<td>45</td>
<td>Clinical Scholars Program Session I</td>
</tr>
<tr>
<td>46</td>
<td>Selected ePoster Discussions I</td>
</tr>
<tr>
<td>47</td>
<td>Aclaris Sponsored Symposium</td>
</tr>
<tr>
<td>49</td>
<td>debra of America’s EB Symposium</td>
</tr>
<tr>
<td>50</td>
<td>Concurrent Mini-Symposium 1 Adaptive and Autoimmunity</td>
</tr>
<tr>
<td>51</td>
<td>Concurrent Mini-Symposium 2 Clinical Research: Pathophysiology and Therapeutics</td>
</tr>
<tr>
<td>52</td>
<td>Concurrent Mini-Symposium 3 Interdisciplinary Spotlight-Frontiers in Atopic Dermatitis</td>
</tr>
<tr>
<td>53</td>
<td>Concurrent Mini-Symposium 4 Pigmentation and Melanoma</td>
</tr>
<tr>
<td>54</td>
<td>Concurrent Mini-Symposium 5 Skin and Hair Developmental Biology</td>
</tr>
</tbody>
</table>
Social Event

Thursday, April 27, 2017 6:30 pm – 10:30 pm World Trade Center Portland

Join us on Thursday, April 27, 2017 from 6:30 pm - 10:30 pm at the World Trade Center (WTC) Portland. WTC is regarded as one of the city’s most elegant and spacious venues. This unique outdoor space is well known for providing a stunning ambiance, elegant backdrop and breathtaking views. On hand will be some of Portland’s most popular food trucks, as well as craft beer and regional Oregon wines to enjoy!

TICKETED EVENT: PRE-REGISTRATION REQUIRED: $75pp. For ticket availability please visit the registration desk in the Pre-Function A Foyer at the Oregon Convention Center.
# Meeting-At-A-Glance

**THURSDAY, APRIL 27, 2017**

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trainee/Faculty Breakfast</td>
<td>7:00 am – 8:00 am</td>
<td>B110-112</td>
</tr>
<tr>
<td><strong>Pediatric Dermatology Research</strong></td>
<td>7:00 am – 8:00 am</td>
<td>A105-106</td>
</tr>
<tr>
<td><strong>Alliance/Society for Pediatric Dermatology Session</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>International Transplant Skin Cancer Collaborative (ITSCC) Symposium</strong></td>
<td>7:00 am – 8:00 am</td>
<td>B117-119</td>
</tr>
<tr>
<td>Registration</td>
<td>7:30 am – 4:30 pm</td>
<td>Pre-Function A Foyer</td>
</tr>
<tr>
<td><strong>Plenary Session I</strong></td>
<td>8:00 am – 9:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td><strong>Eugene M. Farber Lecture</strong></td>
<td>9:00 am – 9:30 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>From Genetic Discovery To Personalized Outcomes In Psoriasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jonathan Barker, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Naomi M. Kanof Lecture</strong></td>
<td>9:30 am – 10:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Targeting the Epigenome in Cutaneous and Disseminated Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>James Bradner, MD</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Come See My Poster I</strong></td>
<td>10:00 am – 10:15 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Poster #'s 046, 072, 096, 106, 148, 647, 661, 671, 777, 813, 901, 921</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical Scholars Program Session I</strong></td>
<td>10:15 am – 12:00 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Base Pairs to Bedside-Personalized Medicine</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Poster Session I/Coffee Break</strong></td>
<td>10:15 am – 12:15 pm</td>
<td>Exhibit Hall A</td>
</tr>
<tr>
<td>Odd Poster #’s 625-935</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Poster #’s 002-312</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odd Late-Breaking Poster #’s 987-1007</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Late-Breaking Poster #’s 936-960</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Selected ePoster Discussions I</strong></td>
<td>10:45 am – 11:45 am</td>
<td>Exhibit Hall A Foyer</td>
</tr>
<tr>
<td>See Page #46</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Aclaris Sponsored Symposium</strong></td>
<td>12:00 pm – 1:45 pm</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>You Don’t Know JAK</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>debra of America’s EB Symposium</strong></td>
<td>12:00 pm – 2:00 pm</td>
<td>B117-119</td>
</tr>
<tr>
<td><strong>Concurrent Mini-Symposia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. Adaptive and Autoimmunity</td>
<td></td>
<td>Oregon Ballroom 204</td>
</tr>
<tr>
<td>2. Clinical Research: Pathophysiology and Therapeutics</td>
<td></td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td>3. Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis</td>
<td></td>
<td>B113-116</td>
</tr>
<tr>
<td>4. Pigmentation and Melanoma</td>
<td></td>
<td>A105-106</td>
</tr>
<tr>
<td>5. Skin and Hair Developmental Biology</td>
<td></td>
<td>C123-124</td>
</tr>
<tr>
<td><strong>Mini-Symposia Mixers</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Individual Concurrent Meeting Rooms</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Social Event</strong></td>
<td>6:30 pm – 10:30 pm</td>
<td>World Trade Center Portland</td>
</tr>
<tr>
<td>Ticketed Event: Pre-Registration Required</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Trainee/Faculty Breakfast

Thursday, April 27, 2017 7:00 am – 8:00 am B110-112

Throughout the years, the SID has encouraged meeting between Residents and Post-Doc Fellows. To continue this promotion of collegiality, the SID presents a Trainee/Faculty Breakfast - small group discussions in which senior and junior faculty Residents, Pre-Doctoral Students and Post-Doctoral Fellows-discuss issues in an informal atmosphere. These gatherings provide an opportunity to talk informally about subject matters of interest including research opportunities in dermatology, life in academia or how to combine clinical work with research.
PEDIATRIC DERMATOLOGY AT THE SID MEETING

Thursday, April 27, 2017  7:00 am – 8:00 am  A105-106

Coffee will be served

7:00 am  Welcome and Overview: Pediatric Dermatology at SID
Megha Tollefson, MD; Mayo Clinic

7:15 am  Something New Under the Sun for Tuberous Sclerosis Complex
Thomas Darling, MD/PhD; Professor and Chair of Dermatology, Uniformed Services University of the Health Sciences

7:40 am  Rare constitutional variants influence phenotype of somatic cutaneous vascular malformations
Jenna Streicher, MD, et al.; Children’s Hospital of Philadelphia.
Abstract #483

7:50 am  Discussion and Concluding Remarks

Special thanks to the Pediatric Dermatology Research Alliance (PeDRA) and the Society for Pediatric Dermatology (SPD) for supporting this session.
International Transplant Skin Cancer Collaborative (ITSCC) Symposium

Thursday, April 27, 2017 7:00 am – 8:00 am B117-119

www.itssc.org

ITSCC’s Mission: To integrate and support basic scientific and clinical research to address the special needs of immunosuppressed patients and organ transplant recipients with skin cancer in order to improve quality of care. To educate patients, scientists, primary care doctors and specialist physicians on the unique needs and clinical care issues in immunosuppressed and transplant patients.
PLENARY SESSION I
Presiders: Daniel Kaplan, MD/PhD and Ethan Lerner, MD/PhD

Thursday, April 27, 2017 8:00 am - 9:00 am Oregon Ballroom 201-202

1. Gut microbiota plays a role in the development of alopecia areata. L. Nair, Z. Dai and AM. Christiano. New York, NY. 8:00 am, Abstract #649

2. Discovery of differential RNA binding and regulation by the APOL4 protein to disease-linked psoriasis CDSN gene variants using RaPID. JD. Ransohoff, M. Ramanathan and PA. Khavari. Stanford, CA. 8:12 am, Abstract #408


4. Targeting metabolic vulnerabilities of MDSCs to enhance the anti-tumor activity of PD-1 blockade in melanoma. B. Zheng, S. Kim, M. Li and S. Trousil. Charlestown, MA. 8:36 am, Abstract #798

5. CD301b+ macrophages activate proliferation of CD29+;CD34+;Sca1+ fibroblasts through multiple secreted factors during wound healing. B. Shook, G. Rivera Gonzalez, R. Wasko and V. Horsley. New Haven, CT. 8:48 am, Abstract #934
EUGENE M. FARBER LECTURE

From Genetic Discovery To Personalized Outcomes In Psoriasis

Thursday, April 27, 2017  9:00 am - 9:30 am  Oregon Ballroom 201-202

Introduction by:  Nicole Ward, PhD

Jonathan Barker, MD
St John's Institute of Dermatology, King's College
London, UK

Jonathan Barker is Professor of Medical Dermatology and Academic Head of Department at St John’s Institute of Dermatology, King’s College London. He is Co-Director of the Skin Therapy Research Unit and the Psoriasis Service at the Institute, a large tertiary referral service for patients with severe disease. His research interests extend from genetic discovery through to clinical outcome measurement. As such he is a key investigator in international consortia aiming to map psoriasis susceptibility genes and heads the International Psoriasis Council (IPC) exome consortium. He is deputy director of a multi-centre MRC stratified medicine programme in psoriasis outcomes to biologic therapy (PSORT) and heads its genetics working group. Professor Barker has published over 200 peer-reviewed papers, authored and edited several books including the new edition of the ‘Rook Book’. Highly cited publications include those in Nature Genetics, American Journal of Human Genetics and New England Journal of Medicine. He sits on the editorials boards of several dermatology journals. He is past President of the European Dermatology Forum. Currently he is board member and chair scientific committee of IPC and President of the European Society for Dermatological Research.

LECTURESHIP HISTORY

The Eugene M. Farber endowment was established by the family of Eugene M. Farber, MD, who devoted his scientific career to understanding the pathogenesis of psoriasis. In 2007, the SID Board of Directors voted to create the Eugene M. Farber Endowed Lecture. It is presented at the Society’s Annual Meeting by an investigator whose work is relevant to expanding our insights into the pathophysiology and treatment of psoriasis.
NAOMI M. KANOF LECTURE

Targeting the Epigenome in Cutaneous and Disseminated Malignancies

Thursday, April 27, 2017 9:30 am – 10:00 am Oregon Ballroom 201-202

Introduction by: Paul Nghiem, MD/PhD

James Bradner, MD
Novartis Institutes of BioMedical Research
Cambridge, Massachusetts

James (Jay) E. Bradner, MD is President of the Novartis Institutes for BioMedical Research (NIBR) and a member of the Executive Committee of Novartis. Prior to joining Novartis Dr. Bradner served on the research faculty of Harvard Medical School and as an attending physician in stem cell transplantation within the Department of Medical Oncology at the Dana-Farber Cancer Institute. The research focus of the Bradner laboratory has been the study of BET bromodomain proteins and their function in gene control, innovating chemical probes and investigational drugs to study and treat cancer. Dr. Bradner is a co-founder of five biotechnology companies and has co-authored more than 130 scientific publications and 30 United States patent applications. Dr. Bradner is a graduate of Harvard College and the University of Chicago Medical School. He completed residency in Medicine at Brigham & Women’s Hospital, fellowship in Medical Oncology and Hematology at the Dana-Farber Cancer Institute and postdoctoral training in chemistry and chemical biology at Harvard University (Prof. Stuart Schreiber). He is the recipient of many honorific awards and was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.

LECTURESHIP HISTORY

Established in 1988, this award was established to honor the memory of Naomi Kanof, MD. The Naomi M. Kanof Lectureship honors an individual making significant contributions to the improvement of health through clinical research. Clinical research is broadly defined as any scientific endeavor with a direct application to improving the prevention, diagnosis or treatment of clinical disease. This investigative work can be based in the laboratory and should be implemented or just ready to be implemented in clinical practice.
Come See My Poster I

Thursday, April 27, 2017 10:00 am – 10:15 am Oregon Ballroom 201-202

Presider: Ethan Lerner, MD/PhD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID’s Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. Dynamic regulatory network controlling Tr1 cell development in epithelial tissue inflammation.
   A. Ho, A. Madi, N. Chihara, A. Regev and V. Kuchroo. Boston, MA and Cambridge, MA. 10:01 am, Abstract #046

2. Type I interferon signaling suppresses the development of vitiligo as well as the response to melanoma immunotherapy.
   RL. Riding, K. Fukuda, JM. Richmond and JE. Harris. Worcester, MA. 10:02 am, Abstract #072

   J. Wu, H. Doan, R. Simonette, Q. He, P. Rady and S. Tyring. Houston, TX. 10:03 am, Abstract #096

4. Hedgehog signaling inhibitors fail to reduce merkel cell carcinoma viability.

5. Combined activation of MAP kinase and beta-catenin signaling define deep pene trating nevi.

   PK. Mukherjee, J. Chandra, R. Sherif, M. Retuerto, MA. Ghannoum and T. McCormick. Cleveland, OH. 10:06 am, Abstract #647

7. Characterization of the skin microbiota in rosacea.

   E. Hsia, M. Tian and D. Gil. Irvine, CA. 10:08 am, Abstract #671

9. Pro-apoptotic protein BIM influences PD-L1 expression in melanoma.

10. Melanoma and chronic low dose ethinyl estradiol contraceptives in young women: A large midwestern U.S. patient population retrospective study.
    KA. Mueller, AE. Verzi, KA. Orrell, EL. Hagstrom, KS. Flood, BJ. Schlosser, K. Bhatt, B. Nardone and DP. West. Chicago, IL. 10:10 am, Abstract #813

11. TSLP and SDF-1a/CXCR4 axis in skin fibrosis.

12. Laminin alpha 5 stimulates keratinocyte attachment and migration and wound repair.
    D. Castillo, S. Davis and J. Li. Miami, FL. 10:12 pm, Abstract #921
CLINICAL SCHOLARS PROGRAM SESSION I
Base Pairs to Bedside-Personalized Medicine

Thursday, April 27, 2017           10:15 am – 12:00 pm           Oregon Ballroom 201-202

10:15 am  Introduction
Doug Grossman, MD/PhD
Dr. Grossman is a Professor of Dermatology and an Investigator at the Huntsman
Cancer Institute at the University of Utah. He received his undergraduate degree
from Duke University and completed the Medical Scientist Training Program at
Baylor College of Medicine in 1994. He completed his dermatology residency and
postdoctoral research training at Yale University. Dr. Grossman’s research focuses
on tumor suppressors in melanoma and chemoprevention.

10:20 am  Mutations in KLHL24 add to the molecular heterogeneity of
epidermolysis bullosa simplex
JY. W. Lee, L. Liu, C. Hsu, S. Aristodemou, L. Ozoemena, M. Ogboli,

10:35 am  Anthony Oro, MD/PhD
Cells as Drugs: Genetically modified Cell-based Therapies for Skin
Diseases
As a practicing Dermatologist, Anthony Oro, MD/PhD has focused for the
last 18 years on determinants of epithelial development, morphogenesis, and
tumorigenesis using the skin as a model system. He has studied early embryonic
development in Drosophila, focusing on the function of orphan nuclear receptors
in pattern formation. As a post doc and now PI, he has studied the role of the
hedgehog signaling pathway in skin and hair stem cell biology, hair stem cell
regulation and patterning, and epithelial-mesenchymal regulation.

11:05 am  Keith Choate, MD/PhD
Genetic investigation of rare skin disorders reveals novel pathways for
disease pathogenesis
Dr. Choate grew up in Connecticut and California and attended Caterbury School
and Stanford University where he graduated in 3 years with honors in biological
sciences in 1995. As a researcher in Paul Khavari’s laboratory, he performed the first
successful ex vivo gene therapy for the genetic skin disorder lamellar ichthyosis
and came to Yale in 1996 to begin the Medical Scientist Training Program. He
received the M.Phil (’00), PhD (Cell Biology, ’01), and MD (’04, cum laude) before an
internship at Yale-New Haven Hospital in Internal Medicine and residency in
Dermatology. He pursued post-doctoral training in human genetics. Dr. Choate
has published over 30 peer-reviewed articles in Science, Nature, Human Molecular
Genetics, The American Journal of Human Genetics, The Journal of Clinical
Investigation, Nature Medicine, and the Journal of the American Academy of
Dermatology. He serves on committees for the Society for Pediatric Dermatology,
the Pediatric Dermatology Research Alliance, the Society for Investigative
Dermatology, the Yale Medical Scientist Training Program, and the American Board
of Dermatology. His research is funded by the National Institutes of Health and
the Foundation for Ichthyosis and Related Skin Types. Dr. Choate’s laboratory is
dedicated to understanding fundamental genetic and biologic pathways relevant
to human disease.

11:35 am  The genomic landscape of sebaceous cell carcinoma
RJ. Cho, K. McMullen, D. Solomon, S. Benz, J. Golovato, B. Goode and
JP. North. Abstract # 114.

11:50 am  Q & A
New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Poster Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Clinical Research: Patient Outcomes Research</strong></td>
<td>400, 371, 360, 382, 337, 342, 343, 350, 363, 379</td>
</tr>
<tr>
<td>Moderator: Jonathan Silverberg, MD/MPH/PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Genetic Disease, Gene Regulation and Gene Therapy</strong></td>
<td>515, 487, 500, 518, 524, 529, 490, 496, 530, 532</td>
</tr>
<tr>
<td>Moderator: John McGrath, MD</td>
<td></td>
</tr>
<tr>
<td><strong>Innate Immunity, Microbiology, Inflammation</strong></td>
<td>632, 635, 599, 628, 589, 608, 611, 564, 586, 616</td>
</tr>
<tr>
<td>Moderator: Delphine Lee, MD/PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Photobiology</strong></td>
<td>792, 733, 725, 749, 486, 727, 744, 754, 751</td>
</tr>
<tr>
<td>Moderator: Richard Wang, MD/PhD</td>
<td></td>
</tr>
<tr>
<td><strong>Tissue Regeneration &amp; Wound Healing</strong></td>
<td>893, 906, 576, 894, 915, 920, 929, 914, 896</td>
</tr>
<tr>
<td>Moderator: Rivkah Isseroff, MD</td>
<td></td>
</tr>
</tbody>
</table>
Aclaris Sponsored Symposium

You Don’t Know JAK: Development of JAK inhibitors in Dermatology

Thursday April 27, 2017  12:00 pm - 1:45 pm  Oregon Ballroom 201-202

12:00 pm  Welcome and Introduction
John Harris, MD/PhD

12:05 pm  Paul Changelian, PhD
Getting to know JAKs

Paul completed his undergraduate studies at the University of Michigan, received his PhD in Immunology at Harvard in 1979, and his postdoctoral fellowship at Washington University. He joined Pfizer 1989 in Groton, Connecticut with a focus on the identification of molecular targets that would lead to drugs for preventing renal transplant rejection and therapy for autoimmune disease. His lab developed a program to find JAK3 inhibitors, which led in 2000 to the discovery of CP-690,550 – a nanomolar inhibitor of JAK3. In 2003 they published work demonstrating efficacy of this compound in a rigorous model of renal transplantation in non-human primates. Expanding these studies to focus on autoimmune disease, CP-690,550 was renamed to facitinib, and approved in 2012 as Xeljanz – the first oral JAK kinase inhibitor for rheumatoid arthritis. Xeljanz is currently in clinical trials for psoriasis, ulcerative colitis, Crohn’s disease and ankylosing spondylitis. After leaving Pfizer in 2007, Paul has worked as a consultant for several companies and is currently the head of biology at Confluence Life Science, a company focused on autoimmune disease and oncology.

12:15 pm  Jon Jacobsen, PhD
JAKs be nimble: Building a Better Inhibitor

Dr. Jacobsen joined Confluence Life Sciences as Director of Chemistry in 2011. He is a trained organic chemist completing his undergraduate studies at Harvey Mudd College and PhD with Larry Overman at the University of Geneva he joined the Upjohn Company in 1985. During his 25-year career in the pharmaceutical industry working with Upjohn, Pharmacia and Pfizer he successfully led drug discovery project teams that advanced multiple compounds from discovery into clinical development. Over his career, he worked on multiple projects within CNS, cancer, cardiovascular and inflammation disease areas. During the last ten years at Pfizer and Confluence his research has focused on the inhibition of multiple kinase targets involved in cancer and inflammation pathways.

12:35 pm  John Harris, MD/PhD
See Spots Disappear: JAK Inhibitors in Vitiligo and Beyond

John E. Harris, MD/PhD, is an Associate Professor of Dermatology at the University of Massachusetts Medical School (UMMS) in Worcester, MA. He serves as Director of the Vitiligo Clinic and Research Center at UMMS, focusing both on the clinical management of vitiligo patients as well as research into new therapeutic strategies. His approach includes basic, translational, and clinical studies that incorporate the use of mouse models, human tissues, and small clinical trials that determine disease mechanisms of vitiligo, identify quantifiable markers of disease activity, and test new treatments. Previous work from his research team revealed that the IFN- signaling pathway is central to both the progression and maintenance of vitiligo, and recent studies in both mice and humans have demonstrated efficacy of new immunotherapies that target this pathway. Ongoing research seeks to better characterize the mechanism of action of these new treatments and to identify new targets in order to design an optimal therapeutic strategy for vitiligo patients, who currently have no FDA-approved treatment options. Long-term goals are to bring new treatments with better safety and efficacy into the clinic, to develop more durable, long-lasting treatments, and ultimately to find a cure for this psychologically devastating disease.

12:45 pm  Brian S. Kim, MD/MTR
Scratch that Itch: JAK Inhibitors in Pruritus

Dr. Brian Kim is Assistant Professor of Dermatology, Anesthesiology, Pathology and Immunology, and Co-Director of the Center for the Study of Itch at Washington University School of Medicine in St. Louis. His laboratory focuses on innate immune mechanisms that underlie skin inflammation and the sensation of itch. Specifically, the Kim Lab identified previously unrecognized contributions of group 2 innate lymphoid cells (ILC2s) and basophils to the pathogenesis of atopic dermatitis (AD). These cells have emerged as critical sources of the type 2 cytokines IL-4, IL-5 and IL-13, which are now among the most important targets for biologic therapy in AD and other allergic disorders. Current studies in the Kim Lab are aimed at better understanding how innate immune cells and pro-inflammatory mediators specifically regulate the sensation of itch. These studies have broad therapeutic implications for numerous medical disorders that manifest as chronic itch. His research on the immune regulation of AD has led to awards and funding from the National Institutes of Health, Doris Duke Charitable Foundation, American Skin Association, American Academy of Dermatology and the American Society for Clinical Investigation.

CONTINUED ON NEXT PAGE
Aclaris Sponsored Symposium

You Don’t Know JAK: Development of JAK inhibitors in Dermatology

Thursday April 27, 2017 12:00 pm - 1:45 pm Oregon Ballroom 201-202

12:55 pm  Julian Mackay-Wiggan, MD/MPH

Hair Raising Experiences: JAK Inhibitors in Alopecia

Dr. Mackay-Wiggan is an Associate Professor of Dermatology, Director of the Clinical Research Unit, and the Dermatology Resident Clinic, in the Department of Dermatology at Columbia University, College of Physicians & Surgeons. She has primary responsibility for the development of protocols in clinical trials, compliance with regulatory requirements, and direct patient contact, including recruitment, evaluation, retention and safety of study subjects at Columbia University. Dr. Mackay-Wiggan completed a Master of Science in Biostatistics/Patient Oriented Research at the Columbia’s Mailman School of Public Health. Over the past 15 years, Dr. Mackay-Wiggan has successfully designed and/or conducted over 50 clinical trials of all phases (phase 0-IV), ranging from topical applications of products to chemoprevention trials for multiple dermatologic indications. Dr. Mackay-Wiggan has an active focus on research into treatment options for alopecia areata (AA), including pilot trials to evaluate the efficacy of Intranasal steroidal, abatacept, ruxolitinib and tofacitinib in the treatment of alopecia areata. Dr. Mackay-Wiggan has 2 FDA INDs related to AA trials. Many of the other trials Dr. Mackay has conducted are focused on diseases in which the immune system is known, or believed, to play a primary role, and believe, to play a primary role and include studies funded by the NIH, investigator initiated studies and studies involving pharmaceutical companies. She also regularly evaluates and treats patients, and teaches residents the nuances of evaluation and treatment of a variety of hair disorders as well as general dermatologic conditions.

1:05 pm  Vijendra Nalamothu, PhD

JAK hammers: Topical Delivery for JAK Inhibitors

Dr. Vijendra Nalamothu is CEO and Co-Founder of Tergus Pharma, the industry leader in topical formulations and development services, analysis, testing and cGMP clinical supply manufacturing. Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades and holds several patents. His efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves. After earning his PhD in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization. Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles and accolades. He is a sought-after speaker at conferences worldwide.

1:18 pm  Come to My Poster, JAK

Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias.

Lindsey Bordone, MD, Columbia University, New York, NY Abstract #075

1:22 pm  Treatment of vitiligo with topical janus kinase inhibitor ruxolitinib.

Brooke Rothstein, Tufts Medical Center, Boston, MA Abstract #770

1:26 pm  Predictive modeling of drug response and mechanism of action in alopecia areata clinical trials.

James Chen, PhD Columbia University, New York, NY Abstract #397

1:30 pm  Panel Discussion and Q&A with Presenters

Stuart Shanler, MD

Stuart D. Shanler, MD co-founded Aclaris Therapeutics, Inc. and has served as their Chief Scientific Officer since their inception in July 2012. Between July 2011 and July 2012, Dr. Shanler co-invented a topical rosacea drug for, and co-founded and served as Chief Scientific Officer of Vicept Therapeutics, Inc. from 2009 until its acquisition by Allergan, Inc. in July 2011. Previously, Dr. Shanler was a dermatologic surgeon in private practice. Dr. Shanler is a board-certified dermatologist and received his MD degree from Albany Medical College of Union University and received BS degrees in Biology and the Biological Basis of Behavior from the University of Pennsylvania.

Neal Walker, DO

Dr. Walker is a board certified dermatologist and serial entrepreneur with over 18 years of experience in the pharmaceutical industry. He served as a consultant to a number of pharmaceutical companies, co-founded and served as President and Chief Executive Officer and a member of the board of directors of Vicept Therapeutics, a dermatology-focused specialty pharmaceutical company, from 2009 until its acquisition by Allergan. Previously, Dr. Walker co-founded and led a number of life science companies including Octagon Research Solutions, Trigenesis Therapeutics, and Cutix.
debra of America’s EB Symposium

Thursday, April 27, 2017 12:00 pm – 2:00 pm B117-119

Lunch will be served
Agenda is subject to change

12:00 pm Welcome, Opening Remarks
Jouni Uitto, MD/PhD

12:15 pm Keynote Lecture, What’s new in EB Research: Clinical & Basic Science Advances
John McGrath, MD

12:45 pm Development of New Technologies for EB Diagnosis & Treatment
Moderator: Jouni Uitto, MD/PhD
Abstracts presented by:
  - Mahla Zahabiyon, Abstract #521
  - Ignacia Fuentes, Abstract #512
  - Amir Saeidian, Abstract #509
  - Jonathan O’Keeffe Ahern, Abstract #532

1:05 pm Gene Editing & CRISPr Based Approaches for EB
Moderator: Katsuto Tamai, MD/PhD
Abstracts presented by:
  - Sean McGrath, Abstract #527
  - Joanna Jackow, Abstract #858
  - Shota Takashima, Abstract #480
  - Julie Reichelt, Abstract #535

1:25 pm Advances in Skin Cancer Research in EB
Moderator: John McGrath, MD
Abstracts presented by:
  - Tran Nguyen, Abstract #097
  - Andrew South, Abstract #122

1:45 pm Perspectives & Closing Remarks
Brett Kopelan, MA
Executive Director, debra of America

This symposium was supported in part by:
Amicus Therapeutics and Castle Creek Pharma
CONCURRENT MINI-SYMPOSIUM 1
Adaptive and Autoimmunity

Studies of adaptive immune responses involving T and B lymphocytes, dendritic cells, other antigen presenting cells, and antigen processing and presentation; Basic and pre-clinical experimental studies focused on autoimmunity.

Thursday, April 27, 2017                2:00 pm – 4:30 pm Oregon Ballroom 204

Presiders:  Niroshana Anandasabapathy, MD/PhD and Amanda MacLeod, MD


6. Expression of αvβ8 by Langerhans cells is required for Th17 differentiation and tethering of LC in the epidermis. S. Kashem, J. Mohammed and D. Kaplan. Minneapolis, MN and Pittsburgh, PA. 3:00 pm, Abstract #069


8. IL-17RA and not IL-17RE is required for IL-17C-mediated psoriasiform inflammation. S.L. Sigurdardottir, Y. Fritz, P. Klenotic, X. Zhang, D. Diaconu, L. Zhang and N.L. Ward. Cleveland, OH. 3:24 pm, Abstract #021


11. FcgRIIb is important for clonal ignorance and prevents pemphigus phenotype in pathogenic anti-desmoglein 3 antibody knock-in mice. H. Nomura, Y. Kase, J. Yamagami, N. Wada, S. Koyasu, H. Takahashi and M. Amagai. Tokyo, Japan. 4:00 pm, Abstract #010

12. FilI-deficient B cells induce scleroderma-like vascular disorganization via activating pro-angiogenic gene program in dermal microvascular endothelial cells – A possible role in scleroderma vasculopathy. R. Saimusa, Y. Asano, A. Yoshizaki, M. Trojanowska and S. Sato. Tokyo, Japan and Boston, MA. 4:12 pm, Abstract #005

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 2
Clinical Research: Pathophysiology and Therapeutics
Including studies involving human tissue and human cells that furthers our understanding of skin disease.

Thursday, April 27, 2017                  2:00 pm – 4:30 pm Oregon Ballroom 203

Presiders: Shawn Demehri, MD/PhD and Jean Tang, MD/PhD

1. PD-1 blockade and T cell responses in merkel cell carcinoma. NJ. Miller, C. Church, S. Fling, R. Kulikauskas, N. Ramchurren, M. Shinohara, M. Cheever, SL. Topalian and P. Nghiems. Seattle, WA and Baltimore, MD. 2:00 pm, Abstract #266

2. PD-L1 expression is a positive prognostic factor in cutaneous angiosarcoma. A. Otsuka, Y. Honda, S. Ono and K. Kabashima. Kyoto, Japan. 2:12 pm, Abstract #289


4. A randomized, double-blind, placebo-controlled crossover trial of levocarnitine for vis modegib-associated muscle spasms (NCT1893892). JG. D Cannon, DC. Tran, S. Li and AL. S Chang. Palo Alto, CA; Redwood City, CA and Stanford, CA. 2:36 pm, Abstract #302


6. An open label clinical trial of Abatacept (CTLA4-Ig) for alopecia areata. F. Sansaricq, J. Mackay-Wiggan, A. Jabbari, AM. Christiano and R. Clynnes. New York, NY. 3:00 pm, Abstract #320


Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 3

Interdisciplinary Spotlight: Frontiers in Atopic Dermatitis

This session has been organized around a theme rather than a category and includes a full range of bench to bedside approaches.

Thursday, April 27, 2017 2:00 pm – 4:30 pm  B113-116

Presiders: Emma Gutman-Yassky, MD/PhD and Eric Simpson, MD


2. PSMα as a key virulence in Staphylococcus aureus-induced skin inflammation through IL-36 and IL-1 release from keratinocytes. S. Nakagawa, Y. Nakamura, G. Nunez and H. Matsue. Chiba, Japan and Ann Arbor, MI. 2:12 pm, Abstract #624

3. Microbiome controls mast cell differentiation in the skin. Z. Wang, N. Mascarenhas, L. Eckmann, Y. Miyamoto, X. Sun, T. Kawakami and A. Di Nardo. La Jolla, CA. 2:24 pm, Abstract #557


Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 4
Pigmentation and Melanoma

Studies on all aspects of cutaneous and extracutaneous pigmentation; molecular cellular and biological facets of melanoma.

Thursday, April 27, 2017 2:00 pm – 4:30 pm A105-106

Presiders: Marta Bertolini, PhD and Akinori Kawakami, MD/PhD

1. LRP1 is a tumor promoter by inhibiting apoptosis in human melanoma. Z. Zhai, W. Liu, Y. Shellman, D. Norris, C. Dinarello, R. Spritz and M. Fujita. Aurora, CO. 2:00 pm, Abstract #807

2. SRCAP complex subunit YL1 as a novel epigenetic target in melanoma. J. Dong, C. Vardabasso and E. Bernstein. New York, NY. 2:12 pm, Abstract #776

3. Attenuated netrin-1 receptor mediated regulation of tiam1 is required for rac1 mutant melanoma progression. MCG. Winge, J. Kovalski, NT. Nguyen, D. Wu, A. Zehnder, PA. Khavari and M. Marinkovich. Stanford, CA. 2:24 pm, Abstract #811


6. Coordinated changes in mitochondrial biogenesis, dynamics and metabolic tumor suppressor by cryptolepine, an alkaloid, leads to inhibition of melanoma cells growth. HC. Pal, R. Prasad and SK. Katiyar. Birmingham, AL. 3:00 pm, Abstract #778

7. Sestrin2 regulates metabolism reprograming to protect melanoma cells from anoikis. G. Zhu, P. Xu, T. Gao, G. Wang and C. Li. Xi'an, China. 3:12 pm, Abstract #818

8. Myeloid derived suppressor cells are critical in increased melanoma progression in mice lacking BP180/collagen XVII function. B. Hwang, Y. Zhang, B. Peng, N. Li, S. Williams, NE. Thomas, M. Su, L. Diaz and Z. Liu. Chapel Hill, NC. 3:24 pm, Abstract #805

9. Loss of keratinocyte desmoglein 1 occurs during melanoma development and alters crosstalk between keratinocytes and melanocytes. C. Arnette, JL. Johnson, JL. Koetsier and KJ. Green. Chicago, IL. 3:36 pm, Abstract #806

10. Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma. N. Theodosakis, C. Langdon, G. Micevic, D. Stern and M. Bosenberg. New Haven, CT and Memphis, TN. 3:48 pm, Abstract #789

11. CXCL5 and neutrophils determine metastatic routes in cutaneous melanoma. A. Forsthuber, K. Lipp and R. Loewe. Wien, Austria. 4:00 pm, Abstract #783

12. UVB and Poly(I:C) induce PAR-2 and enhance melanosome uptake by normal human epidermal keratinocytes though TLR3 signaling pathway. S. Koike, K. Yamasaki, T. Yamauchi and S. Aiba. Sendai, Japan. 4:12 pm, Abstract #780

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 5
Skin and Hair Developmental Biology

Studies on the hair follicle, sebaceous gland, and other skin appendages; developmental biology of skin and hair; roles of stem cells in pre and post-natal growth and development.

Thursday, April 27, 2017 2:00 pm – 4:30 pm C123-124

Presiders: Mayumi Ito, PhD and Maksim Plikus, PhD

1. Spatiotemporal antagonism in mesenchymal-epithelial signaling in sweat versus hair fate decision. CP. Lu, L. Polak, B. Keyes and E. Fuchs. New York, NY and South San Francisco, CA. 2:00 pm, Abstract #839

2. BRAF activation induces sweat gland neogenesis in a WNT signaling dependent manner. JY. Jin, T. Lechler and JY. Zhang. Durham, NC. 2:12 pm, Abstract #868

3. After skin wounding, noncoding dsRNA coordinates prostaglandins and WNT7b to promote regeneration. A. Zhu, A. Li, D. Kim, T. Ratiiff, M. Melsom and L.A. Garza. Houston, TX; Baltimore, MD and Cleveland, OH. 2:24 pm, Abstract #850


6. WNT10A/β-catenin signaling is required for maintenance of Merkel cells in adult life. M. Xu, Y. Choi, EE. Morrisey and SE. Millar. Philadelphia, PA and Boston, MA. 3:00 pm, Abstract #866


10. Hair progenitor cells dictate hair pigmentation through non-cell autonomous KIT signaling. C. Liao, RC. Booker, SJ. Morrison and LQ. Le. Dallas, TX. 3:48 pm, Abstract #853

11. YBX1 mediated translational control of the senescence secretome in epidermal progenitors. E. Kwon, K. Todorova, J. Wang, M. Hentze and A. Mandinova. Charlestown, MA and Heidelberg, Germany. 4:00 pm, Abstract #871


Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
## Friday Sessions

<table>
<thead>
<tr>
<th>PAGE</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>57</td>
<td>Meeting-At-A-Glance</td>
</tr>
<tr>
<td>58</td>
<td>Pediatric Dermatology Research Alliance/ Society for Pediatric Dermatology Session</td>
</tr>
<tr>
<td>59</td>
<td>Plenary Session II</td>
</tr>
<tr>
<td>60</td>
<td>Stephen Rothman Memorial Award</td>
</tr>
<tr>
<td>61</td>
<td>Julius Stone Lecture</td>
</tr>
<tr>
<td>62</td>
<td>State-of-the-Art Plenary Lecture III &amp; IV</td>
</tr>
<tr>
<td>63</td>
<td>Come See My Poster II</td>
</tr>
<tr>
<td>64</td>
<td>Business Meeting for Members</td>
</tr>
<tr>
<td>65</td>
<td>Selected ePoster Discussions II</td>
</tr>
<tr>
<td>66</td>
<td>International Eczema Council</td>
</tr>
<tr>
<td>67</td>
<td>International Psoriasis Council</td>
</tr>
<tr>
<td>68</td>
<td>American Dermato-Epidemiology Network (ADEN)</td>
</tr>
<tr>
<td>69</td>
<td>Medical Dermatology Society</td>
</tr>
<tr>
<td>70</td>
<td>International Society for Cutaneous Lymphomas/ Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)</td>
</tr>
<tr>
<td>71</td>
<td>Research in Cutaneous Surgery Mini-Symposium</td>
</tr>
<tr>
<td>72</td>
<td>Concurrent Mini-Symposium 6 Clinical Research: Patient Outcomes Research</td>
</tr>
<tr>
<td>73</td>
<td>Concurrent Mini-Symposium 7 Genetic Disease, Gene Regulation and Gene Therapy</td>
</tr>
<tr>
<td>74</td>
<td>Concurrent Mini-Symposium 8 Innate Immunity, Microbiology, Inflammation</td>
</tr>
<tr>
<td>75</td>
<td>Concurrent Mini-Symposium 9 Photobiology</td>
</tr>
<tr>
<td>76</td>
<td>Concurrent Mini-Symposium 10 Tissue Regeneration and Wound Healing</td>
</tr>
<tr>
<td>77</td>
<td>Pfizer Symposium</td>
</tr>
<tr>
<td>78</td>
<td>National Eczema Association</td>
</tr>
<tr>
<td>79</td>
<td>North American Hair Research Society (NAHRS)</td>
</tr>
<tr>
<td>81</td>
<td>National Psoriasis Foundation Reception</td>
</tr>
<tr>
<td>82</td>
<td>SATO Japan Scientific Forum</td>
</tr>
</tbody>
</table>
Looking for a fun activity for the evening?

The city has many different neighborhoods with their own unique flare:

NORTHWEST PORTLAND/NOB HILL
Sophisticated shopping and dining destinations line these leafy avenues, accessible via the Portland Streetcar.

MISSISSIPPI/WILLIAMS
These vibrant North Portland avenue bustle with trend-setting shops, eateries, music spots and watering holes.

PEARL DISTRICT
This stylish neighborhood is filled with chic boutiques, galleries and eateries.

DOWNTOWN
The walkable city center is an energetic hub of eats, sightseeing, shopping and culture.

CENTRAL EASTSIDE
Find global flavors, local fashions and family fun in this dynamic industrial hub.

LLOYD DISTRICT
This transit-connected civic hub is home to many hotels, the Oregon Convention Center, Moda Center and the state’s largest mall.

For more information about Portland please visit www.travelportland.com
## Women's Dermatologic Society
- Networking & Breakfast: 6:30 am – 7:15 am
- Panel Discussion: 7:15 am – 8:00 am

## Pediatric Dermatology Research
- Alliance/ Society for Pediatric Dermatology Session: 7:00 am – 8:00 am

## Registration
- 7:30 am – 4:30 pm
  - Pre-Function A Foyer

## Plenary Session II
- 8:00 am – 9:00 am
  - Oregon Ballroom 201-202

### Stephen Rothman Memorial Award
- Presented to Amy Paller, MS/MD
- Oregon Ballroom 201-202

### Julius Stone Lecture
- Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice
- Bruce Beutler, MD
- Oregon Ballroom 201-202

### State-of-the-Art Plenary Lecture III
- Border Patrol and Melanoma: Keeping the Peace at a Cost?
  - Niroshana Anandasabapathy, MD/PhD
- Oregon Ballroom 201-202

### State-of-the-Art Plenary Lecture IV
- 3D Bioprinting-An Emerging Paradigm in Tissue Engineering
  - Pankaj Karande, PhD
- Oregon Ballroom 201-202

## Come See My Poster II
- 10:45 am – 11:00 am
- Odd Poster #’s 033, 091, 107, 127, 233, 279, 287, 348, 370, 424, 478, 512
- Oregon Ballroom 201-202

## Business Meeting for Members
- 11:00 am – 11:30 am
- Oregon Ballroom 201-202

## Poster Session II/Coffee Break
- Odd Poster #’s 001-311
  - 11:30 am – 1:30 pm
  - Exhibit Hall A
- Even Poster #’s 314-624
- Odd Late-Breaking Poster #’s 937-959
- Even Late-Breaking Poster #’s 962-984

## Selected ePoster Discussions II
- See Page #65
- 12:00 pm – 1:00 pm
- Exhibit Hall A Foyer

### Medical Dermatology Society
- 12:00 pm – 1:45 pm
  - A105-106

### International Society for Cutaneous Lymphomas / Cutaneous T-Cell Lymphoma Symposium (ISCL/CTCL)
- 12:00 pm – 1:30 pm
  - C123-124

### Research in Cutaneous Surgery
- 12:00 pm – 1:30 pm
  - B112

### Satellite Symposium
- 12:00 pm – 2:00 pm
  - Academic-Industry Partnership Project (AIPP)
  - Individual Meetings (set up in advance by the SID)

### Concurrent Mini-Symposia
- 2:00 pm – 4:30 pm
  - 6. Clinical Research: Patient Outcomes Research
    - Oregon Ballroom 204
  - 7. Genetic Disease, Gene Regulation, Gene Therapy
    - B113-116
  - 8. Innate Immunity, Microbiology, Inflammation
    - Oregon Ballroom 203
  - 9. Photobiology
    - C123-124
  - 10. Tissue Regeneration and Wound Healing
    - A105-106

### Mini-Symposia Mixers
- 4:30 pm – 5:00 pm
  - Individual Concurrent Meeting Rooms

### Pfizer Symposium
- 5:00 pm – 5:45 pm
  - Individual Concurrent Meeting Rooms

### National Eczema Association
- 6:00 pm – 7:00 pm
  - A105-106

### North American Hair Research Society (NAHRS)
- 6:00 pm – 8:30 pm
  - Oregon Ballroom 203

### National Psoriasis Foundation Reception
- 6:00 pm – 7:30 pm
  - B117-119

### SATO Japan Scientific Forum
- 6:30 pm – 9:30 pm
  - C123-124

---

**ASSOCIATE GROUPS ARE LISTED IN GREEN**
Pediatric Dermatology at the SID Meeting

Friday, April 28, 2017  7:00 am – 8:00 am  A105-106

Coffee will be served

7:00 am  Introduction and Welcome  
Amy Paller, MS/MD  
Northwestern University

7:05 am  Association between pediatric psoriasis and cardiovascular risk in US children.  
Jonathan Silverberg, MD/PhD/MPH, et al.; Northwestern University. Abstract #238.

7:15 am  Autoinflammation in Psoriasis  
Johann Gudjonsson, MD/PhD  
Professor of Dermatology, University of Michigan

7:40 am  Th17 and Th22 polarization in ichthyosis blood correlates with disease severity and highlights its systemic nature.  
Tali Czarnowicki, MD/MSc, et al; Icahn School of Medicine at Mt. Sinai. Abstract #073.

7:50 am  Discussion and Concluding Remarks

Special thanks to the Pediatric Dermatology Research Alliance (PeDRA) and the Society for Pediatric Dermatology (SPD) for supporting this session.
PLENARY SESSION II
Presiders: Nicole Ward, PhD and Victoria Werth, MD

Friday, April 28, 2017            8:00 am – 9:00 am            Oregon Ballroom 201-202


5. Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. YH. Kim, S. Whittaker, SM. Horwitz, M. Duvic, R. Dummer, J. Scarisbrick, P. Quaglino, P. Zinzani, P. Wolter, Y. Wang, M. Palanca-Wessels, E. Zagadailov, WL. Trepicchio, H. Lin, M. Little and H. Prince. Stanford, CA; London, United Kingdom; New York, NY; Houston, TX; Zürich, Switzerland; Birmingham, United Kingdom; Turin, Italy; Bologna, Italy; Leuven, Belgium; Bothell, WA; Cambridge, MA and Melbourne, Australia. 8:48 am, Abstract #262
STEPHEN ROTHMAN MEMORIAL AWARD

Friday, April 28, 2017  9:00 am – 9:15 am  Oregon Ballroom 201-202

Introduction by:  Angela Christiano, PhD

Amy Paller, MS/MD
Northwestern University Feinberg School of Medicine
Chicago, IL

Amy Paller, MS/MD is the Walter J. Hamlin Professor and Chair, Professor of Pediatrics, and Director of the Skin Disease Research Center at Northwestern University’s Feinberg School of Medicine. She received her undergraduate and graduate degrees from Brown University and her medical degree from Stanford University. Dr. Paller completed residency training in both Pediatrics and Dermatology at Northwestern University and her postdoctoral research fellowship at the University of North Carolina. She served as Chief of Dermatology at the Lurie Children’s Hospital of Chicago prior to becoming Chair of Northwestern’s Dept of Dermatology. An author of more than 350 peer-reviewed publications, Dr. Paller currently serves on Council for the National Institute for Arthritis, Musculoskeletal and Skin Diseases. Her NIH-funded laboratory focuses on the use of nanotechnology for topically applied gene regulation in treating skin disorders and on the role of glycosphingolipids in regulating signaling. Dr. Paller also directs the Pediatric Dermatology Clinical Trials Unit at Northwestern, has been a pioneer in discovery related to diagnosis and therapy of genetic skin disorders, and has been the lead investigator on several landmark papers related to inflammatory skin disease. Dr. Paller has served on the Board of the American Academy of Dermatology and American Dermatological Association, as inaugural co-Chair of the Pediatric Dermatology Research Alliance, and as President and Board of Directors of the Society for Investigative Dermatology, Society for Pediatric Dermatology, Women's Dermatologic Society, International Eczema Council, and Chicago Dermatological Society. She is co-author of Hurwitz’s Clinical Pediatric Dermatology and an Associate Editor of the Journal of Investigative Dermatology. Among recently received honors are the Clarence S. Livingood, MD Memorial Award from the American Academy of Dermatology, the Mentor of the Year Award and Rose Hirschler Award from the Women’s Dermatologic Society, and the Founder’s Award from the Chicago Dermatological Society.

AWARD HISTORY

The Stephen Rothman Memorial Award is presented annually for distinguished service to investigative cutaneous medicine. The recipient of this award has made major scientific achievements and excelled as a teacher and recruiter of outstanding dermatologists. The recipient is an individual who has distinctly altered the course and image of dermatology or its allied fields. It is the Society’s highest award.
JULIUS STONE LECTURE

Automated Discovery of Genetic Diseases by Saturation Mutagenesis in Mice

Friday, April 28, 2017  9:15 am – 9:45 am  Oregon Ballroom 201-202

Introduction by  Ponciano Cruz, MD

Bruce Beutler, MD

UT Southwestern Medical Center
Dallas, TX

Bruce A. Beutler, MD, who shared the 2011 Nobel Prize in Physiology or Medicine, is an internationally recognized leader in immunology and the Director of the Center for the Genetics of Host Defense at UT Southwestern Medical Center. Drs. Beutler and Jules A. Hoffmann of Strasbourg University in France shared the Nobel Prize “for their discoveries concerning the activation of innate immunity,” the first step in the body’s immune response. The late Dr. Ralph M. Steinman of Rockefeller University in New York was also honored in 2011. Dr. Beutler is known for his work in unlocking the secret of how the body detects infection and launches an inflammatory response. His current endeavors involve an attempt to identify every gene involved in the response to potentially infectious agents like bacteria or viruses. At UT Southwestern, Dr. Beutler runs one of the largest mouse mutagenesis programs in the world. He and his group have tracked down several hundred mutations that cause abnormalities in mice. Many of these mutations have important implications in infectious diseases or autoimmune conditions in which the body turns on itself, such as lupus and rheumatoid arthritis. Dr. Beutler’s team also has identified many thousands of other genetic mutations that form the nucleus of a mutation archive that eventually will encompass all mouse genes. Dr. Beutler, a Regental Professor at UT Southwestern who holds the Raymond and Ellen Willie Distinguished Chair in Cancer Research, in Honor of Laverne and Raymond Willie Sr., earned his medical degree from the University of Chicago after graduating from the University of California, San Diego. His postgraduate career at UT Southwestern includes an internal medicine internship and neurology residency. During a brief fellowship and faculty appointment at Rockefeller University, Dr. Beutler isolated tumor necrosis factor, one of the most important mediators of inflammation. He then returned to UT Southwestern as a faculty member and Howard Hughes Medical Institute Investigator from 1986 to 2000. His seminal work during this period was broadly relevant to host responses to viral infection, cancer, and autoimmunity, and ultimately led to the Nobel Prize. Between 2000 and 2011, Dr. Beutler was at The Scripps Research Institute in La Jolla, Calif.

LECTURESHIP HISTORY

The Julius Stone Lectureship is intended to promote the advancement of knowledge in immunology as it relates to the skin and skin disease. The Lectureship is intended to honor Dr. Julius Stone, whose great commitment to the application of new principles of immunology to the benefit of patients with skin disorders is recognized by this award.
STATE-OF-THE-ART PLENARY LECTURES

LECTURE III

Border Patrol and Melanoma: Keeping the Peace at a Cost?

Friday, April 28, 2017                        9:45 am - 10:15 am  Oregon Ballroom 201-202

Introduction by: Peggy Myung, MD/PhD

Niroshana Anandasabapathy, MD/PhD
Brigham and Women's Hospital
Boston, MA

Dr. Niroshana Anandasabapathy is an investigative physician scientist-formally trained in clinical translation, cancer biology, immunology and Dermatology. She attended medical school at Stanford University and completed her residency at NYU Medical Center. Her research program broadly investigates how mechanisms of tissue homeostasis in peripheral tissues such as skin lead to tumor immune escape of skin cancers. She is a faculty member of the BWH Department of Dermatology post-doctoral scholarship oversight committee, the Harvard Stem Cell Institute, and Harvard Program in Immunology.

LECTURE IV

3D Bioprinting- An Emerging Paradigm in Tissue Engineering

Friday, April 28, 2017                        10:15 am - 10:45 am  Oregon Ballroom 201-202

Introduction by: Spiro Getsios, PhD

Pankaj Karande, PhD
Rensselaer Polytechnic Institute
Troy, NY

Dr. Karande joined Rensselaer Polytechnic Institute in 2008 as an Assistant Professor in the Chemical and Biological Engineering Department. Before coming to Rensselaer, Dr. Karande was the Anna Fuller Postdoctoral Fellow in Molecular Oncology (2006-2008) at the Center for Cancer Research at Massachusetts Institute of Technology. He received his PhD at University of California, Santa Barbara (2006) in the area of transdermal drug delivery. His doctoral work at Santa Barbara focused on rational and combinatorial design of permeation enhancers for the delivery of proteins and polypeptides across the skin. Dr. Karande holds several patents in the area of transdermal formulation design, drug delivery formulations, development of high throughput screening platforms, and novel drug delivery systems. His current research interests include 3D Biofabrication of organs and tissues, and novel drug delivery formulations.
Come See My Poster II

Friday, April 28, 2017 10:45am - 11:00 am Oregon Ballroom 201-202

Presider: Victoria Werth, MD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID’s Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. Semaphorin 4D enhances antibody production in bullous pemphigoid.
   S. Shen, Y. Ke, E. Dang, H. Fang and G. Wang. Xi'an, China. 10:46 am, Abstract #033

2. Vemurafenib impairs the repair of UV radiation induced DNA damage.
   S. Kimeswenger, D. Foedinger and C. Jantschitsch. Vienna, Austria. 10:47 am, Abstract #091

3. Inherited cancer susceptibility mutations in individuals who develop high frequency of basal cell carcinomas.
   HG. Cho, KY. Kuo, E. Epstein, JY. Tang and KY. Sarin. Stanford, CA and Oakland, CA. 10:48 am, Abstract #107

4. UV-signature mutations in the nuclear pore complex are elevated in squamous cell carcinoma in situ and adjacent epidermis.

5. Medicare Part D payments for topical steroids: Rising costs and potential savings.
   H. Song, A. Adamson and A. Mostaghimi. Boston, MA and Chapel Hill, NC. 10:50 am, Abstract #233

6. Phase I study of the nivolumab combined with IFN-B in patients with advanced melanoma.
   T. Fujimura, Y. Kambayashi, S. Furudate, T. Hidaka and S. Aiba. Sendai, Japan. 10:51 am, Abstract #279

   B. Wang, X. Shen and J. Zheng. Shanghai, China. 10:52 am, Abstract #287

8. Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: An argument for the routine use of immunohistochemistry and serial sectioning.
   A. Hickman, A. Stowman, A. Gru and C. Slingluff. Charlottesville, VA. 10:53 am, Abstract #348

9. Infiltration of PD-1+ cells is a poor prognostic factor in invasive extramammary Paget disease.

10. Sensitive skin is highly frequent in atopic dermatitis and correlates with disease severity markers but not necessarily with skin barrier assessments.

    M. Lee, VA. Kinsler, SL. Hart and W. Di. London, United Kingdom. 10:56 am, Abstract #478

12. Determining the genetic basis of epidermolysis bullosa symptoms through genotype-phenotype associations and NGS.
    I. Fuentes, M. Yubero, C. Fuentes, M. Mc Nab, S. Kremer, A. Kantor, F. Mellado, A. Klausengger, J. Bauer, R. Cornwall and F. Palisson. Santiago, Chile, Salzburg, Austria and Cincinnati, OH. 10:57am, Abstract #512
Business Meeting For Members

Friday, April 28, 2017  11:00 am – 11:30 am  Oregon Ballroom 201-202

Honorary Membership is one of the highest honors the Society for Investigative Dermatology (SID) bestows. Each of the following SID Members has made sustained and important contributions to the research base in cutaneous biology and has contributed to the organizational success of the SID. Each has also excelled in their role as a mentor to numerous individuals over the course of their academic career.

Congratulations to Drs. Irene Leigh and Douglas Lowy on their appointment to SID Honorary Membership!

Irene Leigh, MD
University of Dundee
Dundee, Scotland

Dr. Leigh is a Professor at the University of Dundee, and her research has centered around all aspects of keratinocyte biology from studying basic epithelial differentiation into disease applications, particularly the molecular mechanisms of skin cancer, genetic disease and tissue engineering and she is widely recognized as an international leader in those fields. Her group has made major contributions to the understanding and treatment of human disease, including Recessive Dystrophic Epidermolysis Bullosa, Non-Melanoma Skin Cancers, and Wound Healing. She was also the Local Chair for the 2013 International Investigative Dermatology meeting in Edinburgh.

Douglas Lowy, MD
National Cancer Institute
Bethesda, MD

Dr. Lowy served as NCI Deputy Director from 2010 to 2015. In addition to serving as Acting NCI Director, Dr. Lowy is chief of the Laboratory of Cellular Oncology in NCI’s Center for Cancer Research. He is a member of the National Academy of Sciences (NAS) and a member of the Institute of Medicine of the NAS. Dr. Lowy received the Federal Employee of the Year Service to America Medal from the Partnership for Public Service in 2007, and the Sabin Gold Medal Award from the Sabin Vaccine Institute in 2011. In November 2014, he was honored by President Obama with the National Medal of Technology and Innovation.
New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Poster Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carcinogenesis and Cancer Genetics</td>
<td>105, 114, 137, 143, 123, 120, 122, 140, 097, 095</td>
</tr>
<tr>
<td>Moderator: Masaoki Kawasumi, MD/PhD</td>
<td></td>
</tr>
<tr>
<td>Clinical Research: Epidemiology of skin diseases</td>
<td>181, 190, 193, 159, 165, 174, 209, 217, 220, 227</td>
</tr>
<tr>
<td>Moderator: Robert Dellavalle, MD/PhD</td>
<td></td>
</tr>
<tr>
<td>Epidermal Structure and Barrier Function</td>
<td>636, 602, 410, 414, 456, 451, 438, 428, 403</td>
</tr>
<tr>
<td>Moderator: Theodora Mauro, MD</td>
<td></td>
</tr>
<tr>
<td>Growth Factors, Cell Adhesion and Matrix Biology</td>
<td>551, 563, 543, 553, 552, 550, 555, 560, 561, 627</td>
</tr>
<tr>
<td>Moderator: James Elder, MD/PhD</td>
<td></td>
</tr>
<tr>
<td>Pharmacology and Drug Development</td>
<td>666, 675, 689, 704, 712, 722, 669, 694, 696, 701</td>
</tr>
<tr>
<td>Moderator: Michael Girardi, MD</td>
<td></td>
</tr>
</tbody>
</table>
International Eczema Council at the SID Meeting

Friday, April 28, 2017                  12:00 pm – 1:30 pm Oregon Ballroom 204

LUNCH WILL BE SERVED

12:00 pm  Welcome/Overview of the IEC and Roadmap of AD at the SID
          Amy Paller
          IEC President, Northwestern University, Chicago, IL, USA

12:10 pm  Abstract Presentations

          Increased interleukin-19 expression in cutaneous T-cell lymphoma as well as atopic dermatitis. Oka Tomonori et al. Univ. of Tokyo, Tokyo, Japan #256

          Cutaneous acquisition of Staphylococcus quorum-sensing agr mutations protects against atopic dermatitis development. Yuumi Nakamura et al., Chiba Univ., Chiba, Japan. #623

          The serum proteomic signature of pediatric AD suggests early Th2/Th17 skewing and an inverse correlation of disease severity with Th1 markers. Patrick Brunner et al. Rockefeller Univ., New York, NY, USA #642

12:45 pm  Special Presentation:
          The precise control of skin barrier homeostasis
          Masayuki Amagai, Keio University, Tokyo, Japan

1:10 pm   Abstract Presentations

          Bleach baths promote early induction of inflammatory pathway genes with no effect on skin bacterial dysbiosis in AD subjects. Sara Knowlden et al., Univ. of Rochester, Rochester, NY, USA #296

          Treatment interruption did not impact efficacy or long-term safety of dupilumab: A phase 3 open-label trial. Lisa Beck et al. Univ. of Rochester, Rochester, NY, USA #251

Special thanks to the International Eczema Council for supporting this session.
International Psoriasis Council Symposium: Scientific and Clinical Advances in Psoriasis: 2017 and Beyond

Friday, April 28, 2017 12:00 pm – 1:30 pm B113-116

This symposium will explore recent advances in the understanding of both the innate and adaptive immune pathways leading to the psoriasis phenotype. Global experts will present evidence describing the functional roles of novel cellular (neutrophils and Tregs) and molecular (Act1) drivers and their contribution to the inflammatory response. In addition, this symposium will highlight new epidemiological evidence demonstrating increased risk of comorbid development in children with psoriasis and premature death in adult patients with severe psoriasis.

PROGRAM CO-CHAIRS
Andrew Blauvelt, MD, MBA – Portland, Oregon
Oregon Medical Research Center
Johann Gudjonsson, MD, PhD – Ann Arbor, Michigan
University of Michigan

CONTRIBUTING CHAIR
Hervé Bachelez, MD, PhD – Paris, France
Hôpital Saint-Louis & Sorbonne Paris Cité Université

To view the full program agenda, please visit www.psoriasiscouncil.org/sid2017.

About the International Psoriasis Council (IPC)
Founded in 2004, the International Psoriasis Council (IPC) is a dermatology-led, voluntary, global nonprofit organization dedicated to innovation across the full spectrum of psoriasis through research, education and patient care.

Mission
IPC’s mission is to advance the care of people with psoriasis world-wide, through education, research and advocacy.
American Dermato-Epidemiology Network (ADEN) Symposium

Friday, April 28, 2017 12:00 pm – 1:30 pm B117-119

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:00 pm</td>
<td>Welcome and introductions</td>
</tr>
<tr>
<td>12:05 pm</td>
<td>Founders Award Presentation</td>
</tr>
<tr>
<td>12:25 pm</td>
<td>Trainee awards</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>Natural history of basal cell carcinoma: A longitudinal study of clinically suspicious lesions in Ikaria, Greece #185</td>
</tr>
<tr>
<td>12:40 pm</td>
<td>Disparities in the incidence and survival of eccrine malignancies in the United States #167</td>
</tr>
<tr>
<td>12:50 pm</td>
<td>Global skin disease morbidity and mortality: An update from the Global Burden of Disease Study 2013 #181</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Real world systemic corticosteroid (SCS) utilization patterns and costs in adult patients with atopic dermatitis (AD) #243</td>
</tr>
<tr>
<td>1:10 pm</td>
<td>Influence of market competition on Tetracycline pricing and impact of price increases on clinician prescribing behavior #165</td>
</tr>
<tr>
<td>1:20 pm</td>
<td>ADEN business meeting</td>
</tr>
</tbody>
</table>
Medical Dermatology Society at the Society For Investigative Dermatology

Friday, April 28, 2017  12:00 pm – 1:45 pm  A105-106

12:00 pm  Introduction and Welcome

12:05 pm  Psoriasis age of onset: Effect on treatment outcomes in the PSOLAR registry. Sanminder Singh, University of California, Davis. Abstract #189

12:17 pm  The balance between the malignant clone and reactive T-cells in skin reliably predicts progression in CTCL. Adèle de Masson, MD, Brigham and Women’s Hospital. Abstract #400

12:29 pm  Changes of lesional and non-lesional skin microbiome in the treatment course of atopic dermatitis. Jung-Im Na, PhD, Seoul National University Bundang Hospital. Abstract #656

12:41 pm  Skin surface temperature detection with thermal imaging camera aids in cellulitis diagnosis. Adam Raff, MD/PhD, Massachusetts General Hospital. Abstract #319

12:52 pm  Molecular basis of hair follicle donor dominance in androgenetic alopecia and sexual dimorphism of the skin. Yanne Doucet, PhD, Columbia University. Abstract #863

1:04 pm  Systematic review of treatments for keratinocyte carcinoma. Aaron Drucker, MD, The Warren Alpert Medical School of Brown University. Abstract #402

1:16 pm  Bone marrow/cord blood transplantation (BMCBT) ameliorates symptoms in some, but not all, subtypes of severe generalized junctional epidermolysis. Jakub Tolar, MD/PhD, University of Minnesota/Pediatric BMT. Abstract #308

1:28 pm  The cost of acne/rosacea prescriptions in Medicare patients varies by prescriber specialty. Myron Zhang, The Ohio State University College of Medicine. Abstract #159

1:40 pm  Discussion and Concluding Remarks

Members of the Medical Dermatology Society (MDS) represent the heart and soul of our specialty: Medical Dermatology. The MDS is made up of the thought leaders of clinical dermatology and the teachers of the next generation of practicing dermatologists. Our members include academicians, private practitioners, and resident physicians. We specialize in the care of patients with serious dermatologic diseases. Our mission is to improve the care of patients with these conditions.

Dermatologists are encouraged to pursue a career in medical dermatology by:
- Encouraging resident presentations at our Annual Meeting
- Developing Advanced Medical Dermatology Rotations for residents to work with experts in our field across the country
- Encouraging dermatology programs to sponsor 5-year combined Internal Medicine/Dermatology training programs
- Coordinating and providing lectures and sessions on medical dermatology topics at major dermatology meetings
- Providing lectures, discussions and case presentations at the annual Medical Dermatology Society Meeting
International Society for Cutaneous Lymphomas
Cutaneous T Cell Lymphoma Symposium

Friday, April 28, 2017 12:00 pm – 1:30 pm  C123-124

Presiders: Joan Guitart, MD, Larisa Geskin, MD, Sam Hwang, MD/PhD, and Gary Wood, MD

12:00 pm  ISCL Announcements
8 minutes for presentation + 2 minutes for Q&A and change of speaker

1. 12:10 pm  Cutaneous Lymphoma Foundation’s Young Investigator’s Award


3. 12:30 pm  Epigenetically-enhanced PDT (ePDT) induces significantly higher levels of multiple extrinsic pathway apoptotic factors than conventional PDT, resulting in greater extrinsic and overall apoptosis of CTCL. Gary Wood, K. Salva and Y. Kim. Abstract #312


6. 1:00 pm  MicroRNA based classifiers in diagnosis and prognosis of cutaneous T cell lymphoma. Bo Wang, X. Shen and J. Zheng. Abstract #287


Visit www.cutaneouslymphoma.org for more information about the ISCL and membership!
Research in Cutaneous Surgery Mini-Symposium

Friday, April 28, 2017 12:00 pm – 1:30 pm B112

The Research in Cutaneous Surgery Mini-Symposium is a forum for clinically relevant, patient-directed research in dermatologic surgery, including cancer surgery, laser surgery, and cosmetic surgery. With a primary emphasis on clinical research, the symposium aims to highlight clinical trials on procedure safety and effectiveness, as well as epidemiologic investigations. As research in cutaneous surgery is a growing field, the symposium also serves to bring together investigators to facilitate future collaborations. Pilot studies and early work are appropriate for submission. Those interested in directing an abstract to this session next year are encouraged to contact any of the co-moderators for more information.

Moderator: Murad Alam, MD
Co-Moderators: Kachiu Lee, MD & Stephanie Rangel, PhD

1. 12:00 pm Acne Core Outcomes Research Network (ACORN) reaches consensus on outcomes to measure. Diane Thiboutot. Abstract #338
2. 12:07 pm Patient Centered Outcomes for Skin Cancer Management; a single-day skin cancer patient Delphi process to assess the importance of treatment themes. Ian Maher and Amanda Maisel
3. 12:14 pm Potential adverse psychosocial impacts of skin biopsies in the context of melanoma screening. Natalie Matthews. Abstract #161
4. 12:21 pm Surveillance adherence of patients after treatment of primary cutaneous melanoma. Jeave Reserva. Abstract #177
5. 12:28 pm Melanoma and chronic low dose ethinyl estradiol contraceptives in young women: A large midwestern U.S. patient population retrospective study. Kelly Mueller. Abstract #813
6. 12:35 pm Risk factors of high frequency basal cell carcinoma: Gender, histologic subtypes, anatomic distribution, and associated immunosuppression. Grace Cho. Abstract #174
7. 12:42 pm A systematic review on the use of cryotherapy versus other treatments for basal cell carcinoma. Catherine Tchanque-Fossuo. Abstract #372
10. 1:03 pm Factors associated with skin dehiscence in a large single center, U.S. population. Beatrice Nardone.
11. 1:10 pm Impact of topical 5-fluorouracil cream on photodamage using four validated photonumeric scales. Kaveri Korgavkar. Abstract #171
12. 1:17 pm Laser treatment in ffa. Jacob Subash. Abstract #340
CONCURRENT MINI-SYMPOSIUM 6
Clinical Research: Patient Outcomes Research
Includes meta-analysis of interventional trials, and patient outcomes research.

Friday, April 28, 2017                2:00 pm – 4:30 pm  Oregon Ballroom 204

Presiders: Benjamin Chong, MD and Mary-Margaret Chren, MD

1. Serious infections among a large cohort of subjects with systemically-treated psoriasis. A. Dobry. Boston, MA. 2:00 pm, Abstract #399


6. Establishing severity strata for 5 different patient-reported outcomes in adults with atopic dermatitis. R. Sacotte, P. Vakharia, R. Chopra, N. Patel, S. Immaneni, T. White, R. Kantor, D. Hsu, E. Simpson and J. Silverberg. Chicago, IL and Portland, OR. 3:00 pm, Abstract #383


8. Type VII collagen (C7) expression and chimerism after bone marrow/cord blood transplantation (BMCT) for severe generalized dystrophic epidermolysis bullosa (RDEB). J. Tolar, J. McGrath, M. Osborn, D. Keene, M. Riddle, K. Hook, M. Hordinsky, M. Marinkovich, D. Woodley, M. Chen, R. Tryon, T. DeFor, C. Ebens, K. Tamai, A. Hovnanian, B. Blazar and J. Wagner. Minneapolis, MN; London, United Kingdom; Portland, OR; Stanford, CA; Los Angeles, CA; Osaka, Japan and Paris, France. 3:24 pm, Abstract #377


12. Effect of a single course of topical 5-fluorouracil (5FU) on basal cell carcinoma (BCC) chemoprevention in older veterans. AD. Means, NF. Leader and MA. Weinstock. Boston, MA and Providence, RI. 4:12 pm, Abstract #362

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 7
Genetic Disease, Gene Regulation and Gene Therapy
Studies on cutaneous gene expression and genetic diseases including gene therapy.

Friday, April 28, 2017  2:00 pm – 4:30 pm  B113-116

Presiders:  Keith Choate, MD/PhD and Alain Hovnanian, MD/PhD


6. GNA14 somatic mutation causes congenital and sporadic vascular tumors by MAPK activation.  Y. Lim, A. Bacchiocchi, J. Qiu, A. Bruckner, L. Bercovitch, D. Narayan, J. McNiff, C. Ko, L. Robinson-Bostom, R. Antaya, R. Halaban and K. Choate. New Haven, CT; Aurora, CO and Providence, RI. 3:00 pm, Abstract #513


10. SNPs within the MHC associated with atopic dermatitis are located within miRNA sequences.  P. Clark, N. Chitnis, M. Kamoun, B. Johnson, DJ. Margolis and D. Monos. Philadelphia, PA. 3:48 pm, Abstract #492


Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPHOSIUM 8

Innate Immunity, Microbiology, Inflammation

Studies of cells, receptors and effector molecules of the innate immune response; studies on skin microbes and infectious processes of the skin.

Friday, April 28, 2017  2:00 pm – 4:30 pm  Oregon Ballroom 203

Presiders:  Anna Di Nardo, MD/PhD and Heidi Kong, MD


2. Plasmacytoid dendritic cell-derived type I interferon drives flares of rosacea. A. Mylonas, O. Demaria, S. Meller, H. Friedrich, B. Homey, J. Di Domizio, M. Gilliet and C. Conrad. Lausanne, Switzerland; Marseille, France and Dusseldorf, Germany. 2:12 pm, Abstract #584

3. Resistin-like molecule α (relmα) is a skin antimicrobial protein that is regulated by vitamin A. T. Harris, S. Gattu, D. Propheter and L. Hooper. Dallas, TX. 2:24 pm, Abstract #568

4. Microbiome-induced S1P released from keratinocytes promotes antimicrobial activity in mast cells. Y. Chang, Z. Wang, N. Mascarenhas and A. Di Nardo. La Jolla, CA. 2:36 pm, Abstract #637

5. Specific strains of S. epidermidis suppress UV-induced skin tumor formation by production of 6-N-hydroxyaminopurine, a DNA synthesis inhibitor. T. Nakatsuji, T. Chen and RL. Gallo. San Diego, CA. 2:48 pm, Abstract #612


8. Neutrophil extracellular traps exacerbate the inflammation in psoriasis by inducing CXCL1/CXCL10 secretion in keratinocytes. J. Lei, S. Shao, H. Fang, E. Dang and G. Wang. Xi’an, China. 3:24 pm, Abstract #590

9. Imiquimod has strain-dependent effects in mice and does not uniquely model human psoriasis. WR. Swindell, K. Michaels, A. Sutter, D. Diaconu, Y. Fritz, X. Xing, MK. Sarkar, Y. Liang, LC. Tsol. JE. Gudjonsson and NL. Ward. Athens, OH; Cleveland, OH and Ann Arbor, MI. 3:36 pm, Abstract #645

10. Microbial-sensing liver γ/δ T-cells modulate cutaneous inflammation. E. Merrill, M. Constantinides, S. Nakajima and Y. Belkaid. Bethesda, MD. 3:48 pm, Abstract #600

11. TLR2/MyD88 signaling on T cells mediates a compensatory protective immune response to IL-1β/MyD88 signaling against secondary S. aureus skin challenge. C. Dillen, B. Pinsker, H. Liu, Y. Wang, R. Ortizes, N. Archer and L. Miller. Baltimore, MD. 4:00 pm, Abstract #631

12. Staphylococcal lipopeptide induces beta-catenin to suppress TLR3-mediated skin inflammation in diabetes. D. Li and Y. Lai. Shanghai, China. 4:12 pm, Abstract #571

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPOSIUM 9
Photobiology

Studies on biological, biochemical, and molecular responses to ultraviolet radiation in cells, animals and humans.

Friday, April 28, 2017  2:00 pm – 4:30 pm  C123-124

Presiders:  Sewon Kang, MD and Thomas Ruenger, MD/PhD

1. Phosphorylation of XPC regulates XPC’s function in UV-induced DNA damage repair.  
P. Shah, B. Zhao, L. Qiang and Y. He. Chicago, IL.  2:00 pm, Abstract #752

2. Enhanced skin tumor development in CHOP knockout mice after UVB exposure involves modulation of multiple survival and apoptotic signaling pathways.  
S. Anand and EV. Maytin. Cleveland, OH.  2:12 pm, Abstract #746

3. In-vivo evidence that mitochondrial (mt) DNA mutagenesis drives skin aging.  
Düsseldorf, Germany and Madrid, Spain.  2:24 pm, Abstract #742

2:36 pm, Abstract #764

5. The role of p62-dependent regulation of COX-2 in UVA response and skin tumor progression.  
A. Sample, L. Qiang, B. Zhao and Y. He. Chicago, IL.  2:48 pm, Abstract #753

6. The aryl hydrocarbon receptor (AHR) protects keratinocytes (KC) against the UVA phototoxicity of 6-formylindolo[3,2-b]carbazole (FICZ), an AHR ligand formed after UVB irradiation.  
Düsseldorf, Germany and Nagoya, Japan.  3:00 pm, Abstract #737

7. ALA-PDT induced immunogenic apoptotic cells enhanced DC vaccine for skin squamous cell carcinoma.  

8. REDD1 and AKT signaling in UVB-induced apoptosis.  
RP. Feehan and LM. Shantz. Hershey, PA.  3:24 pm, Abstract #745

9. Pollution and sunlight synergistically contribute to skin photodamage.  
L. Marrot, A. Dimitrov and J. Soeur. Aulnay sous Bois, France.  3:36 pm, Abstract #729

10. Chemoprevention of ultraviolet-B radiation mediated skin carcinogenesis by dietary grape powder in SKH-1 hairless mice.  

11. Gasdermin C is induced by ultraviolet and contributes to MMP-1 expression via activation of ERK and JNK pathways.  
N. Kusumaningrum. Seoul, Republic of Korea.  4:00 pm, Abstract #760

12. Protective effects of ROCK Inhibition on Neutrophil NETosis in UVB induced-skin inflammation.  
M. Liu, M. Sharma and V. Werth. Philadelphia, PA.  4:12 pm, Poster #758

Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
CONCURRENT MINI-SYMPHOSUM 10

Tissue Regeneration and Wound Healing

Wound healing and regeneration studies; processes/signaling that regulate vascular development and angiogenesis; interactions between different skin components (epithelial cells, dermal cells, nerves, vasculature, melanocytes, fat) in homeostasis and regeneration.

Friday, April 28, 2017 2:00 pm - 4:30 pm A105-106

Presiders: Christian Posch, MD and Marjana Tomic-Canic, PhD

1. MicroRNA-132 with therapeutic potential in chronic wound. X. Li, D. Li, A. Wang, T. Chu, W. Lohcharoenkal, E. Herter, M. Ehrström, L. Eidsmo, A. Pivarcsi, E. Sonkoly, S. Catrina, M. Stähle and N. Xu Landén. Stockholm, Sweden and Dalian, China. 2:00 pm, Abstract #933

2. CD44 and p38 participate in regulating the pro-fibrotic capability of dermal fibroblasts during skin wound healing. Y. Wang, J. Mack and EV. Maytin. Shaker Heights, OH and Cleveland, OH. 2:12 pm, Abstract #917


6. Suppression of DNA repair and lack of cellular migration are major contributors of diabetic foot ulcer pathophysiology. H. Ramirez, I. Pastar, R. Stone, T. Cao Wikramanayake, I. Jozic, O. Stojadinovic, N. Ojeh, RS. Kirsner and M. Tomic-Canic. Miami, FL and Bridgetown, Barbados. 3:00 pm, Abstract #905


11. Adipose multilineage-differentiating stress enduring (Muse) cell maintain pluripotency regardless of donors’ age. T. Yamauchi, K. Yamasaki, K. Tsutiyama, S. Koike and S. Aiba. Sendai, Japan. 4:00 pm, Abstract #904


Immediately following this session, a 30 minute mixer will be held. Presenters, moderators and attendees will be able to interact as they enjoy light refreshments and snacks. These mixers are designed to encourage informal discussion, mingling and networking among SID meeting attendees.
Introducing a New Topical Prescription Treatment Option for Atopic Dermatitis

Friday, April 28, 2017             5:00 pm – 5:45 pm               Oregon Ballroom 201-202

Come learn about a new nonsteroidal treatment option for patients with mild-to-moderate atopic dermatitis.

Please join us for a non-CME program presented by:

Lawrence Eichenfield, MD
Professor of Dermatology and Pediatrics
Chief of Pediatric and Adolescent Dermatology
University of California, San Diego
Rady Children’s Hospital–San Diego
San Diego, California

Refreshments will be provided.

Notice: This event is conducted in accordance with the PhRMA Code on Interactions with Healthcare Professionals and is limited to healthcare professionals (HCPs). Attendance by guests or spouses is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit their ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this or any Pfizer event. Your attendance will be considered confirmation to Pfizer that you have obtained any necessary approvals to attend this event.

State Laws and Pfizer Disclosures: The cost of meals and refreshments provided to US licensed Healthcare Professionals attending this Pfizer-sponsored program will be subject to public disclosure on www.pfizer.com as part of Pfizer’s Healthcare Professional Disclosure policies, and may also be subject to disclosure by state governmental authorities pursuant to your state law and applicable federal law such as the National Physician Payment Transparency Program (otherwise known as “Sunshine”). Pfizer’s disclosure will allocate the cost of meals and refreshments equally across all attendees regardless of actual consumption. If you are licensed to practice in Minnesota or Vermont, we are prohibited from providing you any meals and/or refreshments due to your state limitation on meals, gifts or other items of value to HCPs and ask that you do not partake in the hospitality provided.
National Eczema Association

Friday, April 28, 2017 6:00 pm – 7:00 pm A105-106

The National Eczema Association invites you to join us at our cocktail reception at the 2017 Annual SID Meeting.

Raise a glass to celebrate advancements in eczema!

It’s been a great year for advancements in eczema care and treatment. Clinical research is moving at a rapid rate and life-changing medications are entering the market for the first time in decades.

We have much to celebrate, so join us and toast the health of the millions of people with eczema who can see the future – and it’s clear.

Thank you to our presenting sponsor

GALDERMA
North American Hair Research Society Scientific Meeting and Annual General Meeting

Friday, April 28, 2017                      6:00 pm – 8:30 pm Oregon Ballroom 203

Presiders: John T. Seykora, MD/PhD, Chair, Scientific Program Committee, and Maria K. Hordinsky, MD, President

6:00 pm Poster Viewing & Reception


2. The role of astrotactin2 in regulating mammalian skin polarity. Hao Chang. Abstract #851

3. Human scalp-derived fibroblasts alter FGF expression profile upon WNT activation: implication of their role to provide folliculogenetic microenvironment. Misaki Kinoshita-Ise, A. Tsukashima, T. Kinoshita, Y. Yamazaki and M. Ohyama. Abstract #846


11. Treatment of severe alopecia areata with the oral Janus kinase inhibitor, tofacitinib: A retrospective chart review. Omer Ibrahim, S. Hogan, M. Piliang and W. Bergfeld. Abstract #378


CONTINUED
CONTINUED:

North American Hair Research Society Scientific Meeting and Annual General Meeting

Friday, April 28, 2017                     6:00 pm – 8:30 pm Oregon Ballroom 203

6:45 pm Keynote Speaker

**Immune regulation mediated by the hair follicles**
Keisuke (Chris) Nagao, MD/PhD
Earl Stadtman Investigator, Dermatology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

7:15 pm Oral Presentations

12 minutes for presentation + 3 minutes for Q&A and change of speaker

1. **Small T antigen from a folliculotropic polyomavirus activates canonical Wnt/β-catenin signaling in vivo.** LJ. Syu, M. Verhaegen, M. Grachtchouk, D. Mangelberger, H. Zabawa and A. Dlugosz. 7:15 pm, Abstract #877

2. **Dermal lymphatic vessels promote hair follicle growth via the BMP inhibitor Sostdc1.** Sun-Young Yoon, LC. Dieterich, S. Karaman, ST. Proulx, S. Bachmann, C. Sciaroni and M. Detmar. 7:30 pm, Abstract #845

3. **Large-scale screening for T cell epitopes in human alopecia areata.** Eddy Hsi Chun Wang, T. Gordon, A. de Jong, P. Sinu, P. Lindestam, A. Sette and AM. Christiano. 7:45 pm, Abstract #028

8:00 pm NAHRS Business Meeting

Visit www.nahrs.org for more information about the NAHRS and membership!
National Psoriasis Foundation Reception at SID

Friday, April 28, 2017 6:00 pm – 7:30 pm B117-119

Join us for an exciting opportunity to network and learn about NPF research grants and fellowships, patient engagement in research and membership opportunities.

Hosted bar and light hors d’oeuvres will be provided.

Questions please contact NPF Research Program Coordinator Samantha at research@psoriasis.org
SATO JAPAN Scientific Forum
at SID 2017

Friday, April 28, 2017
6:30 pm – 9:30 pm
C123-124

Please join us for a contemporary scientific lecture and social gathering.

Chair: Kenshi Yamasaki, MD/PhD
Associate Professor, Vice-Chair, Department of Dermatology
Tohoku University Graduate School of Medicine
Tohoku University School of Medicine
Tohoku University Hospital, Sendai Japan

Acne – Now and the Future: Figuring Out Puzzles of Pathogenesis and Translating Insights into Therapy

Lawrence F. Eichenfield, MD
Chief, Pediatric and Adolescent Dermatology
Professor of Dermatology and Pediatrics
Vice Chair, Department of Dermatology
University of California, San Diego School of Medicine and Rady Children’s Hospital, San Diego, CA

Dr. Lawrence F. Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital-San Diego, Vice Chair of the Department of Dermatology, and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine. He received his medical degree from Mount Sinai School of Medicine in New York, was a pediatric resident and Chief Resident at Children’s Hospital of Philadelphia, and completed his dermatology residency at the Hospital of the University of Pennsylvania. Dr. Eichenfield’s clinical interests include atopic dermatitis, acne, psoriasis, vascular lesions including port wine stains and hemangiomas, neonatal dermatology, laser surgery, nevi, and skin signs of systemic disease. He has authored more than 300 journal articles, chapters, abstracts, and books on these topics and has served as the senior editor of Neonatal and Infant Dermatology, published by Elsevier, as well as The Eczemas, published by Summit Communications. He is also Editor-in-Chief of Pediatric Dermatology and serves on the editorial boards of multiple journals and periodicals. In addition, Dr. Eichenfield has been honored as a member of the Alpha Omega Alpha Medical Honor Society during medical school, as a recipient of the Benjamin Ritter Award at Children’s Hospital of Philadelphia, and as a recipient of excellence in teaching awards from UCSD Pediatrics, UCSD Dermatology, and Rady Children’s Hospital-San Diego. He has been named one of the “Best Doctors in America” since 1994. Dr. Eichenfield is past president of the Society for Pediatric Dermatology, past Board member of the American Academy of Dermatology as well as Chair for the 69th Annual Meeting of the American Academy of Dermatology. Dr. Eichenfield is also a founding board member of the American Acne and Rosacea Society. He is a founder and Co-Chair of the Pediatric Dermatology Research Alliance (PeDRA).
### Saturday Sessions

<table>
<thead>
<tr>
<th>PAGE</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>85</td>
<td>Meeting-At-A-Glance</td>
</tr>
<tr>
<td>86</td>
<td>Plenary Session III</td>
</tr>
<tr>
<td>87</td>
<td>William Montagna Lecture</td>
</tr>
<tr>
<td>88</td>
<td>Herman Beerman Lecture</td>
</tr>
<tr>
<td>89</td>
<td>Come See My Poster III</td>
</tr>
<tr>
<td>90</td>
<td>Clinical Scholars Program Session III</td>
</tr>
<tr>
<td>91</td>
<td>Selected ePoster Discussions III</td>
</tr>
</tbody>
</table>
| 92   | Concurrent Mini-Symposium 11  
Carcinogenesis and Cancer Genetics |
| 93   | Concurrent Mini-Symposium 12  
Clinical Research: Epidemiology of Skin Diseases |
| 94   | Concurrent Mini-Symposium 13  
Epidermal Structure and Barrier Function |
| 95   | Concurrent Mini-Symposium 14  
Growth Factors, Cell Adhesion and Matrix Biology |
| 96   | Concurrent Mini-Symposium 15  
Pharmacology and Drug Development |
Stay in touch with the SID throughout the year!

@SocietyforInvestigativeDermatology
@SocInvestDerm
Society for Investigative Dermatology
socinvestderm

Claim your CME Credits

In order to receive CME credit, participants must sign-in, review the CME information (accreditation, learning objectives, faculty disclosure, etc.) and attend the CME activity. To access the program evaluation, claim CME Credits, or print your certificate, go to www.cme.urmc.edu or use the QR Code.
# Meeting-At-A-Glance

## SATURDAY, APRIL 29, 2017

<table>
<thead>
<tr>
<th>Event</th>
<th>Time</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>7:30 am - 12:00 pm</td>
<td>Pre-Function A Foyer</td>
</tr>
<tr>
<td>Plenary Session III</td>
<td>8:00 am - 9:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>William Montagna Lecture</td>
<td>9:00 am - 9:30 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>From Morphogenesis to Disease: A Wnt’ers Tale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sarah Millar, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Herman Beerman Lecture</td>
<td>9:30 am - 10:00 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>How to Make Antibodies for Tumor Immunotherapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alan J. Korman, PhD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Come See My Poster III</td>
<td>10:00 am - 10:15 am</td>
<td>Oregon Ballroom 201-202</td>
</tr>
<tr>
<td>Poster #’s 325, 357, 421, 427, 535, 623, 714, 812, 884</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical Scholars Program Session II</td>
<td>10:15 am - 12:00 pm</td>
<td>Oregon Ballroom 203</td>
</tr>
<tr>
<td>Emerging Immunotherapies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Poster Session III/Coffee Break</td>
<td>10:15 am - 12:15 pm</td>
<td>Exhibit Hall A</td>
</tr>
<tr>
<td>Odd Poster #’s 313-623</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Poster #’s 626-934</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Odd Late-Breaking Poster #’s 961-985</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Even Late-Breaking Poster #’s 986-1008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selected ePoster Discussions III</td>
<td>10:45 am - 11:45 am</td>
<td>Exhibit Hall A Foyer</td>
</tr>
<tr>
<td>See Page #91</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concurrent Mini-Symposia</td>
<td>12:30 pm - 3:00 pm</td>
<td></td>
</tr>
<tr>
<td>11. Carcinogenesis and Cancer Genetics</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Clinical Research:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Epidermal Structure and Barrier Function</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14. Growth Factors, Cell Adhesion and Matrix Biology</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15. Pharmacology and Drug Development</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
PLENARY SESSION III
Presiders: Ponciano Cruz, MD and Paul Nghiem, MD/PhD

Saturday, April 29, 2017              8:00 am – 9:00 am           Oregon Ballroom 201-202

1. Gentamicin therapy induced functional type VII collagen in recessive dystrophic epidermolysis bullosa patients harboring nonsense mutations. M. Chen, J. Cogan, Y. Hou, D. Keene and D. Woodley. Los Angeles, CA and Portland, OR. 8:00 am, Abstract #299


3. Temporally controlled B cell depletion with universal chimeric antigen receptor (CAR) T cells for pemphigus vulgaris (PV) therapy. CT. Ellebrecht, X. Mao, JJ. Melenhorst, S. Lacey, Y. Zhao, MC. Milone and AS. Payne. Philadelphia, PA. 8:24 am, Abstract #035


5. Aging and diet-induced obesity impair activation of adipocytes that protect against invasive Staphylococcus aureus skin infection. L. Zhang, F. Li and RL. Gallo. San Diego, CA. 8:48 am, Abstract #634
WILLIAM MONTAGNA LECTURE

From Morphogenesis to Disease: A Wnt'ers Tale

Saturday, April 29, 2017              9:00 am – 9:30 am           Oregon Ballroom 201-202

Introduction by:  Alice Pentland, MD

Sarah Millar, PhD
University of Pennsylvania
Philadelphia, Pennsylvania

Sarah Millar, PhD is internationally recognized as a leading researcher in epithelial development, stem cells and regeneration and has over 60 publications in leading peer-reviewed journals. Her research group has made seminal discoveries on the roles of Wnt inter-cellular signaling in epithelial development and regeneration. They also identified key roles for miRNAs in epidermal development and regeneration, and essential requirements for histone deacetylases in epidermal stem cell proliferation and survival. Their current research directions include elucidating the functions of Wnt ligands and their receptors, and chromatin repressive complexes, in the development and regeneration of skin, hair follicles, mammary glands and teeth. They are also developing genetic mouse models for human ectodermal dysplasias to delineate disease mechanisms and test potential therapeutic approaches. NIH has continuously supported Dr. Millar’s laboratory’s research since 2001. In addition, Dr. Millar is the Director and PI of a new NIH P30-supported UPenn Skin Biology and Diseases Resource-based Center. She has mentored, or is currently mentoring, 14 graduate students and ten post-doctoral fellows in her laboratory, four of whom now have faculty positions at Texas A & M University, Vanderbilt University, the University of Pennsylvania, and the University of Cincinnati. She is PI of the UPenn Dermatology T32 training grant which supports research training for medical students, graduate students, post-doctoral fellows and research track dermatology residents, 10 of whom are now on the faculty at academic institutions. She also served as Chair of the Developmental Stem Cell and Regenerative Biology (DSRB) graduate group at UPenn from 2009-12. In this capacity she was in charge of administration, admissions, advising, mentoring, and fund raising. Under her leadership the program grew from 43 applicants and 3 matriculating students in 2008 to 94 applicants and 11 matriculating students in 2011. She serves as an Editorial Board member for Developmental Cell and Experimental Dermatology, was a Standing Member of the NIH ACTS study section from 2006-10, and has served on numerous other national and international grant review committees. She is regularly invited to speak at research conferences and institutions worldwide and has received several awards in recognition of her research contributions, including an NIH MERIT Award for her research on Wnt signals in skin and hair development and hair growth, and the Albert Kligman Endowed Chair in Dermatology.

LECTURESHIP HISTORY
The William Montagna Lecture is given annually at the Society’s Annual Meeting. This award is intended to honor and reward young active investigators. Primary emphasis is given to researchers in skin biology.
HERMAN BEERMAN LECTURE

How to Make Antibodies for Tumor Immunotherapy

Saturday, April 29, 2017            9:30 am – 10:00 am            Oregon Ballroom 201-202

Introduction by:  Angela Christiano, PhD

Alan J. Korman, PhD
Vice President of Immuno-Oncology Discovery
Bristol-Myers Squibb
Redwood City, California

Alan J. Korman received his PhD degree from Harvard University (Cambridge, Massachusetts, USA) in 1984 and was a Whitehead Fellow at the Whitehead Institute, Massachusetts Institute of Technology (Cambridge, Massachusetts, USA) from 1984 to 1989. He was also a Chargé de Recherche at the Institut Pasteur (Paris, France) from 1990 to 1993. He has worked in the biotechnology and pharmaceutical industry since 1993 and is currently Vice President of Immuno-Oncology Discovery at Bristol-Myers Squibb (Redwood City, California, USA). He led the preclinical development of the FDA approved checkpoint inhibitor antibodies, ipilimumab (anti-CTLA-4) and nivolumab (anti-PD-1), as well as their combination for the treatment of cancer.

LECTURESHIP HISTORY

This award is given in recognition of Dr. Herman Beerman’s long and devoted service to the SID and his efforts to secure for it a position of respect in the scientific community. The Herman Beerman Lecture is given by a distinguished medical scholar at a scientific session of the Society’s Annual Meeting. Traditionally, lecturers from fields other than dermatology are chosen in order to give meeting attendees the opportunity to learn about scientific advances in other fields.
Come See My Poster III

Saturday, April 29, 2017  10:00 am - 10:15 am  Oregon Ballroom 201-202

Presider:  Paul Nghiem, MD/PhD

The Come See My Poster sessions give opportunities to select presenting authors of highly scored abstracts to give a brief one-minute (and one slide) introduction to their submitted abstract. This rapid paced session leads right into one of the SID’s Poster Sessions, providing both an excellent starting point into the Poster Hall and the generation of excitement for all attendees.

1. Analysis of sirolimus treatment response in lymphatic malformations with and without PIK3CA mutation.
   MN. Pyles, JH. Tu, W. Donahue, E. Tafoya, Z. Zinn, A. Marqueling, MR. Jeng and J. Teng. Stanford, CA and Salt Lake City, UT. 10:01 am, Abstract #325

2. Surgical delays in melanoma vary by insurance type.
   AS. Adamson, L. Zhou, C. Baggett, NE. Thomas and A. Meyer. Chapel Hill, NC. 10:02 am, Abstract #357

3. Elevated serum IgE level, but not TARC and LDH, may reflect the impairment of stratum corneum barrier function in healthy individuals; Results of cross-sectional study of 1141 Japanese healthy individuals.

4. Three dimensional ultrastructural analysis of lamellar granules in stratum granulosum by focused ion beam scanning electron microscopy.
   H. Yamanishi, T. Soma, A. Ishida-Yamamoto and T. Hibino. Yokohama, Japan and Asahikawa, Japan. 10:04 am, Abstract #427

5. Ex vivo COL7A1 editing via CRISPR/Cas9 in recessive dystrophic epidermolysis bullosa.

6. Cutaneous acquisition of Staphylococcus quorum-sensing agr mutations protects against atopic dermatitis development.


8. An imbalance between IL-1 and IL-1Ra in human melanoma cells accounts for autoinflammation and contributes to tumor progression in metastatic melanoma.
   Y. Li, M. Okamoto, C. Dinarello and M. Fujita. Aurora, CO. 10:08 am, Abstract #812

9. Olfactory receptor stimulation promotes human hair growth.
   J. Chéret, M. Bertolini, T. Tsai, M. Alam, H. Hatt and R. Paus. Muenster, Germany and Manchester, United Kingdom. 10:09 am, Abstract #884
**CLINICAL SCHOLARS PROGRAM SESSION II**

*Emerging Immunotherapies*

**Saturday, April 29, 2017**  
10:15 am – 12:00 pm  
Oregon Ballroom 203

---

**10:15 am**  
Introduction  
Heidi Kong, MD

Dr. Kong is an Investigator in the Dermatology Branch at the NIH. She received her undergraduate degree in biological sciences from Stanford University and earned her medical degree from the Baylor College of Medicine. She completed her dermatology residency at Duke University Medical Center and clinical research fellowship training in the Dermatology Branch, NCI and the Duke-NIH Master’s Program in Clinical Research. Dr. Kong’s research on the human microbiome focuses on understanding host-microbial relationships, particularly of human skin.

---

**10:20 am**  
Paul Nghiem, MD/PhD

Merkel cell carcinoma & the immunogenic principles transforming the care of all UV-induced skin cancers

Dr. Paul Nghiem (pronounced NEE-em) is Head, Division of Dermatology, Department of Medicine and the George F. Odland Endowed Professor, Department of Medicine/Dermatology. He is also Adjunct Professor in the Departments of Oral Health Sciences and Pathology and an Affiliate Investigator in the Clinical Research Division at Fred Hutchinson Cancer Research Center. He grew up in Olympia, Washington, and attended college at Harvard University. He then pursued MD and PhD degrees at Stanford University where he studied Cancer Biology and Immunology. He then completed a medicine internship at Brigham and Women’s Hospital in Boston, a Dermatology residency at Massachusetts General Hospital in Boston and a Howard Hughes Post-Doctoral Fellowship with Stuart Schreiber in the Harvard Department of Chemistry and Chemical Biology. In 2003, he started his own lab at the Cutaneous Biology Research Center at Massachusetts General Hospital in Boston. In 2006, he and his wife moved ‘home’ to Seattle. He leads a multi-disciplinary team that follows a cohort of approximately 1200 patients with Merkel cell carcinoma. In April, 2015, he became Head of Dermatology in the Department of Medicine at the University of Washington. He has published over 90 papers that in aggregate have been cited over 3500 times. He currently has 4 grant awards from the NIH, including a K24 grant for mentoring young physicians and scientists.

---

**10:50 am**  
Johann E. Gudjonsson, MD/PhD

Psoriasis – where are we and where are we heading

Dr. Johann E. Gudjonsson is an assistant Professor of Dermatology at the University of Michigan and Director of Inpatient Dermatology and Consultation. He is also the Frances and Kenneth Eisenberg Emerging Scholar of the Taubman Medical Research Institute. Dr. Gudjonsson is a graduate of the University of Iceland Medical School and completed his Internship and Dermatology Residency Training at the University of Michigan. Dr. Gudjonsson’s laboratory is focused on the intersection between genetics and immunology, and he has published over 100 peer-reviewed publications in journals such as Nature Immunology, Nature Genetics, Journal of Clinical Investigation and Journal of Investigative Dermatology. He received the Young Investigator Award from the American Academy of Dermatology in 2007 and his work has earned several research awards, including awards from the American Skin Association, National Psoriasis Foundation, the Dermatology Foundation, Pfizer Aspire Award, Doris Duke Foundation and the NIH.

---

**11:20 am**  
Q & A

---

**11:25 am**  
SRF/MRTF drive basal cell carcinoma growth through hedgehog pathway activation  

---

**11:40 am**  
Modulation of eIF4F complex assembly in Merkel cell carcinoma cells: Translational regulation of oncogenes and new therapeutic implications  
J. Wu, H. Doan, R. Simonette, Q. He, P. Rady and S. Tyring. Abstract #096

---

**11:55**  
Q & A
New to the 2017 SID Annual Meeting is “Selected ePoster Discussions.” In an effort to further increase participation and visibility of abstracts submitted to the Annual Meeting, the SID is pleased to add this new feature to the meeting.

Selected ePoster Discussions will take place during Poster Sessions that will occur on Thursday, Friday, and Saturday of the Annual Meeting at five (5) iPad terminals located outside of the Poster/Exhibit Hall. The discussions will be thematic tours of selected electronic posters accompanied by a presenting author. Each poster presenter will be asked to briefly describe their work (3 min), followed by a short group discussion (3 min), that will be held with the help of a moderator. If your poster has been selected for ePoster Discussions, please join the appropriate group at the relevant ePoster kiosk.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Poster Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Adaptive and Autoimmunity</strong></td>
<td>001, 007, 049, 059, 070, 002, 003, 022</td>
</tr>
<tr>
<td><strong>Clinical Research: Pathophysiology and Therapeutics</strong></td>
<td>322, 294, 272, 274, 291, 296, 301, 303, 308</td>
</tr>
<tr>
<td><strong>Pigmentation and Melanoma</strong></td>
<td>770, 795, 832, 835, 775, 788, 796, 799, 772, 765</td>
</tr>
<tr>
<td><strong>Skin and Hair Developmental Biology</strong></td>
<td>859, 873, 870, 845, 846, 851, 877, 883, 885</td>
</tr>
<tr>
<td><strong>Late-Breaking Abstracts</strong></td>
<td>LB947, LB966, LB965, LB968, LB970, LB962, LB993, LB948, LB967, LB971</td>
</tr>
</tbody>
</table>

OPEN TO ALL MEETING ATTENDEES
CME CREDITS: 0
CONCURRENT MINI-SYMPOSIUM 11
Carcinogenesis and Cancer Genetics
Studies on the genetics and other causes of cancer as well as mechanisms relevant to metastasis.

Saturday, April 29, 2017 12:30 pm – 3:00 pm  B113-116

Presiders: Raymond Cho, MD/PhD and Brian Pollack, MD/PhD

1. A cohort of miRNAs can be used as an early predictive biomarker of UV-driven cutaneous squamous cell carcinoma. T. Nguyen, K. Rajapakse, V. Chitsazzadeh, C. Nicholas, C. Coarfa and K. Tsai. Tampa, FL and Houston, TX. 12:30 pm, Abstract #098

2. Complement C5a regulates squamous carcinogenesis. TR. Medler and LM. Coussens. Portland, OR. 12:42 pm, Abstract #139


8. Merging mass cytometry and flow-assisted cell sorting to simultaneously characterize a tumor and its microenvironment. A. Crouch, B. Kubick and DR. Roop. Aurora, CO. 1:54 pm, Abstract #128

9. Eyes absent gene (EYA1) is a pathogenic driver and a therapeutic target for melanoma. J. Zhou, R. Huang, X. Zhang, Y. Cheng and L. Tang. Vancouver, Canada; Xiamen, China and Burnaby, Canada. 2:06 pm, Abstract #132


11. K-RAS oncogene activation is regulated by a snoRNA/SNARE protein axis that controls its subcellular transport. Y. Che, Z. Siprashvili, J. Kovalski and PA. Khavari. Stanford, CA. 2:30 pm, Abstract #117

CONCURRENT MINI-SYMPHOSIUM 12  
Clinical Research: Epidemiology of Skin Diseases

Saturday, April 29, 2017  12:30 pm – 3:00 pm  Oregon Ballroom 203

Presiders:  Suephy Chen, MD and Joel Gelfand, MD


4. Black children less likely to receive outpatient care for eczema than whites, but show signs of more severe disease: A cross-sectional analysis of the medical expenditure panel surveys. DB. Shin, AH. Fischer, DJ. Margolis and J. Takeshita. Philadelphia, PA and Baltimore, MD. 1:06 pm, Abstract #198


7. Comprehensive analysis of CTCL incidence and mortality in Canada identifies geographic clustering of cases in industrial areas and low incidence in Ottawa and other administrative cities. F. Al-Ghazawi, E. Rahme, D. Sasseville and I. Litvinov. Montreal, Canada and Ottawa, Canada. 1:42 pm, Abstract #150

8. Associations of phenotypic characteristics, MC1R variants, and prior amelanotic melanoma with incident amelanotic melanoma. S. Vernali, PA. Kanetsky, I. Orlow, L. Luo, M. Berwick and NE. Thomas. Chapel Hill, NC; Tampa, FL; New York, NY and Albuquerque, NM. 1:54pm, Abstract #163


CONCURRENT MINI-SYMPOSIUM 13
Epidermal Structure and Barrier Function

Research on the components or regulation of keratinocyte proliferation, differentiation, including epidermal barrier function.

Saturday, April 29, 2017                  12:30 pm – 3:00 pm Oregon Ballroom 204

Presiders: Luis Garza, MD/PhD and Spiro Getsios, PhD

1. A role for nuclear-localized keratin 17 in the response of skin tumor keratinocytes to DNA damaging agents. **RP. Hobbs, J. Hsu, JT. Jacob and PA. Coulombe. Baltimore, MD. 12:30 pm, Abstract #449**


4. PFKFB3 is a p63 target gene that is required for proliferation, and inhibits differentiation in epidermal keratinocytes. **RB. Hamanaka and GM. Mutlu. Chicago, IL. 1:06 pm, Abstract #467**


6. The Vps33b-Vipar complex is required for epidermal homeostasis. **C. Rogerson and P. Gissen. London, United Kingdom. 1:30 pm, Abstract #404**


8. Transient elevation of cytoplasmic calcium ion precedes the cornification of epidermal keratinocytes. **T. Murata, T. Honda and K. Kabashima. Kyoto, Japan. 1:54pm, Abstract #426**

9. Real time 3D in vivo pH imaging reveals tightly-regulated pH layers with distinct properties in mouse stratum corneum. **Y. Furuichi, T. Matsui and M. Amagai. Yokohama, Japan and Tokyo, Japan. 2:06 pm, Abstract #450**


11. Recent evolution for an involucrin/sperm mitochondria haplotype associated with epidermal function in modern humans. **Z. Goodwin, I. Oh, M. Mathyer, A. Quiggle and C. de Guzman Strong. St. Louis, MO. 2:30 pm, Abstract #461**

12. GJA1 mutations causing erythrokeratoderma variabilis et progressiva display increased connexin hemichannel activity. **HM. Khan, L. Boyden, S. Tomita and K. Choate. New Haven, CT. 2:42 pm, Abstract #463**
CONCURRENT MINI-SYMPHOSIUM 14

Growth Factors, Cell Adhesion and Matrix Biology

Studies on growth factors and the interactions of cells with their local cellular and extracellular environment that affect signaling, adhesion, migration and development.

Saturday, April 29, 2017  12:30 pm – 3:00 pm  C123-124

Presiders: Ryan Driskell, PhD and Alexa L. Mattheyses, PhD

1. **Proteomic evaluation of desmosomes reveals novel components essential for maintaining epidermal integrity.**  KA. Badu-Nkansah, J. Underwood and T. Lechler. Durham, NC. 12:30 pm, Abstract #558

2. **Dynamic organization and order of desmoglein 3 in desmosomes determined by fluorescence polarization microscopy.**  EI. Bartle, TM. Uner and AL. Mattheyses. Atlanta, GA. 12:42 pm, Abstract #554


4. **Palmitoylation of plakophilin-3 requires the carboxyl terminal domain.**  NJ. Eurek and JK. Wahl. Lincoln, NE. 1:06 pm, Abstract #540

5. **Ganglioside GM3, which mediates insulin resistance, disrupts insulin/IGF-1 receptor heterodimerization by receptor membrane mobilization.**  D. Dam, S. Jelsma and A. Palier. Chicago, IL. 1:18 pm, Abstract #541

6. **Hyaluronan synthase 3 induces epidermal hyaluronan production by hapten stimulation and modulate contact hypersensitivity response.**  H. Terui, K. Yamasaki and S. Aiba. Sendai, Japan. 1:30 pm, Abstract #549


8. **The role of ECM in inducing complex human skin morphogenesis in vitro.**  G. Imparato, F. Urciuolo, C. Casale and PA. Netti. Naples, Italy. 1:54pm, Abstract #562

9. **Evaluation of native and non-native bio-inks for 3D printing of human tissues.**  C. Catarino, T. Baltazar, G. Dai, S. Maria-Engler and P. Karande. Troy, NY and Sao Paulo, Brazil. 2:06 pm, Abstract #542


11. **Inhibitory regulation of MFG-E8 on fibrosis in systemic sclerosis.**  C. Fujiwara, A. Sekiguchi, O. Ishikawa and S. Motegi. Gumma, Japan. 2:30 pm, Abstract #548

12. **Mechanistic insight into the extracellular ATP-induced IL-6 via purinergic receptor in systemic sclerosis dermal fibroblasts.**  B. Perera, A. Uchiyama, A. Sekiguchi, C. Fujiwara, O. Ishikawa and S. Motegi. Gumma, Japan. 2:42 pm, Abstract #547
CONCURRENT MINI-SYMPOSIUM 15
Pharmacology and Drug Development

Basic and preclinical studies aimed at developing therapeutics, elucidating their mechanisms of action, and identifying biomarkers of drug activity.

Saturday, April 29, 2017
12:30 pm - 3:00 pm
A105-106

Presiders: Masaoki Kawasumi, MD/PhD and Georg Wondrak, PhD

1. Viral status of Merkel cell carcinoma impacts responses to small molecule inhibitors.

2. Efficacy of topical Vorinostat in the reversal of alopecia areata. E. Wang, JC. Chen and AM. Christiano. New York, NY. 12:42 pm, Abstract #688

3. Allergen-loaded microneedle patches efficiently induce Treg cells in atopic dermatitis.

   D. Dam, L. Zhao, S. Jelsma, Y. Zhao and A. Paller. Chicago, IL and Singapore, Singapore. 1:06 pm, Abstract #687

5. PI3-Kinase inhibitors represent a novel class of drug repurposing candidates to prevent/ alleviate glucocorticoid-induced skin atrophy.
   S. Agarwal, G. Baida, B. Readhead, J. Dudley and I. Budunova. Chicago, IL and New York, NY. 1:18 pm, Abstract #707

6. Folic acid conjugated hollow mesoporous silica nanoparticles encapsulating dacarbazine for targeted melanoma drug delivery and therapy.
   N. Xu, J. Li, J. Zhu and J. Tao. Wuhan, China. 1:30 pm, Abstract #679

7. ITK and RLK inhibitor improves skin disease in a psoriatic mouse model.
   JM. Fuhriman, MCG. Winge, H. Haberstock-Debic, J. Oliver Funk, M. Bradshaw and M. Marinkovich. Stanford, CA and South San Francisco, CA. 1:42 pm, Abstract #700

   K. Lewandowski, R. Edelmayer, M. Guerrero-Zayas, P. Honore and AS. Paller. Chicago, IL and North Chicago, IL. 1:54 pm, Abstract #681

   M. Dany and B. Ogretmen. Charleston, SC. 2:06 pm, Abstract #685

10. Adenosine A2A receptor (A2AR) modulation attenuates innate and adaptive immune cell signaling during pathogenesis of psoriasis-like dermatitis in mice.
    A. Welihinda, P. Ravikumar, M. Kaur, J. Mechanic and E. Amento. Sunnyvale, CA. 2:18 pm, Abstract #690

11. Induced DNA repair in xeroderma pigmentosum group C cells by readthrough of premature termination codons.

    V. Deshmukh, A. Hood and Y. Yazici. San Diego, CA. 2:42 pm, Abstract #706
The 42nd Annual Meeting of the Japanese Society for Investigative Dermatology

42nd JSID
We’ve got science under your skin

Kohasu, Oko-cho, Nankoku, Kochi 783-8505, Japan

Secretariat Office:
Department of Dermatology,
Kochi Medical School, Kochi University

Secretariat:
Kimiko Nakajima, M.D., Ph.D.

Secretary-General:
The Japanese Dermatological Association
1-4, Hongo 4-chome, Bunkyo-ku, Tokyo 113-0033, Japan
Fax: +81-3-3812-6790
E-mail: jsid42@dermatol.or.jp
URL: http://jsid42.jp/

December 15 (Fri.) - 17 (Sun.) 2017
KOCHI CITY CULTURE PLASA CULPORT
Kochi, Japan

Venue

President
Shigetoshi Sano, M.D., Ph.D.
Department of Dermatology,
Kochi Medical School, Kochi University
47th Annual ESDR Meeting

The Sound of Dermatology

27–30 September 2017
Salzburg, Austria

www.esdr2017.org
IID 2018
International Investigative Dermatology

Rosen Shingle Creek Resort
Orlando, Florida